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Abstract 
 
To unravel the molecular pylons of innate anxiety, a well established animal model 
has been characterized using transcriptome- and sequence-based analyses. The 
animal model – hyper (HAB) and hypo (LAB) anxious mice – has been created by 
selective inbreeding based on outbred CD1 mice using the extreme values the mice 
spent on the open arm of the elevated plus-maze, a test also used to screen drugs 
for anxiolytic or anxiogenic effects.  
These mice proved a robust phenotypic divergence, also for depression-like 
behavior and stress-axis reactivity.  
In a first assay, brain regions unambiguously involved in regulating anxiety-related 
behavior were screened for gene expression differences between HAB and LAB 
animals in a microarray experiment covering the whole genome. This led to the 
identification of thousands of differentially expressed transcripts. The highest 
significant results were further validated by quantitative PCR or other techniques 
focusing either on protein quantification or enzyme activity. Applying this strategy, 
differential regulation of 15 out of 28 transcripts could be validated: vasopressin, 
tachykinin 1, transmembrane protein 132D, RIKEN cDNA 2900019G14 gene, 
ectonucleotide pyrophosphatase/phosphodiesterase 5, cathepsin B, coronin 7, 
glyoxalase 1, pyruvate dehydrogenase beta, metallothionein 1, matrix 
metallopeptidase 15, zinc finger protein 672, syntaxin 3, solute carrier family 25 
member 17 and ATP-binding cassette, sub-family A member 2. Additionally, 
analysis of cytochrome c oxidase activity resulted in the identification of differences 
in long-term activity between HAB and LAB mice in the amygdala and the 
hypothalamic paraventricular nucleus pointing to an important role of these brain 
regions in shaping the anxiety-related extremes in these mice.  
In a second genome-wide screening approach, 267 single nucleotide 
polymorphisms were identified to constantly differ between HAB and LAB animals 
(i.e. to carry the opposite homozygous genotype at these loci) and subsequently 
genotyped in 520 F2 mice, the offspring of reciprocally mated HABxLAB animals. 
These F2 mice have been previously phenotyped in a broad variety of behavioral 
tests and show – as descendants of intermediate heterozygotes for all polymorphic 
genomic loci between HAB and LAB mice – a free segregation of all alleles, thus 
allowing genotype-phenotype associations based on whole-genome analysis. Only 
focusing on the most significant findings, associations have been observed between 
anxiety-related behavior and loci on mouse chromosomes 5 and 11, between 
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depression-like behavior and chromosome 2 and between stress-axis reactivity and 
chromosome 3.  
The locus on chromosome 11 is marked by a polymorphism located in the 3’ 
untranslated region of zinc finger protein 672, a gene also markedly overexpressed 
in LAB mice and expressed at lower levels in HAB mice leading to a probable causal 
involvement in shaping the phenotype. Further associations on chromosome 5 
include two functional polymorphisms in enolase phosphatase 1 that result in a 
different mobility of the enzyme in proteomic assays and with a polymorphism 
located in the transmembrane protein 132D gene. Furthermore, independently, an 
association of a polymorphism in this particular gene, together with the resulting 
gene expression differences has been observed in a group of panic disorder 
patients, highlighting this gene as a causal factor underlying anxiety-related 
behavior and disorders in both the HAB/LAB mouse model and human patients.  
The combination of expression profiling and confirmation by quantitative PCR, single 
nucleotide polymorphism analysis and F2 association studies, i.e. unbiased and 
hypothesis driven approaches were key to the identification and functional 
characterization of loci, genes and polymorphisms causally involved in shaping 
anxiety-related behavior. Thus, it provides an overview of some new promising 
targets for future pharmaceutic treatment and will contribute to a better 
understanding of the molecular processes that shape anxiety and thereby also 
animal and human behavior. 
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1. Introduction 
 
1.1. The evolution of threat assessment systems 
Anxiety and fear are two similar, but nevertheless well distinguishable emotions 
combined with physical and physiological reactions. Both have a common 
background and sense at a former evolutionary stage (Flannelly et al., 2007; Rosen 
and Schulkin, 1998). 
Fear itself is an adequate evolutionary adaptation, to prevent being eaten by 
predators, or to escape from life-threatening situations, that an individual is 
confronted with suddenly (Belzung and Philippot, 2007). This reaction ability might 
already play a vital role in organisms that are capable of actively changing their 
position.  
To differentiate between fear and anxiety, fear is the reaction to an acute threat with 
a defined danger, whereas anxiety is strictly context-based and evokes the 
impression of a threatening situation without the direct contact with something that 
would justify the described reaction. This way, to perceive something as anxiogenic, 
an individual must have the cognitive ability, to (I) perceive a threat per se, (II) to 
learn associations with a specific context and (III) to recall the memory (association). 
From this point of view fear is a basic prerequisite to any kind of higher emotion 
related to threat assessment, like anxiety (Belzung and Philippot, 2007). 
Belzung and Philippot (2007) indeed summarized these conditions resulting in five 
distinct stimulus evaluation checks (SEC) in organisms that have to be 
accomplished in order to provoke an anxiety-related reaction. However, even 
protozoans or nematodes show the capability to perform at least the first three SECs 
(“novelty check”, “intrinsic pleasantness check” and “goal/need conduciveness 
check”) even if a detailed discrimination of these is hard to prove for these 
organisms. The ability to change morphology and behavior in response to a 
predator-induced threat has even been demonstrated for protozoans like Euplotes. 
Basically, if these three SECs work, many physiological reactions typical of an acute 
stressor can be observed, allowing an adequate threat response. 
The fourth SEC is proven to function in all vertebrates but also for some insects. In 
brief, animals able to learn helplessness, i.e. to learn to cope with and not to escape 
from a hopeless and threatening situation, but as soon as the opportunity is given to 
do so, are able to perform this fourth SEC. Nevertheless, the fifth SEC (“norm/self 
compatibility check”) seems to be unique to primates, as it requires cultural 
transmission (Belzung and Philippot, 2007). This brief description of evaluation 
circuits, demonstrates the sense of threat assessment, i.e. the decision on a fight or 
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flight reaction. For individual survival, it might be favorable to overestimate 
threatening stimuli (i.e. to react, if the organism would not have to, costs less 
compared to loss of life). These SECs already include a bias towards the 
interpretation in favor of a defensive behavior, independent of whether this takes 
place in single cell or more complex organisms.  
With differentiation of more complex classes and species, these SECs increasingly 
require central control. This was taken over quite early in evolutional terms, by 
neurons, the cell type most suitable for intercellular communication and 
coordination. They represent an ancient and vigorously conserved cell type in 
metazoans, with cnidarians and sponges already bearing neuronal cells (Holland, 
2003), able to communicate with each other and coordinate their action. Starting 
from cnidarians, also a basiepidermal nerve net is present in eumetazoa (Holland, 
2003). Emerging complexity gave rise to neuronal agglomerations in these nerve 
nets, forming ganglia in species like Caenorhabditis elegans and other more 
complex organisms building the core of a central nervous system in all 
invertebrates, that was also transferred to vertebrates combined with the 
dorsoventral body axis inversion (Denes et al., 2007). 
A broad variety of changes and adaptations has led to the development of the brain, 
with the hypothalamus and functional equivalents of the hippocampus and amygdala 
already present in fish (Belzung and Philippot, 2007). Many brain structures and 
systems have already been attributed to fear and anxiety in vertebrates, with the 
evolutionary oldest one, the basal ganglia, that already function at a pre-emotional 
level and the limbic system which also already works at a preconscious level. Most 
importantly, the prefrontal cortex also plays an important role in mammals as for the 
modulation of the autonomic nervous system, social cognition and emotional 
decision making. These three systems can be summarized as evolutionary threat 
assessment systems (ETAS). It also has been proposed, that many different kinds 
of threats require different ETAS even at the most rudimentary level of evolution, like 
for threats originating from predators, conspecifics, height or from insects (Flannelly 
et al., 2007), thus forming the basis of multiple systems, involved in the anticipation 
and processing of potentially threatening situations, competing with and 
complementing each other, resulting in the complex trait called anxiety, which 
already include a bias towards the overinterpretation of anxiogenic stimuli. 
 
1.2. The evolution of neuroactive compounds 
In parallel to the morphologic and organogenic evolution of neurons, ganglia and 
brains, a high degree of complexity and diversity was established in mammals, 
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originating from a few neuroactive compounds in the first neurons. First forms of 
substance P-related tachykinin peptides are known from hydra or vasopressin- and 
oxytocin-like peptides are already present in the locust (Gwee et al., 2008; Severini 
et al., 2002). Nevertheless, the basic forms of neuronal communication via 
molecules do not necessarily require a vast degree of complex substances, as pre-
neuronal cell to cell communication might already take place by the release of 
glutamate, gamma-aminobutyric acid, glycine, acetylcholine, serotonin or any other 
small neurotransmitter. Additionally, mechanisms of cell to cell communication to 
convey information also exist for prokaryotes, especially in colony-forming bacteria 
as Pseudomonas aeruginosa. However, most of the best-characterized substances 
used for ‘quorum sensing’ in bacteria comprise substances like quinolones, 
pentandione-based molecules, long fatty acids or short peptides (Williams, 2007). 
This makes a major difference to eukaryotic cells and organisms, as these 
substances are hardly applied in signal transduction processes (except for the short 
peptides). 
Interestingly, this suggests that the broad variety of substances used for intercellular 
communication arose from the same basis of only a few molecules (Landgraf and 
Holsboer, 2005); especially as bacteria show a variety that uses different 
substances). Also release mechanisms from vesicles seem to be quite conserved 
and are not a privilege of neurons. First forms of endo- and exocytosis must have 
been present in the first cells that required more than the uptake of substances via 
diffusion. Equivalently, proteins of the superfamily of soluble N-ethylmaleimide 
sensitive factor attachment protein receptors (SNARE) and their interacting proteins 
seem to play a pivotal role for the release of substances from vesicles. Whereas 
SNAREs are required for the fusion of vesicles with a membrane, NSF (N-
ethylmaleimide sensitive factor) and soluble NSF attachment proteins (SNAP) are 
necessary for the regeneration of used (cis-) SNARE complexes. This principle 
works in all neuronal synapses, but the same way in yeast (Ungar and Hughson, 
2003). Complexity and diversity of signaling molecules significantly increased, also 
displaying a big but not unconservative variety between species. Good examples for 
this are tachykinin and tachykinin-like peptides. Amphibians and other 
submammalian representatives display a broad variation of tachykinins. Their exact 
sequence and of course their function do not completely correspond to that of 
mammalian tachykinins, but some of them are potent agonists of mammalian 
tachykinin receptors. They also share a common hydrophobic C-terminal sequence, 
defined as FXGLM-NH2, where X stands for any hydrophobic residue. Numerous 
studies demonstrated the indispensability of this sequence for the interaction with 
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one of the three known mammalian receptors for tachykinins, NK1, NK2 and NK3. 
Nevertheless it took about 70 years of intense research from the first identification of 
substance P (SP) by von Euler and Gaddum in 1931 over neurokinin A (NKA) and 
neurokinin B (NKB) in mammals to the discovery of more tachykinins that has only 
reached the current state in the last years (Page, 2004; Severini et al., 2002).  
Three genes are known in mammals that encode for tachykinins, that have most 
probably arose from two genome duplications which took place during vertebrate 
and mammalian development. In humans TAC1, TAC3 and TAC4, in rodents 
(mouse and rat) Tac1, Tac2 and Tac4, with Tac2 of mice and rats displaying high 
homology to the human TAC3 gene and both encoding NKB (Duarte et al., 2006). 
The two other genes, Tac1 and Tac4 are similar concerning their structure both 
expressing at least four different splicing variants.  
Tac1 transcripts (i.e. splicing variants) produce the following peptides: SP, NKA, 
neuropeptide K (NPK) and neuropeptide γ (NPγ), with all of these peptides 
representing tachykinin peptide family members (Fig. 1). In contrast, Tac4 transcript 
variants encode the peptides hemokinin 1 (HK-1) and the endokinins A, B, C and D 
(EKA, EKB, EKC, EKD) with the EKC and EKD representing only tachykinin-like 
peptides as their C-terminal sequence bears two significant modifications replacing 
the tachykinin motif FXGLM to FQGLL that also decreases its hydrophobicity. 
Another specialty of Tac4 gene products is represented by the fact that these 
endokinins are only specific to human cells and have not been described to be 
expressed or synthesized in rodents. Nevertheless recent studies indicate that 
similar endokinins might be encoded by Tac4 in rabbits (Page, 2004). 
 
 
Figure 1: Gene, mRNA with splicing variants and peptides encoded by tachykinin 1 (Tac1).  
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Three different receptors are described, all classified as neurokinin receptors and 
consequently named NK1, NK2 and NK3. All tachykinins displaying the FXGLM 
peptide motif bind to all NK receptors differing only in their binding affinity. The 
distribution of receptors is to a certain extent tissue specific. Although mammalian 
tachykinins are the natural ligands of the receptors, other – non-mammalian but 
vertebrate - tachykinins, like uperolein (from Uperuleia marmorata), physalaemin 
(from Physalaemus biligonigerus), kassinin (from Kassina senegalensis) or 
phyllomedusin (from Phyllomedusa bicolor), can bind to the respective receptors 
with fairly high affinity. Beside other tachykinin-like peptides (the locustatachykinins) 
that only differ in their last amino acid residue, concerning the specific five amino 
acid motif, even some authentic tachykinins were isolated from invertebrate species 
like eleidosin (from Eledone aldovrandi) or sialokinin I and II (from Aedes aegypti) 
which display similar receptor binding effects in mammals, thereby representing 
potent agonists NK receptor (Severini et al., 2002).  
Another result of a single gene duplication event is the evolution of arginine-
vasopressin (Avp) and oxytocin (Oxt) gene loci from one single progenitor, 
vasotocin. Beside the high sequence homology of the peptides and also the genes 
in nearly all mammals, the two genes are located on the same chromosome in close 
vicinity with each other, placed on the opposite DNA strands. Although they share a 
big part of their sequence and function as in the body, their function is quite 
different. In the brain they also act as neuromodulators on similar brain systems and 
regions but with different function (Fields et al., 2003; Gwee et al., 2008; Landgraf 
and Neumann, 2004).  
 
1.3. Anxiety and depression disorders 
Arising from the threat assessment systems, there is already a bias towards 
interpreting harmless stimuli as being rather dangerous (Kim and Gorman, 2005). 
As mentioned before, there are many behavioral and physiological consequences of 
confrontations with stressful situations. If now the systems regulating these stress 
responses do not fully return to their former homeostatic state because of the 
repeated confrontation with a small or due to the confrontation with one strong 
stressor, the state of heightened alertness might never recover to basal level 
anymore, or can be triggered by much smaller events to the same strong reactions. 
This is the state, anxiety disorder patients have to cope with. As one can imagine, 
there is a smooth transition along a continuum between normal and pathological 
anxiety. The patients’ genetic predisposition, their nurturing and education, their 
experiences and their environment shape their overall predisposition and likelihood 
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of being affected by any kind of these disorders. The overall lifetime-prevalence in 
industrialized countries for anxiety disorders is above 25% and patients suffering 
from one of these disorders are also prone to develop a second or third kind of 
anxiety disorder (Bittner et al., 2004; Hettema et al., 2004; Hettema et al., 2005; 
Jacobi et al., 2004; Kim and Gorman, 2005) The co-occurrence of multiple anxiety 
disorders clearly points to a kind of stress-dosage effect and the reduced ability of 
the stress-regulation systems to recover to a homeostatic state. These clear-cut 
effects of genetic predisposition, the effects of maternal care and nurturing have 
also been demonstrated for animals and animal models (Caldji et al., 1998; Francis 
and Meaney, 1999; Wilkins and Haig, 2003a). 
Anxiety disorder patients are also highly in danger to develop a depression disorder 
during their later life which is well described as comorbidity of these two disorders. 
The rate of comorbidity is fairly between 50-60% (Landgraf, 2001a). Depression 
disorders – similarly to anxiety disorders – pose a huge burden for affected persons, 
their close environment and also for economy. But whereas anxiety disorders might 
only slightly affect one patient’s life, as is the case with specific phobias, where 
patients do not face the threat in everyday situations, in depression persons might 
be disabled for months or years, not taken into account that depressive episodes 
might return repeatedly.  
Also the currently available pharmaceutic treatment for both, anxiety disorders and 
depression, is still far away from an optimal state. Best recovery can be reached 
utilizing a combination of pharmaceutic and behavioral (cognitive) therapy. 
Nevertheless, treatment response takes weeks or months, only one third of patients 
show a treatment response for the commonly used substances. As anxiolytics, 
benzodiazepines are widely used, although antidepressants like selective serotonin 
reuptake inhibitors, tricyclics and monoamine oxidase inhibitors are also prescribed 
often (Nutt, 2005). However, all of them might cause side effects, like analgesic or 
sedative ones. As the systems that are blocked do not exclusively exert functions in 
the central nervous system, side effects can also affect muscle function, the gut, 
skin, kidney or the complete hormone system (Simon et al., 2008). 
Therefore, many efforts are undertaken to identify new targets for pharmaceutic 
treatment, bearing with higher efficacy and selectivity. A new possible target – the 
neurokinin receptors – were found and analyzed during the last ten years, also 
reaching the clinical trial phase with saredutant. Although the results obtained were 
similar to the treatment with antidepressants, in one study the placebo control group 
was even more effective, so the drug failed (Czeh et al., 2006). With more efforts 
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aimed at the characterization of the underlying mechanisms, new and more specific 
targets can be identified in the near future.  
Furthermore, many studies underline the complex genetics behind anxiety and 
depression and support the consideration of data obtained from linkage and 
association studies in humans and animal models as well as the investigation of 
single specific molecular circuits. Further emphasis is on the fact most analysis from 
patients point to: genetic variation contributing to behavioral effects is not simply 
multifactorial, but each genetic locus contributing to these behavioral effects is 
expected to cause a variance of not more than 3% in the respective phenotype 
(Conti et al., 2004; Hovatta and Barlow, 2008; Peters et al., 2007; Schadt et al., 
2005; Smoller et al., 2000). This increases the importance of quantitative trait locus 
(QTL) analysis (i.e. the identification of loci, contributing to multiple traits to a tiny 
percentage) and also makes the need for an integrative research combining the 
analysis of genetic predisposition (using polymorphisms as genomic markers) with 
gene and peptide expression profiles obvious (Schadt et al., 2005). 
Appling this strategy, new systems can be targeted, where the currently available 
high-throughput genome, transcriptome and proteome analysis systems might be of 
valuable help. Genome analysis systems reveal differences in the genetic sequence 
and can be directed at single nucleotide polymorphisms (SNP), copy number or any 
other kind of polymorphic structure. Transcriptome analysis systems assess the 
gene expression rate on a whole genome basis and proteomic assays can also 
detect quantitative and qualitative differences in proteins and peptides. They might 
provide the basis of a personalized therapy by (I) delivering the necessary 
biomarkers for a detailed molecular diagnosis and (II) the treatment targets for 
anxiety disorders, depression and many more complex diseases including some 
autoimmune syndromes or cancer.  
 
1.4. Assessing anxiety/depression in mice 
Unfortunately, the assessment of the systems involved – especially the central 
nervous system – is rather problematic in humans – not exclusively because of 
ethical concerns – so model organisms have to be studied and can even reveal 
more in some cases, as researchers can follow the line from less to more complex 
nervous systems, from simple to complex behaviors and from metabolic products to 
complex biosynthetic enzymes and enzyme complexes. 
In some cases even invertebrate species can be used to study specific behavioral 
aspects, like aggression in Drosophila sp. (Dierick and Greenspan, 2006). 
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During the 70-ies and 80-ies of the last century a lot of effort has been undertaken to 
assess anxiety-related and depression-like behaviors in rodents, particularly in rats. 
The elevated plus-maze (EPM) test for anxiety-related behavior by Lister and the 
Porsolt forced swim test (FST) for depression-like behavior are the most prominent 
examples that have also been validated with antidepressant and anxiolytic drug 
treatment in countless studies. Later on, these tests have been adapted for mice as 
genetic manipulation found its way into mammalian research (Cryan and Holmes, 
2005).  
On the EPM, as in most other anxiety-related behavioral tests, the rodents’ innate 
anxiety of open and brightly lit spaces is challenged versus the – also innate – 
exploratory drive to investigate unknown terrain. The animals may choose between 
exploring a dark and closed (with walls) or an open and brightly lit compartment, 
where the total amount of time spent in each one is indicative of the individuals’ 
anxiety-related behavior (Bourin et al., 2007; File, 2001). However, this anxiety-
related behavior might be contaminated with locomotor hyperdrive or deficits. To 
exclude this bias, the open field (OF) test may be applied, to receive locomotor 
activity unaffected by anxiety-related behavior by measuring the distance traveled, if 
only moderate illumination is applied in the test. Still, anxiety-related behavior can 
be scored by measuring the time spent near the walls (more protected) against the 
central region, that is less protected (Cryan and Holmes, 2005; Holmes et al., 2002). 
However, also the total number of arm entries on the EPM can be regarded as a 
valid parameter measuring locomotor activity (Ramos et al., 2008).  
Another possibility to assess anxiety-related behavior independent of locomotion is 
the elevated platform (EPF) test where the animals are placed on a round platform 
that is quite big enough, to turn around. Although this test is most commonly used 
as a mild stressor (Ebner et al., 2004; Kavushansky and Richter-Levin, 2006), the 
amount of explorative head dips (going over the edge of the platform) is indicative of 
the animals’ anxiety-related behavior (Kessler, 2007). 
In the FST, depression-like behavior is assessed by challenging the animal in an 
inescapable, desperate situation (a glass cylinder filled with water, but the edge out 
of reach for the animal). The parameter measured is the total time the animal tries to 
escape (active coping) or just floats (passive coping) in the cylinder. Similarly, but 
only working for mice, a test paradigm has been developed that does not require the 
water as a surplus stressor to the inescapable situation, the so-called the tail 
suspension test (TST), where mice are hung up by their tail tip to a bar, some 
centimeters above the ground (Cryan and Mombereau, 2004).  
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Of course these tests do not reflect the full spectrum of anxiety- and stress-related 
phenotypes, as they only work with innate stressors. In other tests, cognitive abilities 
in regard of associative learning, fear-conditioning or social defeat and social 
recognition abilities can be assessed (Bunck, 2008; Frank et al., 2006; Frank and 
Landgraf, 2008). 
 
1.5. The hypothalamo-pituitary-adrenal (HPA) axis, gene expression and 
translation 
For stress responses and the following reestablishment of the homeostatic state, the 
hypothalamo-pituitary-adrenal (HPA) axis is the pivotal contributor. In the 
hypothalamic paraventricular nucleus (PVN) input signals from amygdala nuclei, the 
bed nucleus of the stria terminalis (BNST), the pons or the locus coeruleus ransom 
the release of peptide hormones like corticotrophin-releasing hormone (CRH) and 
vasopressin (AVP). Once released, these neuropeptides trigger the stimulation of 
the pituitary to secrete adrenocorticotropin (ACTH) into the peripheral blood vessels 
(Lang et al., 2000) acting on the adrenal cortex to secrete cortisol or corticosterone 
(CORT) to suppress stress-related reactions of the PVN and other brain nuclei 
(Herman and Cullinan, 1997; Tsigos and Chrousos, 2002). If now either the 
expression or translation of AVP, CRH, ACTH, or CORT is inhibited, the system can 
not work efficiently enough. Interestingly, not only an increased cortisol or CORT 
response has been observed in anxiety-related disorders (Strohle and Holsboer, 
2003), but also hypocortisolism has been reported in many cases of stress-related 
disorders, among others like in post traumatic stress disorder (Frank et al., 2006; 
Raison and Miller, 2003).  
Furthermore, as mentioned before, a big and well-coordinated orchestra of 
molecular signaling molecules has to be available to mediate any stress response. 
Therefore, not only the transmitter molecules have to be available, but the 
synthesizing enzymes and also receptors have to be expressed and translated in 
the cells, where they are required. With respect to the HPA axis, the roles of CRH or 
NK1 receptors are well-described (Ebner and Singewald, 2006; Muller et al., 2001; 
Saria, 1999). The same applies to the respective neuropeptide ligands. Anything 
that might interfere with a correctly operating sequence might lead to severe 
consequences in the required behavioral and physiological responses. As the 
“orchestra” is quite big, the “drop out” of one violin player will not cause the failure of 
the whole concert (especially, as there are many mechanisms which are meant to 
compensate for the failure of single mechanisms). To mention just some of the 
active compounds and peptides: γ-aminobutyric acid, glutamate, glycine, 
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epinephrine, norepinephrine, substance P, glucagon-like peptide 1, serotonin, 
oxytocin, prolactin or urocortin (Herman and Cullinan, 1997; Landgraf, 2001b; Zafra 
and Gimenez, 2008).  
But if more systems are affected and disturb fine-coordination or cause a total failure 
it may lead to serious consequences for the whole system.  
Tissue and especially brain area-specific gene expression therefore is a prerequisite 
to a well-functioning organism. To reveal the specific mechanisms leading e.g. to a 
specific but complex phenotype, examining gene expression is an especially helpful 
tool (Green et al., 2004; Hovatta and Barlow, 2008).  
 
1.6. The influence of genetic polymorphisms 
Besides physical and physiological disturbances that lead to the loss of the 
homeostatic state, genetic polymorphisms play a vital role, first of all for the 
evolution per se, but genetic polymorphisms can enhance or limit individual 
capacities and capabilities in everyday life. 
Genetic polymorphisms arise from mutations, irrespective of their genomic position. 
They can lead to both, loss and gain of function, if they cause a change in the 
genetic triplets (missense mutation) for amino acids in protein-coding genomic 
regions (Lewin, 2004). Polymorphisms may even affect mRNA stability, if they cause 
synonymous mutations at the third ‘degenerate’ base position (Shabalina et al., 
2006). Furthermore they influence mRNA transcription rates, if they are located in 
genomic regions near genes where transcription factors and cofactors can be 
recruited to (cis-regulatory effect). This applies to at least 20% of polymorphisms 
found in promoter regions and even to gene introns (Buckland et al., 2004; Hubler 
and Scammell, 2004; Levine and Tjian, 2003). Trans-regulatory effects on gene 
expression may also come to effect, if a regulatory region is in close spherical 
proximity to the regulated gene but on the physical genomic map would be located 
thousands or millions of basepairs (bp) away from the respective gene. Some 
studies highlight that due to the close and dense package of DNA in cell nuclei such 
interactions are possible (if not even the main mechanism for transcriptional 
regulation) and play a pivotal role in tissue-specific gene expression (Engel et al., 
1992; Yvert et al., 2003).  
The most common class of genetic polymorphisms are SNPs, as they can arise 
from the most simple kind of error that might occur during replication. So far, 30 
million SNPs have been identified in humans that would mean one SNP per 1kbp of 
total DNA. Although other mutations might occur as well, as transitions, deletions or 
duplications of single fragments of different size, and might have a major impact on 
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the individual’s viability, they occur less often and are therefore less well 
documented in different species and also harder to compare in inter-species 
approaches. Nevertheless, recent advances in genotyping large amount of loci, also 
facilitate the discovery and mapping of inter-individual copy number variations (Feuk 
et al., 2006). 
Popular examples for gain-of-function by mutations is the protective mutation in 
hemoglobin that causes sickle-cell anemia, but protects from malaria infection, or a 
polymorphism that has been described to protect from both the bubonic plague 
epidemic known from the Middle Ages and HIV infection (Altschuler, 2000; Ayi et al., 
2004). 
As another example for complex traits, scientists recently succeeded in identifying 
genomic loci, highly associated with the restless-legs syndrome by screening for 
SNPs in a large group of patients vs. unaffected controls (Schormair et al., 2008; 
Winkelmann et al., 2007; Winkelmann et al., 2008).  
The same way, researchers have to search for mutations, involved in anxiety 
disorders and depression to elucidate new ways for more effective and personalized 
treatments (Holsboer, 2008). 
 
1.7. The HAB/LAB mouse model 
For the analysis of any biological mechanism in humans, it is not only because of 
ethical considerations impossible to make these assessments in humans. In service 
of the modular understanding of the existing circuitries, the best possible approach 
is to put emphasis on model organisms that are on one hand simple enough to 
keep, breed and raise them for long-term experiments but are, on the other hand, 
complex enough to reflect complex traits, like anxiety or depression-like behavior in 
a way that can be applied analogously or extrapolated to primates. In this respect, 
rodents play a major role for psychiatric research, although some aspects of the 
respective phenotypes in humans won’t be reflected at all by any model, such as 
feeling of worthlessness.  
Following a breeding strategy that was also successfully applied to rats (Landgraf 
and Wigger, 2002; Liebsch et al., 1998a; Liebsch et al., 1998b) before, a mouse 
model has been established in the same manner, i.e. starting from the CD1 outbred 
mouse strain animals displaying high anxiety-related behavior (HAB) in the EPM test 
have been selected to form the basis of the HAB mouse line. HAB mice usually 
spend less than 10% of the total test time on the open arm of the EPM. Accordingly, 
animals showing low anxiety-related behavior (LAB) were selected and bred to 
generate the LAB mouse line, spending more than 50% on the open arm of the EPM 
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(Kessler et al., 2007; Kromer et al., 2005; Landgraf et al., 2007). During the first 
seven generations, an outbreeding protocol was applied to warrant for the equal 
distribution of anxiety-related susceptibility genes and starting from generation 10 
switched to a strict inbreeding (brother-sister) protocol. This was to ensure the 
fixation of loci critically involved in producing the phenotype in a homozygous state. 
Additionally, a normal anxiety-related (NAB) mouse line has been added two years 
ago, where the animals should spend around 30% of the total test time on the open 
arm of the EPM (Landgraf and Kessler, personal communication), which also 
reflects the mean value of outbred CD1 mice (Bunck et al., submitted; Touma et al., 
2008). Nevertheless, during the last 30 generations, numerous different 
endophenotypes have been assessed in HAB, NAB and LAB mouse lines, also 
involving outbred CD1 (referred to as CD1) in some cases. 
 
1.7.1. Phenotypic characteristics of HAB/LAB mice 
HAB and LAB mice do not only differ in their anxiety-related behavior as measured 
on the EPM, but their divergence in anxiety-related test parameters can also be 
detected and quantified in the dark/light box, OF and EPF tests (Kromer et al., 
2005); Keßler et al., in preparation). Importantly, the difference in the EPM has been 
verified under independent, but similar testing conditions at the University of 
Regensburg and Innsbruck (Bosch et al. and Sartori et al., in preparation). 
Furthermore, HAB and LAB mice show differences in depression-like behavior 
measures as assessed by the TST and FST, with HABs displaying significantly 
more passive, LABs a more active coping strategy in those desperate test situations 
(Kromer et al., 2005). A further interesting finding is the differential HPA axis 
regulation in HAB vs. LAB mice. While neither line shows differences in basal levels 
of CORT or ACTH, HAB mice exhibit a significantly flattened CORT response in 
blood plasma upon a strong physical stressor (restraint stress or stress reactivity 
test) relative to LAB mice (Kessler et al., in preparation).  
Also cognitive differences were observed between the two mouse lines, with HABs 
being able to discriminate for a longer time-interval between a novel and a familiar 
ovariectomized female as compared to LAB mice in the social discrimination test. 
These cognitive differences also apply to the performance in the Morris water maze, 
the Y-maze or fear conditioning related measures (Bunck, 2008).  
Importantly, the mouse lines do not differ in body weight, locomotor activity, 
locomotor capability or their ability to hear, smell or see (Zurmuehlen, 2007). 
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1.7.2. Molecular characteristics of HAB/LAB mice 
A pronounced deficit in AVP peptide and the Avp-coding mRNA has been 
demonstrated in LAB mice in various brain regions, as compared to CD1 or HAB 
mice (Bunck et al., submitted), which is in close association with a polymorphism in 
the AVP preprohormone-coding mRNA and anxiety-related behavior and signs of 
central diabetes insipidus (Kessler et al., 2007). 
Similarly HAB, but not LAB or CD1, mice exhibit an overexpression of Crh in 
multiple regions, linked to depression-like behavior (Bunck et al., in preparation). 
Not much is known about the genetic background of HAB/LAB mice, as both are 
derived from CD1 mice. Up to date there is no information available on genetic 
polymorphisms or their allelic frequency, although the latter might even vary from 
supplier to supplier. The most closely related inbred strains often used in animal 
models are FVB/J and NOD/J (Beck et al., 2000).  
 
1.7.3. The F2 panel 
To test hypothesis in behavioral biology, one can either apply substances to block 
enzymes, hormones, receptors or to enhance them and then take a look at 
behavioral consequences. The other possibility is, but this only applies to model 
systems which are based on the same species with definite (if possible, not too 
many) differences, to take the two lines – in our case HAB and LAB mice, mate 
them reciprocally to create a genetically completely heterozygous F1 generation (in 
all alleles differing between HAB and LAB mice) and to mate these F1 mice to each 
other again to establish the F2 generation, where each genotype and phenotype has 
the possibility to segregate freely, if they are not linked to each other (Henderson et 
al., 2004; Turri et al., 1999; Valdar et al., 2006). So far, the breeding has been 
completed, all HABxLAB F2 intercross mice (N = 521) tested for a number of 
behavioral (EPM, OF, EPF, FST, TST and stress reactivity) and physiological (body 
weight, water consumption) parameters (Kessler et al., in preparation). 
 
The aim of this thesis was to shed some light on the molecular mechanisms 
underlying trait anxiety and depression-like behavior as modeled in HAB and LAB 
mice.  
Therefore, phenotypic stability of HAB mice was addressed by a selective breeding 
approach first, to drive them towards less anxious behavior.  
Then, to screen for gene products differing between HAB and LAB mice, gene 
expression profiles in various brain regions involved in the regulation of anxiety-
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related behavior were generated by using two different microarray platforms. The 
most significant findings were reanalyzed in an independent approach by 
quantitative PCR (qPCR) and could be partially confirmed. Other assays tried to 
assess the effects of differential regulation, based on enzyme-activity or 
measurements of protein levels. 
In another unbiased whole-genome assay, SNPs were identified that constantly 
differed between HAB and LAB animals (i.e. both lines carried the opposite alleles 
homozygously), thus allowing the genotyping of F2 and CD1 mice and helping to 
gain some insight into the genetic variability available in outbred CD1 mice. Further, 
sequencing of candidate genes helped to reveal differences, the observed gene 
expression differences might be related to.  
Finally, to reveal functional associations of genomic loci with behavior, the 
genotyping information on SNPs in F2 mice made the analysis of 
genotype/phenotype associations possible, highlighting the role of single genomic 
regions in actively influencing anxiety-related behavior. In this whole study, the focus 
is on selected, highly significant results, while other findings also of potential interest 
are neglected at this stage.  
Further this thesis represents the first approach to integrate data obtained in gene 
expression analyses and genotyping for a large number of polymorphic loci to 
identify genes causally involved in shaping the anxiety-related and depression-like 
behaviors in HAB vs. LAB mice. These results could partially be extrapolated to 
other animal and – last but not least – to human studies, dealing with anxiety 
disorders and depression. Further this study contributes to the analysis of the 
genetic background in outbred CD1 mice. 
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2. Animals, materials and methods 
All animal experiments were carried out with the approval of local authorities and 
conducted according to current regulations for animal experimentation in Germany 
and the European Union (European Communities Council Directive 86/609/EEC). All 
animals were kept in the animal facility of the Max Planck Institute of Psychiatry 
under standard housing conditions (room temperature 23±2°C, relative air humidity 
60+-5%, 12h/12h dark/light cycle with lights on at 7 a.m) in groups of two to four 
animals per cage. If animals were ordered from a supplier, they were granted at 
least one week of habituation before starting with any behavioral study. Animal 
numbers, the respective generation of animals and the mouse lines used for each 
experiment are indicated each. Behavioral experiments were carried out under 
standard housing conditions and were always performed between 8 a.m. and 1 p.m. 
All animals were tested in a randomized order, blind to the mouse line. This also 
applies to the processing of individual samples from animals. 
All mice used were either HAB, LAB, HABxLAB F1 intercross, HABxLAB F2 
intercross, NAB or CD1 mice. NAB mice are inbred mice, selectively inbred for 
displaying an intermediate phenotype (i.e. spending around 30% of the total EPM 
test time on the open arms). Inbreeding NAB mice, only started by the end of the 
year 2006. Outbred CD1 mice are referred to as CD1 only.  
Except where indicated, all chemicals were purchased from Sigma-Aldrich 
(Taufkirchen b. München, Germany); centrifugations of volumes smaller 2ml were 
done in a Hermle Z 233 MK centrifuge (Hermle Labortechnik, Wehingen, Germany). 
For pipetting volumes up to 1ml, pipets by Gilson (Pipetman, Gilson, Middleton, WI) 
were used with pipet tips manufactured by Sarstedt (Nürnbrecht, Germany). For all 
experimental steps involving handling of RNA filter pipet tips were used. 
 
2.1. The HAB phenotype reversal by selective breeding 
To assess the phenotypic stability of HAB mice and estimate the remaining genetic 
variability in HAB mice after more than 20 generation of bidirectional and more than 
12 generations of strict inbreeding, the selection criterion of HAB mice (high anxiety-
related behavior – as reflected by the EPM test) was intended to be reversed (i.e. to 
selectively breed HAB mice for a less anxious phenotype). Therefore three HAB sib 
pairs were selected of generation 23, which were most non-anxious in the EPM test 
with spending more than 10% of the total test time on one of the open arms, and 
mated to each other, following the standard breeding procedure as already 
described (Kromer et al., 2005). Descendants of six consecutive generations were 
all tested on the EPM, always applying the reversed HAB (rHAB) criterion (reduced 
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anxiety-related behavior) for breeding. Additionally, 14 male mice of the 5th rHAB 
generation (G5) were tested in the TST. Throughout all seven generations two to 
four families were run in parallel. HAB mice descending from the rHAB parental 
mice served as reference. 
 
2.2. Identification of candidate genes 
For the identification of candidate genes relevant to anxiety-related and depression-
like behavior, gene expression profiling was carried out on two different microarray 
platforms, the MPI24K – the 2nd generation microarray platform of the Max Planck 
Institute of Psychiatry – and on a commercially available platform of Illumina (San 
Diego, CA). 
 
2.2.1. Animals and behavioral tests for the gene expression studies 
Mice for microarray analyses on both the MPI24K and Illumina platform were tested 
in both the EPM test and the TST. Only mice were selected for gene expression 
profiling that did not deviate more than 5% from their group means in any measure. 
HAB mice, displaying nearly no locomotion on the EPM were excluded from further 
analysis. For the MPI24K platform based microarray, mouse pools consisting of six 
HAB and six LAB mice each (G16) were compared. For the Illumina platform based 
experiment eight HAB, eight LAB (G25) and seven NAB mice (G3) were selected.  
Animals for the validation of microarray-based gene expression analyses were HAB 
and LAB mice from G22 - G27, unselected CD1 mice as well as NAB animals of G4. 
Both male and female mice were tested on the EPM. Male mice were additionally 
tested in the TST. 
 
2.2.2. Gene expression profiling on the MPI24K-platform 
The gene expression profiling system of the MPI24K array, which is an upgrade of 
the MPI17K microarray platform (Deussing et al., 2007), is based on dual color 
direct comparison experimental protocol using indirect labeling.  
 
2.2.2.1. Tissue dissection 
Anaesthetized animals aged ten weeks were killed by decapitation 3d after the TST. 
Brains were collected, dissected in slices of 200µm and mounted to Superfrost 
microscope slides (Menzel, Braunschweig, Germany) in a cryostat (Microm MH50, 
Microm, Walldorf, Germany) from rostral to caudal. From these frozen slices the 
brain areas of interest were acquired by micropuncture as described before 
(Palkovits, 1973) utilizing punchers with a diameter of 0.5 or 1mm (Fine Science 
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Tools, Heidelberg, Germany). The brain regions collected included the anterior part 
of the cingulate cortex (Cg), the nucleus accumbens core and shell (NAc), the PVN, 
the supraoptic nucleus (SON) and the basolateral/lateral (BLA/LA), central (CeA) 
and medial (MeA) amygdala. Punches of 1mm diameter were collected from 
Bregma +1.3mm to +0.9mm, twice sampling the tissue medially about 0.5mm from 
the dorsal tissue border to receive the Cg and bilaterally sampling the NAc core and 
unpreventably a minor part of its shell around the anterior commissure (Fig. 2A). 
Further tissue was collected medially 0.8mm above the ventral tissue limit (Ø=1mm) 
and bilaterally from the optic tract (Ø=0.5mm) to acquire tissue from the PVN and 
SON, from Bregma -0.56mm to -0.96mm (Fig. 2B). Amygdala tissue samples were 
collected bilaterally from two slides for each region acquiring punches of 1mm 
diameter. CeA was collected from Bregma -0.96mm to -1.36mm dorsomedially from 
the ventral end of the external capsule (Fig. 2C), MeA from -1.16mm to -1.56mm 
dorsolaterally from the optic tract and BLA/LA was collected from Bregma -1.36mm 
to -1.76mm from in between the bifurcation of the external capsule (Fig. 2D).  
 
 
 
Figure 2: Approximate locations in mouse coronal brain sections to acquire the (A) cingulate 
cortex and nucleus accumbens, (B) hypothalamic paraventricular nucleus and supraoptic 
nucleus, (C) central amygdala and (D) basolateral/lateral and medial amygdala. Pictures are 
based on the Mouse Brain Atlas (Paxinos and Franklin, 2001). 
 
Coordinates were selected according to the mouse brain atlas (Paxinos and 
Franklin, 2001) and are subject to vary ±0.05mm. 
A B 
C D 
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2.2.2.2. Total RNA isolation and amplification 
Total RNA was extracted in presterilized 1.5ml Safelock tubes (Eppendorf, 
Hamburg, Germany) using a TRIzol (Invitrogen, Karlsruhe, Germany) chloroform 
standard protocol. After tissue homogenization in 300µl of TRIzol by pipetting, 1µl 
linear acrylamide (5mg/ml, Ambion, Austin, TX) and 60µl of chloroform (Carl Roth, 
Karlsruhe, Germany) were added and the samples vortexed. Centrifugation for 5min 
at 18°C and 13,000rpm followed, then RNA was precipitated with 180µl isopropanol 
(Carl Roth) overnight at -20°C, centrifuged at 4°C and 13,000rpm for 30min and 
washed twice in 500µl 70% ethanol (Carl Roth) with centrifugation steps at 4°C and 
13,000rpm of 10min in between. Following the last centrifugation step, all remaining 
liquid was removed with a pipet, pellets were dried in an incubator for 15min at 45°C 
and resolved in 13µl of autoclaved bidistilled water.  
Extracted total RNA was amplified and dye coupled in two rounds with Ambion’s 
Amino Allyl MessageAmp aRNA kit (Ambion) according to the manufacturer’s 
protocol using T7 oligo(dT) primers for the first round to select specifically for mRNA 
for reverse transcription and random hexamer primers for the second round of 
reverse transcription. The procedure included the synthesis of a first then a second 
strand of cDNA and an in vitro transcription step overnight. cDNA synthesis was 
carried out in PCR tubes (Abgene, Hamburg, Germany) using a thermal cycler 
(GeneAmp PCR System 9700, PE Applied Biosystems, Foster City, CA). For in vitro 
transcription, the tubes provided by the kit’s manufacturer were used, after pipetting 
all reagents, tubes were sealed with parafilm (American National Can, Neenah, WI) 
and incubated at 37°C in a warm room constantly heated. In the second round of in 
vitro transcription, an amino allyl extension to every second uracyl base was 
incorporated to receive the amino allyl RNA (aRNA) for the following indirect dye 
coupling reaction. Before aRNA purification the filters were equilibrated with 100µl 
aRNA binding buffer and incubated for 5min. All samples were pooled to one 
sample per line and brain region. The dye swapped experimental design required 
coupling of one half of each pooled sample to cyanine 3 (Cy3, Amersham 
Biosciences, Buckinghamshire, UK) the other half to cyanine 5 (Cy5, Amersham 
Biosciences). Correct quantification of aRNA was ensured by photometric 
assessment of the optic density in a photometer (Ultrospec II, Pharmacia LKB 
Biochrom, Cambridge, United Kingdom) and additional analysis on agarose gel. 
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2.2.2.3. Array hybridization and quantification 
Prehybridization buffer: 
125ml   formamide 
62.5ml  20xSSC 
2.5ml   10% SDS  
2.5ml  BSA (10mg/ml) 
57.5ml water 
Hybridization buffer: 
 500µl   formamide 
 250µl  20xSSC 
 10µl   10% SDS  
 5µl   mouse-COT1-DNA (20mg/ml, Invitrogen) 
 40µl  poly adenylic acid (2.5µg/µl, Amersham Biosciences) 
Ten array slides per brain region (MPI24K Arrays, MPI of Psychiatry, Munich, 
Germany) – serving as technical replicates - were prehybridized prior to the 
experiment in the prehybridization buffer for 1h at 42°C, then washed in water and 
isopropanol and dried by centrifugation (Megafuge 1.0R, Heraeus, Hanau, 
Germany) at 1500g for 3min in 50ml tubes (Sarstedt). Dye coupled aRNA samples 
were mixed with the contrary dye coupled sample from the other mouse line of the 
specific regions and loaded with a hybridization buffer to five arrays each under m-
Series LifterSlips (Menzel). All arrays were hybridized at 50°C over 16-17h in 
separate hybridization chambers. Then arrays were washed in 2xSSC and 0.1% 
SDS for 5min at 42°C, 10min room temperature in 0.1xSSC and 0.1% SDS, four 
times in 0.1xSSC for 1min and finally for 20s in 0.01xSSC solutions. Slides were 
dried by centrifugation at 1,500rpm for 3min. Then, arrays were scanned on a 
PerkinElmer ScanArray 4000 (PerkinElmer Life and Analytical Sciences, Shelton, 
CT) laser scanner using automatic focusing and adapting laser power between 60 
and 80 for Cy3 and 40 and 70 for Cy5. This ensured that for both dyes - in average - 
the same fluorescence intensities were reached and that not more than 1-2% of 
spots showed fluorescence intensities over the point of saturation. Quantification of 
all arrays was performed with QuantArray-software (GSI Lumonics, Billerica, MA) 
applying a fixed-circle quantification protocol and manual positioning of all grids over 
the hybridized spots. To provide a negative control for the hybridization and 
evaluation procedure, excess aRNA was used for an additional hybridization in both 
Cy3 and Cy5 combinations. 
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2.2.2.4. Statistical analysis 
For statistical evaluation, analytic methods were applied as previously described 
(Dudoit et al., 2002; Yang et al., 2002). In brief, first an MA-plot was generated to 
display raw fluorescence intensities of Cy5 (R) and Cy3 (G) with M = log2 R/G and A 
= log2          . Data were normalized to exclude systematic and technical errors. For 
two normalization steps, a function c was subtracted from the logarithmized 
fluorescence intensities (log2 R and log2 G). First a global normalization was 
performed, based on the assumption that R and G correlate: 
kG
R
c
G
R
G
R
222 logloglog =−⇒ . 
In a second normalization step, an intensity-dependent normalization was added, 
which was performed applying a LOESS smooth, as it is implied in the R software 
package (http://www.r-project.org). This is calculated from: 
GAk
RAc
G
R
G
R
)(log)(loglog 222 =−⇒ ,  
where c(A) stands for the LOESS smooth of the MA-plot. From the MA-plot, 40% of 
values were used to calculate the smooth. In several other normalization steps, 
differences were minimized that resulted from unequal distribution of probes from 
the array production or from unbalanced fluorescence intensities within one array 
slide. All data were merged in a matrix, p-values for multiple testing were calculated 
by permutation and are therefore called adjusted p-values.  
 
2.2.3. Gene expression profiling on the Illumina-platform 
The MouseWG-6 v1.1 Expression BeadChip-system by Illumina (Illumina, San 
Diego, CA), provided a gene expression screening platform that could identify 
46,000 individual gene transcripts that were represented on each array (for each 
sample) between 10 to 30 times. This technology made the manual setup of 
technical replicates (as has been done with the MPI24K platform) obsolete and 
provided the opportunity of measuring individual samples combined with a single 
color labeling protocol that eliminated problems arising from basal differences in 
signal intensity due to different dyes. 
 
2.2.3.1. Tissue laser-microdissection 
Animals and the according brains were treated as described in 2.2.2.1. with the 
difference that 25µm slices were acquired in the cryostat (Microm). Only brain slices 
containing the brain areas of interest were sampled, including the anterior part of the 
Cg, the PVN, the SON, the anterior dentate gyrus (DG), the CeA and the basolateral 
RG
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amygdala (BLA). For the DG, the same coordinates as for the PVN and SON were 
applied. To cover the whole area of interest an overall depth of 400µm per region 
was chosen. While sampling the CG, BLA and CeA four brain slices were mounted 
onto an LMD6000 metallic frame slide covered with a membrane of polyethylene 
terephthalate (Leica Microsystems Deutschland, Bensheim, Germany), the following 
four to Superfrost slides (Menzel). This procedure was repeated for the next eight 
slices. For the region containing the PVN, SON and DG only two slices were 
mounted to one slide always alternating the LMD6000 frame and the Superfrost 
microscope slides. Only the LMD6000 slides were used for further processing and 
stored at -80°C. Right before laser-microdissection, brain slices on the LMD6000 
frame slides were stained with cresyl violet applying a modified staining protocol that 
included 1.5min staining in cresyl violet, followed by washing in 70% and 96% 
ethanol for 20s each and in isopropanol for 5min. The slides were refrozen and 
processed at the laser-microdissection microscope (AS LMD, Leica, kindly provided 
by PD Dr. Gabriele Rieder at the Max von Pettenkofer Institute of the Medical 
Faculty of the Ludwig Maximilians University in Munich). For the dissection 
procedure of the required brain areas, a magnification of 100x was chosen with 
laser power between 80-100% and speed varying between 1 and 4. Cut-out brain 
areas were captured in the caps of 0.2ml PCR soft tubes (Biozym Scientific, 
Hessisch Oldendorf, Germany) and cooled on dry ice immediately after completion 
of one brain region. Pictures of the processed brain slices were acquired by means 
of the IM1000 software (Leica, see Fig. 14). 
 
2.2.3.2. Total RNA isolation and amplification 
From all samples, total RNA was extracted individually (one sample per mouse and 
brain region) as described in chapter 2.2.2.2. RNA was amplified and labeled using 
the Illumina TotalPrep RNA Amplification kit (Ambion) with only one round of in vitro 
transcription, where biotinylated uracyl bases were built in to the newly synthesized 
aRNA. 5µg per sample were required for loading to the microarray slides. Correct 
quantification was ensured by measurement of optic density in a NanoPhotometer 
(Implen, Munich, Germany) and additional analysis on agarose gel. Samples not 
fulfilling all criteria of homogeneity (inadequate concentrations, too many small but 
few larger aRNA fragments) were excluded from further analysis.  
 
2.2.3.3. Array hybridization and quantification 
Each microarray slide had the capacity for six samples, same brain regions were 
hybridized in the same batch comparing a maximum of six individual mice of each 
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breeding line. Reagents and material were provided by Illumina, the procedure was 
strictly conducted according to the manufacturer’s protocol. In brief, each sample 
was mixed with hybridization buffer, loaded onto the designated array field and the 
slides were put into hybridization chambers and incubated for 17h in incubation 
chambers provided by Illumina. Arrays were washed in several steps, incubated with 
Cy3, washed several times again and dried by centrifugation. Finally, fluorescence 
signals were detected on a BeadStation scanner (Illumina) and analyzed by the 
BeadStudio (Illumina) software. The manufacturer's built-in controls have been 
analyzed including hybridization controls and sample dependent parameters. Only 
microarrays fulfilling Illumina's recommendations for quality control have been used 
for further evaluation. 
  
2.2.3.4. Statistical analysis 
Illumina BeadStudio gene expression results were further analyzed similar to the 
statistical analysis as described in 2.2.2.4. All analyses have been performed using 
R-packages, based on ‘beadarray’ system as described by Dunning et al. (2007), 
which simplifies the comparison between a high number of arrays. First, pair wise 
box plots were generated to compare mean expression within each line and brain 
region. Normalization for expression values has been applied to all samples with the 
‘QSpline’ function. Each sample has been clustered to ensure that each brain region 
per line shows similar expression patterns using the ‘hclust’ function. Three samples 
from different brain regions have been identified as inadequate during the scan 
process and have therefore been excluded from further analysis. For differential 
expression analysis, functions of the ‘LIMMA’ package have been applied on log2-
transformed values. The resulting matrix has been used for all subsequent analyses. 
Significantly regulated genes were ranked using an empirical BAYES method 
implemented in the LIMMA R-package (Lonnstedt and Speed, 2002; Smyth, 2004).  
 
2.2.4. Analysis of candidate genes by quantitative PCR 
Candidate genes for anxiety-related behavior and for further characterization were 
picked from the gene expression screening analyses according to their p-values (p < 
0.1) and relative expression. Gene transcripts showing high (around 2-fold) 
expression differences in all brain regions between HAB and LAB mice were 
selected, as well as some other transcripts that were already described in 
connection to anxiety-related behavior, but were only detected as significantly 
regulated in only two or three brain regions. For analysis by qPCR, tissue samples 
for the Cg, PVN, SON, CeA and BLA/LA were acquired by micropuncture as 
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described in chapter 2.2.2.1. For whole brain analyses, three coronal sections of 
200µm were taken at different brain levels. Total RNA extraction from both, 
micropunches or representative whole brain material was performed as described in 
chapter 2.2.2.2. before, but using TRI-Reagent (Sigma-Aldrich) instead of TRIzol. 
The yield of total RNA was between 0.3 and 1.5µg. A maximum of 1µg of total RNA 
was reverse transcribed with Superscript II (Invitrogen, Karlsruhe, Germany) after 
DNAse treatment according to the manufacturer’s protocol. For quality control, a 
small aliquot of each cDNA was analyzed on an agarose gel. For expression 
analysis of unspliced Avp, primers were designed to detect a sequence from the first 
intron and RNA was reverse transcribed using random hexamer primers and three 
samples of HAB and LAB aRNA each from the experiment described in 2.2.2.2. 
cDNA of male or female HAB, unselected CD1 mice, or LAB mice was analyzed by 
qPCR, using the QuantiFast SYBR Green PCR Kit (Qiagen GmbH, Hilden, 
Germany) according to the manufacturer’s instructions, the respective 
oligonucleotide primers were designed based on Primer3 (Rozen and Skaletsky, 
2000) and purchased from Sigma-Aldrich. The same applies to primers for the 
detection of specific splicing variants of Tac1. For this, primers had to hybridize to 
half of one and half of the following exon. Amplificates from the Tac1 splicing variant 
and intronal Avp detection were additionally sequenced. The procedure is described 
in the following chapter 2.3.5. Gene products to be quantified by qPCR were 
selected by the following criteria: significant expression differences between HAB 
and LAB mice (adj. p-value < 0.10, fold regulation at least 1.3 fold and differential 
expression in the microarray experiment (in most cases) for all or some (at least 
three) analyzed regions. All primers for qPCR are listed in table 1. Experiments were 
performed in duplicates on the Lightcycler®2.0 instrument (Roche Diagnostics, 
Mannheim, Germany) under the following PCR conditions: Initial denaturation at 
95°C for 10min, followed by 40 cycles of denaturation (95°C for 10s) and a 
combined annealing and extension phase (60°C for 30s). At the end of every run, a 
melting curve (50-95°C with 0.1°C/s) was generated to ensure the quality of the 
PCR product. Crossing points (Cp) were calculated by the LightCycler®Software 4.0 
(Roche Diagnostics) using the absolute quantification fit points method. Threshold 
and noise band were set to the same level in all compared runs. Relative gene 
expression was determined by the 2-∆∆CT method (Livak and Schmittgen, 2001) 
using the real PCR efficiency calculated from an external standard curve. Cp were 
normalized to the housekeeping genes Gapdh, Hprt1, Atp2b1, Rpl13a and Polr2b or 
any combination of two of the mentioned genes. Fold regulation values were 
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calculated relative to the expression mean of the group displaying the lowest 
expression.  
 
Table 1: List of primers for qPCR with chromosomes and exons the primers hybridized to.  
In-1 refers to the first intron. List is sorted alphabetically according to the gene symbols. A 
clear exon definition was not possible for the first two genes. 
 
Chr. Gene 
symbol 
Orient-
ation 
 
Exon 
 
Primer sequence  
5'3' 
Prod. 
size 
forward  TTG GAA ACC TTC CTT TGC AG 2 2900019 G14Rik reverse  AAA CAC ATT CAC CCC CAT TC 175bp 
forward  TAT GAA ATG GAA TAC ACC GAA GG 1 5230400 G24Rik reverse  ATC TGC TGG TCT TGA AAA TGA AA 210bp 
forward 47 CAT CAG CTT CGA GGA AGA GC 2 Abca2  
reverse 48 CAT TCG GGG AGG ATG GTA G 206bp 
forward 9 TCC TGC TGA AGC AGT TCA AC 11 Aldh3a2 
reverse 10 ACA GGG AAG TCC ACC AGA TC 157bp 
forward 13 TTC TCT CCT TCC TGG CTG TG 7 Apbb1  
reverse 14 GAC ACT TCT GGT AGC GGA GC 162bp 
forward 1 CAT TAC GGA AAA TAC AGG AGA GC 10 Atp2b1 
reverse 2 TGC TTC CCA GAC TAA CTG AAG AA 182bp 
forward 4 TAT TGG CCC AGA GTA TCA GCA 16 Atp5j 
reverse 5 GGG GTT TGT CGA TGA CTT CAA AT 
134bp 
forward In-1 TTC CTT ATG ACT GGG CTT GG 2 Avp 
reverse In-1 GCA CTG CTG GCT AGA AAA GG 170bp 
forward 1 TCG CCA GGA TGC TCA ACA C 2 Avp 
reverse 2 TTG GTC CGA AGC AGC GTC  164bp 
forward 1 AAG AAG AGG ACG AAG TGG AAT G 11 Ccdc104 
reverse 2 TCT TGA TGG ATT TCT GTG TAG G 
180bp 
forward 1 AGG TGT CCA AGT TTC GGC ATA 16 Coro7 
reverse 2 GCA GCT TGA TTT GAT GTG GTT 113bp 
forward 1 CTG CGC GGG TAC TTA GGA GT 14 Ctsb 
reverse 2 CAG GCA AGA AAG AAG GAT CAA G 148bp 
forward 27 GGA GCC TCC TCT GGA TTG TA 14 Dgkh 
reverse 29 AGT GTG ACC ACC CCT CAG AC 211bp 
forward 22 TAC AAG GTG GGC TAC GCT CT 5 Dgkq  
reverse 23 CAA GGT GTC CAC TCG GGT AT 188bp 
forward 3 TGC CCA TCC TAA TCT AAC GG 17 Enpp5 
reverse 4 GGA TGC ATT TCT GCT AAT GC 186bp 
forward 1 GGT GCA AGC GAA CGG GAT AG 5 Ep400 
reverse 2 GAC TGG CTG ATG GAG CGA AAG 202bp 
forward 3 CCA TCA CCA TCT TCC AGG AGC GAG  6 Gapdh 
reverse 4.5 GAT GGC ATG GAC TGT GGT CAT GAG  227bp 
forward 8 CAG GAG AGC AGA GAC AGC AC 3 Gig1 
reverse 9 AAT GGC TCA GTC AAT GAA CC 185bp 
forward 6 CAT GGA GGA GAG CAA AGC AC 19 Gnaq  
reverse 7 GGT TCA GGT CCA CGA ACA TT 178bp 
forward 1 CCT GTG GGG AAA GGT GAA C 7 Hbb-b1  
reverse 2 GGC CTT CAC TTT GGC ATT AC 148bp 
forward 5 AGG TGC TAA GGG GAA GAA GG 9 Hmgn3  
reverse 6 GTC CCG AGA GGT ACG TGA AA 171bp 
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Chr. Gene 
symbol 
Orient-
ation 
 
Exon 
 
Primer sequence  
5'3' 
Prod. 
size 
forward 8 GTC AAG GGC ATA TCC AAC AAC AAA C X Hprt1 
reverse 3 CCT GCT GGA TTA CAT TAA AGC ACT G 240bp 
forward 10 ACG CCC TTC AGA AAG TGC TA 1 Kcnh1  
reverse 11 GTG GTC AGG AGG CAG GAT AA 182bp 
forward 1 ACG ACC AGA CAC GGA ATG TAA 3 Mbnl1 
reverse 2 CGC CCA TTT ATC TCT AAC TGT GT 168bp 
forward 1 CCG AGA TGC AGA GTT TCT ATG G 8 Mmp15 
reverse 2 TGA AGG TCA GGT GGT AAT TGT TC 189bp 
forward 1 CTA AGC GTC ACC ACG ACT TC 8 Mt1 
reverse 2 GCA CTT GCA GTT CTT GCA G 157bp 
forward 1 GCT CTA TCT CTG CTC GTG TGT TT 6 Npy 
reverse 2 GTG TCT CAG GGC TGG ATC TCT 175bp 
forward 9 TCG AAG CCA TAG AAG CCA GT 14 Pdhb  
reverse 10 AGG CAT AGG GAC ATC AGC AC 173bp 
forward 9 CAA GAC AAG GAT CAT ATC TGA TGG 5 Polr2b 
reverse 7 AGA GTT TAG ACG ACG CAG GTG 157bp 
forward 1 ATA ACA GAG GGT GCT TCG ATT CT 3 Ppp3ca 
reverse 2 ACA CAC ACC ACC GAC AAG AG 158bp 
forward 16 AAC AGT GAG GAG CAG CCA GT 14 Pxk 
reverse 19 GGT AAT GCT GAA GAC AGT CC 161bp 
forward 8 GCC TTT CTT GCC TCT TCC TTT 7 Rab6 
reverse 8 GCT CAT AGC CTG GAG CTG TC 244bp 
forward 8 CAC TCT GGA GGA GAA ACG GAA GG 7 Rpl13a 
reverse 10 GCA GGC ATG AGG CAA ACA GTC 
181bp 
forward 9 ACC GAA TGC AGG AAG ACA TC 2 Slc1a2 
reverse 10 AAT TGG CTG AGA ATC GGG TC 221bp 
forward 1 CAT GGC CTC TGT GCT GTC CTA C 15 Slc25a17 
reverse 2 GAA GCC GAA GTC TAG CAG TAT CCA 139bp 
forward 1 CAA TAC TTT TAA CCC TGC GAA GC 5 Smarcd3 
reverse 2 GTC CAA CTC AAT GAC CAA ACT CT 154bp 
forward 24 GCC CAG ACC ATC AAA CAA CT 19 Spnb3 
reverse 25 TCA CGC TCC TGT ATC CAC TG 221bp 
forward 10 CTT CTA CCA TTG GGG GCA TA 19 Stx3  
reverse 11 TGC CCT GTG TTG TGA GTT TC 145bp 
forward 1 GGC CAA GGA GAG CAA AGA G 6 Tac1 
unspecific reverse 2 ACA GTT GAG TGG AAA CGA GAA  127bp 
forward 1 CAT CCC TTC TTC AGC CAG AG 5 Tmem132d 
reverse 2 AGT GAG AAC CGC TGA ATG CT 187bp 
forward 3 AGT ATT GGC CGC AAA AGA GA 3 Tpd52 
reverse 4 CTG AGC CAA CCG ATG AAA AT 194bp 
forward 1 TCG GGA AAT ACT TAC TGT TGG AG 12 Trib2 
reverse 2 AGC TTC GCT CAA AGA ACA CAT AG 219bp 
forward 13 ATC AGT GTG TCC ATG CCT GT 17 Ttbk1 
reverse 14 ACT GTT TGG GAC GGA GGT C 148bp 
forward 1 CCT CGC TGG ACT GGT ATT TG 18 Ttr 
reverse 2 TTA CAG CCA CGT CTA CAG CAG 121bp 
forward 5 TCT GAA AGA CAG ATG GAA TGC C 7 Uros 
reverse 7 CCA CAC GGA AAG AGA AGA GGC 174bp 
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Chr. Gene 
symbol 
Orient-
ation 
 
Exon 
 
Primer sequence  
5'3' 
Prod. 
size 
forward 1 GTC CTC AAG GTC ACA CAA TTA GTC 11 Zfp672 
reverse 2 CAG ACA TGA GTG TAG GGT GCA AG 
207bp 
forward 3/4 CAA GCG GGA TGC TGA TTC  
forward 3/5 AAG CGG GAT GCT GGA CAT  
reverse 5/7 GCC ATT TTG TGA GAG ATC TGG  
6 
Tac1 
specific to 
splicing 
variants reverse 6/7 CGC TTC TTT CAT AAG CCA CAG  
    
 
 
 
2.2.5. Assessment of candidate gene functions 
Similarly to the candidate genes analyzed by qPCR, for some genes the protein or 
peptide level, its activity or capability for manipulation was assessed. Also basic 
metabolic parameters were analyzed in HAB and LAB mice, as many of the 
ostentatious candidate genes were part of metabolic pathways (many kinase, 
phosphatase and carrier-coding proteins). 
Glyoxalase I (GLO1), as an example was identified to be expressed at different 
levels between HAB, CD1 and LAB mice, with HAB animals displaying the lowest 
and LAB mice the highest concentration of the protein, not only in the brain, but 
even in red blood cells (Kromer et al., 2005; Landgraf et al., 2007). As the present 
study revealed that this is also true for mRNA expression (not exclusively to the 
protein), together with the ubiquitous expression differences of some other proteins 
connected to metabolism, first blood plasma concentrations of lactate and other 
blood plasma parameters related to metabolism were assessed, followed by a 
metabolism challenging behavioral manipulation study using CD1 mice to examine 
the effects of higher calorie intake.  
As also different transcript variants for tachykinin 1 (Tac1) are known and have been 
investigated using qPCR, also a subsequent detection and quantification of the 
peptides encoded by these transcript variants has been performed to investigate 
how gene expression differences translate into peptide levels.  
Furthermore, as many subunits of cytochrome c oxidase (COX) were differentially 
expressed between HAB and LAB mice in a variety of brain regions, the complete 
enzyme’s activity has been measured in HAB vs. LAB brains to elucidate the effects 
of differential expression of COX-subunits on overall COX activity. Moreover COX 
activity also serves as a long-term cellular activity marker as it’s a vital part of the 
enzymatic system forming ATP. Additionally, it has also been demonstrated that a 
decrease in COX activity is associated with reduced mRNA expression (Christen, 
2000; Simonian and Hyman, 1993).  
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2.2.5.1. Glyoxalase I (GLO1) and metabolic stimulation 
As metabolic factors seemed to show differences, first some metabolic and 
metabolism-related blood plasma parameters were investigated followed by a 
metabolic manipulation experiment. Glo1 encodes for a detoxifying enzyme, that 
eliminates methylglyoxal, a destructive byproduct from the citrate cycle. As reported 
by a previous study (Kromer et al., 2005) and confirmed in this study, the enzyme is 
ubiquitously overexpressed in LAB mice, whereas HAB mice rather show a deficit of 
this enzyme. So, if basic metabolic processes are involved in shaping the anxiety-
related phenotype, an artificial imbalance in the metabolic system should influence 
the behavioral phenotype.  
 
2.2.5.1.1. Metabolism and blood plasma parameters 
Characterizing the metabolic system of HAB and LAB mice, first food intake was 
monitored in single-housed HAB, LAB and CD1 mice aged nine weeks (ten per line), 
measuring the amount of food in gram (standard diet, Altromin, Lage, Germany), 
that was consumed over a period of six days. 
Blood plasma analysis of ten HAB and nine LAB animals (aged ten weeks each) 
was performed from trunk blood. Blood was sampled via decapitation of the animals 
after anesthesia in isoflurane (Forene, Abbott, Wiesbaden, Germany) into EDTA-
coated tubes (KABE Labortechnik, Nürnbrecht-Elsenroth) and immediately 
centrifuged at 4°C and 400rpm for 10min. Plasma was separated and kept on ice. 
Blood plasma concentrations of L-lactate, cholesterol, triglycerides, high- (HDL) and 
low- (LDL) density lipoproteins were assessed using commercially available kits 
(Roche Diagnostics) according to the manufacturer’s instructions.  
 
2.2.5.1.2. Behavioral manipulation via metabolism 
44 CD1 mice were purchased from Charles River (Sulzfeld, Germany) aged four 
weeks and single-housed upon arrival. Bodyweight, food and water consumption 
were measured every two to three days. After one week habituation time to the new 
location and housing conditions, water was replaced by an 0.5M saccharose 
solution for every second mouse, with changing to a fresh saccharose solution every 
second time of measurement. EPM and OF testing was carried out in these animals 
aged ten weeks. Three days after testing, six mice per group (treatment vs. control) 
were sacrificed for blood plasma and urine osmolality analysis with an osmometer 
(Vogel, Gießen, Germany) as well as for GLO1 protein concentration measurement. 
Saccharose feeding was continued until all mice were aged 14 weeks with a 
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repetition of the EPM and OF testing. Then all animals were sacrificed for the 
analysis of GLO1 protein concentration by Western blot from red blood cells.  
 
2.2.5.1.3. Western Blot analysis of glyoxalase 1 (GLO1) 
Required solutions: 
4x sample buffer for protein gels 
1.25ml  1M Tris; pH = 6.8 
4.6ml   20% SDS 
0.6g  dithiothreitol DTT  
 4ml   glycerol (100%) 
0.001% bromphenol blue   
Mix and add H2O to 10ml. 
Transfer buffer without SDS 
 12g   Tris  
60g   glycine 
800ml  methanol 
Mix and add H2O to 4000ml. 
1x TBS 
8g   NaCl 
2.43g   Tris 
0.05ml  Tween 20 
Mix and add H2O to 1000ml. 
100µl of red blood cells, settling at the bottom of EDTA-coated tubes after 
centrifugation, have been transferred to 15ml tubes and washed three times in 
1xPBS (phosphate buffered saline). After centrifugation at 2,500rpm at 4°C for 5min, 
the supernatant was removed. Then samples were kept at -80°C until further 
processing. Pellets were then transferred to 1.5ml tubes and 400µl of cold water 
containing 1mM PMSF (phenylmethanesulphonyl-fluoride) as a protease inhibitor 
were added. After centrifugation, the supernatant was transferred to a fresh tube. 
For protein quantification by Bradford protein assay 1:100 dilutions were prepared. 
Concentrations were assessed by calculation to a standard curve based on bovine 
serum albumin (BSA). Concentrations (i.e. optic density) were assessed in 96-well 
microtiter plates in an ELISA reader Dynatech MR5000 (Dynatech Laboratories, 
Denkendorf, Germany) at 595nm wavelength.  
100µg of total protein mixed with 5µl of 4x sample buffer and the volume filled up to 
25µl with water were loaded to a combined stacking and separating polyacrylamide 
gel that was prepared in a gel pouring frame by Bio-Rad (Bio-Rad, Hercules, CA). 
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Gels were electrophorized at 150V for 45min in 1xTGS (Tris/glycine/SDS) buffer 
(Stock 10xTGS, Bio-Rad). Before blotting to the polyvinylidene difluoride (PVDF) 
membrane, the membrane was briefly incubated in methanol and in water then the 
transfer chambers were laid into transfer buffer. On layers of sponges and filter 
paper, first the polyacrylamide gel was placed onto the black side (negative pole) 
and covered with the PVDF membrane. Transfer to PVDF membrane was 
performed in the blotting apparatus (Criterion blotter, Bio-Rad) at 100V for 1h with 
water cooling and changing of cooling packs after 30min). Membranes were blocked 
with 5% milkblock (2.5g milk powder + 50ml TBS-T) at 4°C overnight on a shaker. 
After rinsing them in TBS-T, they were incubated with an anti-glyoxalase-I antibody 
(10µl/30ml TBS-T plus 5% milk powder; the antibody was kindly provided by Dr. 
Kenneth Tew, Fox Chase Cancer Center, Philadelphia, PA) for 2h at room 
temperature on a shaker. The membranes were washed five times with water, then 
about three times for 15min with TBS-T followed by the incubation with the 
secondary antibody protein A horseradish peroxidase from Amersham Biosciences 
(1µl/10ml TBS-T) for about 40min and shaken at room temperature. Again 
membranes were washed five times in water, then for 1h in TBS-T with changing to 
a fresh solution every ten minutes. Finally the membranes were incubated in ECL+ 
solution (Amersham Biosciences) for 5min and fixed in a film cassette. Before 
developing, the film (ECL Film, Amersham Biosciences) was placed in ruby light on 
the membranes for 5min. Films were scanned, signal intensity of the GLO1 bands 
was determined using the Scion Image software (Alpha 4.0.3.2; Scion, Frederick, 
MD).  
 
2.2.5.2. Tachykinin 1 (Tac1) encoded peptide quantification 
Required solutions (all data on percentage is volume-based): 
Solvent A: 
 100%   50mM potassium phosphate buffer, pH=2.5 
Solvent B:  
70%   acetonitril 
 30%   37mM potassium phosphate buffer, pH=2.5 
PBS-T: 
99.05%  1x phosphate buffered saline (PBS), pH=7.2 
0.05%  TWEEN 20 
Blocking buffer: 
3%   BSA 
96.98% PBS-T  
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0.02%  sodium azide 
Based on the qPCR results, the following question was how the differential 
expression of single splicing variants translates into peptide levels. Therefore high 
performance liquid chromatography (HPLC) was applied to first separate fractions 
with the respective peptides and then to identify them in an enzyme-linked 
immunosorbent assay (ELISA) with an antibody specific for the last five amino acids 
of tachykinin peptides.  
Brains of female HAB, CD1 and LAB mice (twelve each) were harvested, the PVN 
and BLA/LA were dissected as described in chapter 2.2.2.1. For peptide extraction, 
tissue punches were lysed in 50µl of boiling 5% acetic acid by gentle shaking at 
95°C for 30min in a thermomixer (5436, Eppendorf, Hamburg, Germany). After 
chilling the samples on ice for 10min, samples were sonified (Sonifier Cell Disruptor 
B15, Branson Ultrasonics, Danbury, CT) using 15 impulses twice and frozen at -
80°C overnight. Then, lysed tissue was centrifuged at 4,000rpm and 4°C for 20min 
after thawing on ice, the supernatant was separated and centrifuged again under the 
same conditions for 10 min. Again only the supernatant was kept and concentrated 
to a volume of 12µl at 45°C (Concentrator 5301, Eppendorf). For reversed phase 
HPLC (rpHPLC), all instruments (HPLC Series 1100) were manufactured by Agilent 
Technologies (Böblingen, Germany) and used with C-18 columns (EC550/2 
Nucleosil 300-5 C18, Macherey-Nagel). For fractioning of the samples a gradient 
protocol was applied (see table 2). Specific elution time for each peptide was 
determined by analysis of 5µg of each peptide and a mixture of 0.2µg of each 
peptide (SP, NKA, NKB, NPK and NPγ) in a solution of 12µl 5% acetic acid. Details 
of the elution protocol are documented in table 3 with the respective fractions 
sampled.  
Table 2: The gradient protocol of solvents for rpHPLC fractioning of peptide extractions from 
the BLA/LA and the PVN.  
 
Step Time [min] Solvent A Solvent B Flow rate µl/min 
1 0 100% 0% 200 
2 10 72% 28% 200 
3 70 43% 57% 200 
4 75 0% 100% 200 
5 76 100% 0% 200 
6 96 100% 0% 50 
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Table 3: Elution protocol of tachykinin peptides during rpHPLC. Not further required 
fractions, like from steps 2 or 8 were discarded later.  
 
Step Time [min] Elution period [min] 
Total elution 
volume [µl]  Peptide 
1 18.5 3 600 NPγ 
2 21.5 2 400  
3 23.5 3 600 NKA 
4 26.5    
5 29 6 1200 SP 
6 35    
7 40 5 1000 NPK 
8 45 2 400  
9 47 5 1000 NKB 
10 52 4 1200 X 
 
Further processed samples were transferred from U96 MicroWell plates (Nunc, 
Wiesbaden, Germany) to 1.5ml tubes and concentrated to a volume of 5µl.  
ELISA was prepared and performed on F96 Immobilizer Amino plates (Nunc), with 
measuring one standard curve for each peptide in eleven concentrations from 2 to 
400 pg/µl. Samples were diluted to a total volume of 100µl in sodium carbonate 
buffer (100mM, pH=9.6), sealed and incubated overnight at 4°C under gentle 
shaking (Polymax 1040, Heidolph Instruments, Schwabach, Germany). After 
washing all wells three times with 200µl PBS-T, plates were sealed and incubated 
for 5h at 4°C on a shaker with 300µl blocking buffer in each well. After incubation, 
samples were washed with 200µl PBS-T each and incubated overnight at 4°C on a 
shaker with 100µl of a 1:700 dilution of the primary antibody (rat monoclonal 
[NC1/34 HL] to substance P, Abcam, Cambridge, UK) in blocking buffer. Samples 
were subsequently washed four times in 200µl PBS-T and incubated in 100µl of a 
1:1000 dilution of the secondary antibody (goat polyclonal to rat IgG – H&L AP; 
Abcam) in blocking buffer for 4h at 4°C on a shaker. Washing was repeated four 
times and incubation with 100µl of an alkaline phosphatase chromogen, p-
nitrophenyl phosphate (pNPP, 1µg/µl) followed. Optic density was assessed after 
20, 30, 40 and 60min after addition of pNPP in the Dynatech MR5000 ELISA reader. 
Blank value means were subtracted from each individual value per plate, individual 
values per plate were normalized based on control measurements on each plate. 
Based on the standard curves for each peptide, absolute quantity of material [mol] 
could be calculated.  
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2.2.5.3. Cytochrome c oxidase (COX) activity 
Required solutions: 
0.1M phosphate buffer pH 7.4: 
 22.8g   NaH2PO4 
 115g   Na2HPO4 
 add H2O to 2000ml. 
4% PFA (paraformaldehyde): 
Dilute 20% paraformaldehyde to 4% with 0.1M phosphate buffer 
Cytochrome c / DAB solution: 
140mg  3,3-diaminobenzadine (DAB) 
 50mg   cytochrome c 
 11.11g  saccharose 
 50mg  nickel ammonium sulfate 
 50ml  0.1M phosphate buffer 
Brains of six basal HAB and LAB mice each were prepared as described before in 
2.2.2.1. Brains were sectioned to 40µm slices, with keeping the same sections as in 
2.2.2.1. Microscope slides containing the brain sections were stained during 
incubation for 2h at 37°C in the cytochrome c / DAB solution, protected from light 
and under mild shaking. Brains were then washed for 10min in 0.1M phosphate 
buffer on ice, followed by fixation for 30min in 4% PFA. Then washing was 
continued by washing the slides twice in 0.1M phosphate buffer for 5min, in 50% 
ethanol for 1min, in 70% ethanol for 1min, in 96% ethanol for 1min followed by 5min 
in isopropanol and finally by 10min in Roti-Histol (Roth). Slices were embedded in 
Roti-Histokitt (Roth) and covered by cover slips. Slides were captured using a 
binocular camera system with the same settings for all slides (Leica). Quantification 
of each slide was performed using Scion Image.  
 
2.3. Identification of polymorphisms 
Most studies on mouse genetics focus on mice from inbred strains. They are 
supposed to have the same genetic configuration and the only thing differing 
between individuals is probably their hierarchical status, if they are not single-
housed. Nevertheless, even these mice acquire different experiences during their 
development and interpret similar stimuli as more or less pleasant or harmful. The 
other advantage of studying inbred mice is that there is a lot known about variations 
occurring in the genes of these mouse strains. About 25,000 SNPs are known to 
exist if a variety of inbred strains is compared only on a middle-sized chromosome 
like chromosome 10 (MGD).  
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Unfortunately less is known about the occurrence of polymorphisms and other 
variations in outbred mouse strains. Although their frequency would be lower, as 
compared to wild mice, up to date, nearly no information about their genetic 
variability is available (Chia et al., 2005). Therefore, a better genetic characterization 
of outbred stocks is urgently needed, with the following experiments contributing to 
this issue. However, as the focus of the present experiments lies on the genetic 
background of anxiety-related behavior, the main interest was to identify genetic 
polymorphisms in a variety of candidate genes that are associated with the anxiety-
related phenotype.  
 
2.3.1. Animals and behavioral tests 
For SNP screenings, i.e. the determination of the frequency of polymorphisms, 
animals used were unselected male (N = 77) and female CD1 (N = 165) mice, 16 
male and female HAB and LAB mice (the grandparental generation of the HABxLAB 
F2 intercross mice), 18 male and female heterozygous HABxLAB F1 intercross mice 
(referred to as F1) and 521 male HABxLAB F2 intercross mice (referred to as F2). 
These mice have been phenotyped (except for the female CD1 mice) in a broad test 
battery, including EPM and TST.  
DNA samples from two HAB and LAB mice from G18 or higher were used for the 
detection of polymorphisms by sequencing, as they don’t show all the variation in 
CD1 mice, but represent the variation responsible for the phenotypic variance. For 
most genomic variations, they should have a homozygous state and are therefore 
easy to detect.  
 
2.3.2. DNA isolation  
required reagents: 
Tail buffer: 
 20ml   20xTris; pH = 8 
 80ml  0.5M EDTA 
 8ml   5M NaCl 
 20ml   20% SDS 
Mix and add H2O to 400ml. 
TE buffer: 
1.21g   Tris; pH = 8 
0.37g  EDTA 
Mix and add H2O to 1000ml. 
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DNA was isolated from mouse tail tips (about 6mm) were sampled after euthanasia 
of the animals. Tail tips were kept on -20°C until DNA isolation. For DNA isolation 
the NucleoSpin Tissue (Macherey-Nagel) kit was applied according to the 
manufacturer’s instructions. Alternatively, for smaller sample amounts (e.g. for 
sequencing), DNA was isolated from the tail tips by starting with a digestion by 
adding 10µl of proteinase K (20mg/ml) and 700µl of tail buffer to the tail tips and 
incubating them at 56°C in a thermo-shaker (Eppendorf) for 3h. After vortexing, 
300µl of a saturated NaCl solution (7M) were added to the samples that were 
vigorously shaken afterwards and centrifuged at 13,000rpm for 10min. 750µl of 
supernatant were transferred to fresh tubes and 500µl of isopropanol were added. 
Then samples were mixed again manually and centrifuged for 5min at 13,000rpm 
followed by one wash step with 500µl of 70% ethanol. After a final centrifugation 
step at 13,000rpm for 5min, all liquid was removed and the pellets were dried at 
65°C for 5-10min. Then pellets were dissolved in 100µl of TE buffer and DNA 
quantity and quality were assessed by photometric measurement (Nanophotometer, 
Implen or Ultrospec II, Pharmacia LKB Biochrom, Cambridge, United Kingdom).  
 
2.3.3. Prescreening  
To receive an overview of SNPs available as specific markers for HAB and LAB 
mice that would further provide the basis of genotype-phenotype associations in F2 
mice, 16 male and female HAB and LAB mice, 18 F1 and 34 F2 mice were 
genotyped. For SNPs, where HAB and LAB mice would show the opposite genotype 
homozygously (AA vs. BB), F1 mice should show only a heterozygous genotype 
(AB), for biallelic markers. To assess a large number of SNPs, the Mouse Medium 
Density Linkage Panel (Illumina) was chosen to allow the determination of 1449 
genotypes simultaneously. DNA samples were all prepared in 96 well plates (Nunc) 
and diluted to a concentration of 50ng/µl. Random inspection of every tenth sample 
on agarose gel was performed to ensure DNA quality and quantity. Samples were 
processed according to the manufacturer’s instructions as described in the Illumina 
Golden Gate Assay for Sentrix Array Matrix workflow sheets. After purification and 
sequence amplification, samples were hybridized from a 96-well plate to probes 
placed on top of fiber bundles (Fig. 3).  
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Figure 3: Illumina Sentrix Array Matrix (for GoldenGate Assay). (A) The upper side of the 
array matrix, this side is scanned. (B) Bottom side of the array matrix, probes were fixed 
here and the samples hybridized. (C) Scan picture of one fiber bundle.  
 
Fluorescence signals of hybridized samples were captured in the Illumina 
BeadStation, genotypes were called from fluorescence intensity clusters using the 
Illumina BeadStudio software Ver. 3.1.0.0, with the genotyping module Ver. 3.1.12. 
All intensity clusters were inspected individually and adjusted manually, if 
necessary. Analysis of genotypes focused on the detection of valid genotypic SNP 
markers to distinguish between HAB and LAB mice.  
 
2.3.4. Screening of the F2 panel and CD1 mice 
Based on the prescreening experiment (as described in chapter 2.3.3.) a custom 
designed oligo pool (384 SNPs) was set up for genotyping all 521 F2 mice, 32 HAB 
and LAB mice as well as 77 CD1 mice, to receive further insight into the distribution 
of genotypes in unselected outbred CD1 mice, i.e. the progenitors of the HAB and 
LAB lines. The custom designed oligo pool was designed to work on the Illumina 
GoldenGate Assay-based Sentrix Array Matrix 250 SNPs were added, which were 
identified in the screening from the previous chapter (table 2). Two further 
polymorphisms have been identified between HAB and LAB mice, resulting in 
qualitative differences in the enzyme enolase-phosphatase 1 (coding gene is 
referred to as Enoph1) by 2D-gel electrophoresis (Ditzen et al., submitted). 
Furthermore, two polymorphic loci around the Avp locus (see chapter 2.5.2.3 and 
the results) were added for detection by the customer designed oligo pool. As about 
130 slots were still available for SNPs, the loci to analyze were recruited from 10kbp 
around candidate genes from the MPI24K gene expression analyses or from other 
research groups of the Max Planck Institute of Psychiatry focusing on human 
anxiety and depression patients (Ising, Erhardt and Binder, personal 
communication). Putative SNPs were selected from MGD and are also displayed in 
table 4. All samples were processed and analyzed as described in chapter 2.3.3.  
 
 
 
A B C 
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Table 4: Single nucleotide polymorphisms (SNP) to test with the custom designed oligo pool. 
Source (1) refers to SNPs, taken from the Medium Density Linkage Panel, (2) described 
added SNPs based on genes known from gene expression studies or from research groups 
of the Max Planck Institute of Psychiatry focusing on human anxiety and depression patients. 
Gene association is assumed, if a SNP is located 10kbp around a gene locus. 
 
Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
1 mCV23695025 1 22,398,088 - 
1 mCV24784983 1 25,476,000 Bai3 
1 rs3677683 1 27,321,156 - 
1 rs4137502 1 30,887,618 Phf3 
1 rs3707642 1 32,568,345 Khdrbs2 
1 rs3683997 1 35,935,818 - 
1 rs13475827 1 40,990,938 - 
1 CEL-1_44668113 1 44,620,787 - 
1 rs13475881 1 58,439,402 - 
1 rs13475919 1 73,020,555 - 
2 Rs30238170 1 82,719,300 - 
2 rs30238169 1 82,720,355 5230400G24Rik 
2 rs30238168 1 82,720,980 5230400G24Rik 
2 rs30237262 1 82,722,282 5230400G24Rik 
2 rs30236408 1 82,726,579 5230400G24Rik 
2 rs30242174 1 82,749,582 - 
1 UT_1_89.100476 1 87,014,950 Chrnd 
1 rs13476012 1 101,,801,487 Cntnap5b 
1 CEL-1_103251925 1 103,228,922 - 
1 rs3685919 1 111,528,321 - 
1 rs13476050 1 112,508,292 - 
1 rs3699561 1 132,988,758 Mapkapk2 
1 rs3672697 1 147,028,489 - 
1 rs13476163 1 148,717,645 B830045N13Rik 
1 rs6393307 1 152,872,095 - 
1 rs13476187 1 156,052,564 ENSMUSG00000066797 
1 rs6157620 1 185,385,733 - 
1 rs3667164 1 190,511,531 Ush2a 
1 rs6240512 2 10,900,065 100040690 
1 CZECH-2_15618849 2 15,594,129 - 
1 rs13476366 2 19,320,592 - 
1 rs13476503 2 53,042,643 Prpf40a 
1 rs4223189 2 61,638,140 Psmd14 
1 rs3664661 2 71,436,620 - 
1 CEL-2_73370728 2 73,174,311 - 
1 rs13476639 2 92,666,968 - 
1 rs6406705 2 100,200,136 - 
1 rs13476666 2 101,163,197 - 
1 rs13476689 2 107,305,294 - 
1 rs13476723 2 117,118,533 Rasgrp1 
2 chlcdelavp2 2 130,273,975 Avp 
2 cmlcsnpavp1 2 130,276,153 Avp 
1 rs13476783 2 133,686,867 - 
1 rs3664408 2 161,205,958 - 
1 CEL-2_168586738 2 168,032,354 Nfatc2 
2 rs31438972 3 19,586,067 Trim55 
2 rs31145247 3 19,586,366 Trim55 
2 rs30796162 3 19,597,491 - 
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Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
2 rs31286319 3 19,598,902 - 
1 rs13477043 3 31,379,500 - 
1 gnf03.030.222 3 32,722,005 - 
1 rs6376008 3 86,465,169 Lrba 
1 rs6211610 3 90,025,782 Rab13 
1 rs13477268 3 93,138,727 - 
1 rs4138887 3 102,493,088 - 
1 CEL-3_120379605 3 118,794,515 - 
1 rs13477379 3 122,540,626 Pde5a 
1 rs3671119 3 126,116,580 Arsj 
2 rs13477411 3 131,922,067 - 
2 rs6166189 3 132,079,726 - 
2 rs31556559 3 132,298,496 EG433653 
2 rs30263909 3 132,299,981 EG433653 
1 rs3676039 3 135,880,574 Bank1 
1 rs6407142 3 142,720,843 - 
1 gnf03.160.599 3 156,149,851 Negr1 
2 rs3022975 4 8,073,046 Car8 
1 CEL-4_30653207 4 30,606,147 - 
2 rs3090720 4 57,221,105 Ptpn3 
1 rs3708471 4 76,516,632 Ptprd 
1 rs13477873 4 101,102,850 Ak3l1 
2 rs3022996 4 111,044,395 4931433A01Rik 
1 rs3023025 4 142,772,319 Prdm2 
1 rs13478110 5 9,741,228 - 
1 rs3714258 5 12,371,157 - 
1 rs6341620 5 37,492,799 Jakmip1 
1 CEL-5_45872918 5 46,008,170 - 
1 rs3664008 5 54,048,319 Rbpj 
1 mCV23386455 5 62,987,260 Tbcd1d 
1 rs3667334 5 83,471,068 - 
1 rs13459087 5 87,521,105 Ugt2b36 
1 CEL-5_87173557 5 88,825,844 Amtn 
1 gnf05.084.686 5 89,982,732 Npffr2 
1 rs3673049 5 90,116,719 Adamts3 
2 rs31780700 5 92,889,948 Scarb2 
2 rs29583970 5 92,983,999 - 
2 rs31786987 5 93,102,064 4932413O14Rik 
1 rs3661241 5 98,266,375 - 
2 rs13460000 5 100,488,240 Enoph1 
2 rs13460001 5 100,490,027 Enoph1 
1 rs13478433 5 104,357,982 - 
1 rs13459186 5 110,534,259 Gtpbp6 / Plcxd1 
1 rs13478483 5 118,405,617 Nos1 
1 rs13478518 5 128,264,975 Tmem132d 
2 rs33711358 5 128,515,999 Tmem132d 
2 rs13478520 5 128,616,797 Tmem132d 
1 rs6298689 5 140,240,607 Ints1 
2 rs36247439 5 149,857,285 Hmgb1 
2 rs29781244 5 149,862,877 Hmgb1 
2 rs33343556 5 149,865,874 - 
2 rs36309698 5 149,868,499 - 
2 rs37452785 5 149,868,789 - 
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Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
2 rs30116240 6 7,499,262 - 
2 rs30221186 6 7,503,288 Tac1 
2 rs30206506 6 7,512,626 Tac1 
2 rs30771076 6 7,512,775 Tac1 
1 rs3655269 6 17,922,618 - 
1 rs13478649 6 18,518,251 - 
1 rs13478656 6 21,893,927 - 
1 rs3684494 6 24,365,693 - 
1 rs13478697 6 32,800,650 Chchd3 
1 rs4139698 6 49,819,544 - 
2 rs13478762 6 54,175,671 Chn2 
2 rs30228387 6 54,224,143 Chn2 
1 rs3672029 6 75,345,665 - 
1 rs6285738 6 93,485,969 - 
1 rs6239023 6 94,005,991 Magi1 
1 rs6349084 6 96,697,598 - 
1 rs6339546 6 133,917,751 - 
1 rs13479053 6 134,201,252 Etv6 
1 rs3672808 6 139,805,730 Pik3c2g 
1 rs3711088 6 148,260,469 Tmtc1 
1 rs3659551 7 6,909,503 Usp29 
1 mCV23738426 7 8,465,811 Vmn2r52 
1 CEL-7_5627457 7 12,296,204 - 
2 rs32116079 7 19,147,099 Psg27 
2 rs13461382 7 19,591,025 Irf2bp1 
2 rs31505570 7 19,721,049 Fbxo46 
1 CEL-7_36725559 7 43,396,959 - 
1 rs4232449 7 48,581,740 - 
2 rs31525495 7 53,894,287 Sergef 
2 rs31708001 7 53,903,710 Tph1 
2 rs32373825 7 53,904,154 Tph1 
2 rs6279417 7 53,931,049 - 
2 rs6279463 7 53,931,082 - 
2 rs6281625 7 53,931,473 - 
1 rs6160140 7 73,426,174 Lrrk1 
1 rs3705155 7 75,667,606 - 
1 rs13479347 7 83,432,559 - 
1 rs13479355 7 85,431,231 Ntrk3 
1 rs13479358 7 86,843,104 5730590G19Rik 
2 rs31060727 7 107,753,415 Mrpl48 
2 rs32330100 7 107,755,420 Mrpl48 / Rab6 
2 rs32034601 7 107,756,141 Mrpl48 / Rab6 
2 rs31746209 7 107,758,176 Rab6 
2 rs31908266 7 107,771,055 Rab6 
2 rs32020539 7 107,791,025 Plekhb1 
1 rs3713052 7 108,918,190 Clpb 
1 rs6357312 7 109,389,815 Rhog 
2 rs13479460 7 118,818,343 Galntl4 
1 rs6194926 7 121,509,575 4933406I18Rik 
1 CEL-7_115892950 7 122,464,255 Rgs10 
1 CEL-7_122752866 7 129,495,978 Dock1 
1 rs13479506 7 131,822,778 3100003L05Rik 
1 rs3682038 7 133,483,665 - 
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Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
1 rs13479535 7 138,763,317 - 
1 rs3663988 7 146,505,067 - 
1 CEL-8_33812776 8 33,652,415 Tnks 
2 rs33319598 8 54,406,484 - 
2 rs32893761 8 54,441,823 - 
2 rs32900718 8 54,584,421 - 
2 rs37502172 8 54,664,031 - 
1 rs3707439 8 61,429,008 - 
1 rs13479807 8 68,141,750 Mar1 
1 rs13479811 8 69,577,205 - 
1 rs13479871 8 87,590,219 Fbxw9 
1 rs6257357 8 88,071,460 Dnaja2 
1 rs13479880 8 89,271,028 ENSMUSG00000074178 
1 rs13479884 8 90,183,245 - 
1 gnf08.108.032 8 106,104,093 Tmco7 
1 gnf08.118.027 8 116,136,203 - 
1 rs6400423 8 129,106,325 - 
2 rs3697596 8 130,354,209 - 
1 mCV25073238 9 10,596,883 - 
1 gnf09.012.310 9 17,874,218 - 
1 rs13480092 9 18,926,807 Olfr836 
1 rs3088801 9 24,802,456 - 
1 rs4135590 9 42,796,186 Arhgef12 
1 rs13480173 9 46,336,655 - 
1 rs3676124 9 83,013,939 Hmgn3 
1 rs3669564 9 87,780,386 - 
1 rs3711089 9 105,393,993 Atp2c1 
1 rs13480421 9 111,761,261 - 
1 rs6320810 9 115,065,092 Osbpl10 
1 rs3669563 9 117,827,882 - 
1 rs13459114 9 121,825,029 Cyp8b1 
1 rs13459119 10 20,045,489 Bclaf1 
1 rs3679120 10 22,641,085 - 
1 rs13480581 10 38,685,357 Lama4 
2 rs3090642 10 44,860,993 Prep 
1 rs13480630 10 67,283,841 - 
1 rs13480638 10 68,907,415 - 
2 rs29326309 10 95,590,622 - 
2 rs13480738 10 102,999,447 - 
2 rs13480739 10 103,185,336 - 
1 rs13480740 10 103,515,832 - 
2 rs6282517 10 103,725,176 - 
1 rs3688351 10 103,953,112 - 
2 rs13480742 10 103,966,226 - 
2 rs13480743 10 104,097,543 - 
2 rs13480744 10 104,441,816 100042383 
2 rs13480749 10 105,437,651 - 
1 rs6243755 10 108,174,849 Syt1 
1 rs13480773 10 114,179,165 Trhde 
2 rs6350239 10 114,513,832 Tph2 
2 rs4228474 10 114,515,997 Tph2 
2 rs29341895 10 114,624,510 - 
2 rs29354500 10 114,624,607 - 
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Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
2 rs29327697 10 114,625,405 - 
1 mCV24217147 10 117,503,347 Smgp21b 
1 rs13480803 10 122,568,425 Usp15 
1 mCV22832306 10 125,997,604 - 
2 rs3697243 10 126,250,067 - 
1 rs13480836 11 3,454,200 - 
1 rs6190775 11 6,312,209 - 
1 gnf11.017.294 11 18,007,065 - 
1 rs3723987 11 19,368,928 - 
2 rs13480933 11 29,118,539 Smek2 
2 rs26822202 11 29,122,316 Ccdc104 
2 rs29469152 11 29,122,634 Ccdc104 
2 rs29473241 11 29,147,356 Ccdc104 
2 rs26822189 11 29,147,449 Ccdc104 
2 rs29410558 11 29,149,274 - 
1 rs13459123 11 30,958,902 Asb3 
2 rs26950069 11 58,126,592 Zfp692 
2 rs29402173 11 58,128,820 Zfp672 
2 rs29406291 11 58,129,646 Zfp672 
2 rs29387701 11 58,138,073 1700047K16Rik 
2 rs29427167 11 58,138,512 - 
2 rs29397704 11 58,140,748 - 
1 rs3697686 11 58,381,052 Olfr327-ps1 
1 rs3711357 11 61,266,066 Zfp179 
1 rs13481061 11 62,806,119 Cdrt4 
1 rs13481071 11 65,014,320 Myocd 
2 rs26888740 11 74,739,049 Smg6 / Srr 
2 rs26888739 11 74,739,210 Smg6 / Srr 
2 rs26888734 11 74,740,289 Smg6 
2 rs6192434 11 74,745,116 Smg6 
2 rs29479272 11 74,978,579 Hic1 
2 rs6155957 11 74,978,877 Hic1 
2 rs28226774 11 76,806,816 - 
2 rs28226773 11 76,806,890 - 
2 rs28226748 11 76,840,125 Slc6a4 
2 rs28226747 11 76,840,970 Slc6a4 
2 rs28226743 11 76,841,856 Slc6a4 
2 rs28226734 11 76,846,429 - 
1 rs13481119 11 79,360,701 Nf1 
1 rs13481161 11 92,322,572 - 
1 rs13481313 12 14,876,064 - 
1 rs13481321 12 16,687,164 Greb1 
1 rs13481371 12 30,883,465 Sntg2 
1 rs6223000 12 34,867,610 - 
1 rs13481445 12 51,443,486 Prkd1 
1 rs3677344 12 65,698,044 - 
1 rs13481541 12 77,479,299 Zbtb1 
1 rs3662628 12 80,362,465 Zfyve26 
1 rs13481556 12 81,763,540 Slc39a9 
1 rs13481588 12 93,207,169 EG667589 
1 rs3023711 12 117,417,767 - 
2 rs3692361 12 118,957,587 Rapgef5 
1 rs13481673 13 5,584,894 - 
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Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
1 rs6348604 13 15,502,938 - 
1 rs13481706 13 16,432,650 - 
1 rs3710348 13 31,365,187 - 
1 rs3688207 13 45,454,657 - 
2 rs13462828 13 62,915,954 - 
2 rs30073403 13 63,213,965 2010111I01Rik 
2 rs29584318 13 63,383,551 2010111I01Rik 
2 rs29636134 13 63,405,500 Fancc 
1 rs13481871 13 71,432,597 - 
1 rs3686443 13 86,662,750 - 
1 rs3655061 13 89,723,142 Hapln1 
1 rs13481961 13 98,040,192 - 
1 rs4230144 14 8,924,022 Rpp14 
1 rs6322899 14 10,651,880 Fhit 
1 rs6290836 14 13,378,532 Cadps 
2 rs3696385 14 18,195,504 - 
1 rs13482104 14 27,163,606 - 
1 rs6396829 14 28,814,149 Erc2 
1 gnf14.055.608 14 55,370,255 Mipep 
2 rs3703075 14 63,543,436 Wdfy2 
2 rs13459144 14 76,317,480 Gtf2f2 
1 rs13482327 14 97,600,347 - 
2 rs3692362 14 100,175,288 - 
1 rs6191117 14 100,606,904 - 
1 rs3708779 14 111,167,655 EG668772 
1 rs13482375 14 112,079,790 Slitrk5 
1 rs6169105 14 117,657,346 Gpc6 
1 rs13459176 15 3,229,130 Sepp1 
1 CEL-15_9687257 15 9,601,488 - 
1 rs13482431 15 11,241,219 Adamts12 
1 rs3715857 15 19,181,733 - 
1 rs13482509 15 31,971,924 - 
2 rs32005588 15 32,841,248 - 
2 rs31983176 15 32,849,387 Sdc2 
2 rs32228111 15 32,858,088 Sdc2 
2 rs32250555 15 32,874,418 Sdc2 
2 rs4230687 15 32,964,635 Sdc2 
2 rs3695416 15 38,414,152 - 
1 rs3683326 15 41,219,409 - 
1 rs6400804 15 56,637,987 - 
2 rs36320059 15 81,147,953 Slc25a17 
2 rs37939180 15 81,148,568 Slc25a17 
2 rs37394767 15 81,148,663 Slc25a17 
2 rs38717462 15 81,151,100 Slc25a17 
2 rs36586819 15 81,167,126 Slc25a17 
2 rs36346494 15 81,192,154 - 
2 rs32320164 15 83,392,328 Tspo 
2 rs31717709 15 83,393,007 Tspo 
2 rs32046139 15 83,399,802 Tspo 
2 rs31565634 15 83,400,032 Tspo 
2 rs31717505 15 83,406,204 Ttll12 
1 rs13482712 15 92,076,446 Cntn1 
1 rs4152638 16 4,326,609 Adcy9 
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Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
1 rs4152790 16 4,850,158 4930562C15Rik 
1 rs4173902 16 37,352,904 Stxbp5l 
1 rs4177651 16 40,683,387 - 
2 rs3696661 16 51,676,815 - 
1 rs4197150 16 66,296,803 - 
1 rs3718160 16 76,867,900 - 
1 rs6317052 16 79,493,030 - 
1 rs4211364 16 80,830,317 - 
1 rs3672065 17 14,336,401 Dact2 
1 rs3726555 17 16,539,606 - 
1 rs13482899 17 17,761,307 Lnpep 
1 rs13482914 17 20,982,760 V1re8 
2 rs3696835 17 22,818,022 ENSMUSG00000046088 
2 rs3693494 17 29,917,069 - 
2 rs33798776 17 30,661,307 Btbd9 
2 rs33800126 17 30,695,419 - 
2 rs33798569 17 30,702,010 - 
2 rs33797503 17 30,703,669 - 
2 rs30778922 17 30,809,092 Dnahc8 
2 rs3145477 17 30,814,214 Dnahc8 
1 rs6298471 17 36,684,410 H2-M11 
1 rs6272475 17 53,622,040 Rab5a 
1 rs3714226 17 55,409,410 - 
1 rs3715723 17 58,810,428 - 
1 rs3675634 17 71,590,806 Lpin2 
2 rs33372832 17 74,733,598 - 
2 rs33595841 17 74,733,692 - 
2 rs33340320 17 74,733,758 - 
2 rs13465627 17 74,787,631 Spast 
2 rs33394982 17 74,790,564 - 
1 rs6229946 17 75,590,536 Ltbp1 
1 rs13483157 17 89,287,847 - 
1 rs6397044 17 93,594,172 - 
1 rs13483183 18 3,516,539 Bambi 
1 gnf18.001.688 18 4,647,835 - 
2 rs30263474 18 20,822,913 Ttr 
2 rs31313820 18 20,822,943 Ttr 
2 rs6273344 18 20,825,921 Ttr 
2 rs31315882 18 20,830,086 Ttr 
1 rs13483271 18 29,116,312 - 
2 rs29540760 18 31,595,494 Syt4 
2 rs29551386 18 31,598,369 Syt4 
2 rs30031611 18 31,600,912 Syt4 
2 rs30133602 18 31,683,612 EG383420 
2 rs29823717 18 31,699,317 - 
2 rs30303190 18 31,703,097 - 
1 rs3718586 18 33,291,841 Camk4 
1 rs3658163 18 68,820,968 - 
1 rs6161154 18 71,609,676 Dcc 
1 rs4137441 18 88,803,388 - 
1 rs13483525 19 10,518,533 Syt7 
1 rs6316813 19 11,396,714 Ms4a7 
2 rs38304960 19 12,859,265 Zfp91 
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Source SNP identifier 
 
Chr. 
 
Position [bp] Associated gene 
2 rs31193418 19 12,862,342 Zfp91 
1 rs6372656 19 21,917,692 Tmem2 
1 rs13483643 19 45,386,221 - 
1 rs6194426 19 50,203,520 - 
1 mCV23069572 19 52,369,475 - 
1 rs6304326 19 53,512,609 - 
1 rs6191324 19 59,396,320 Pdzd8 
1 gnfX.026.801 X 36,745,486 Stag2 
1 rs13483765 X 54,787,689 - 
1 gnfX.080.189 X 90,784,538 - 
1 rs13483894 X 93,694,393 Heph 
1 rs6182892 X 94,171,734 - 
1 rs6221690 X 127,572,284 - 
1 rs13483997 X 128,648,050 - 
1 rs13484004 X 130,310,074 - 
2 rs3697198 X 132,751,198 Tceal7 
1 rs13484043 X 139,242,663 Tmem164 
1 gnfX.148.995 X 162,427,214 Arhgap6 
 
2.3.5. Sequencing of candidate genes  
To identify polymorphic sites between HAB and LAB mice, the Avp, corticotropin-
releasing hormone (Crh), Tac1, cathepsin B (Ctsb), metallothionein 1 (Mt1) and the 
transmembrane protein 132D (Tmem132d) coding genes were sequenced. In all 
cases, except for Tmem132d, about 2,500bp of the gene promoter, the complete 
exons and introns and about 2,000bp of the downstream enhancer regions (DER) 
were sequenced. For Tmem132d, only 1,500bp of the promoter, the exons, 
conserved sequences from intron 3 and intron 4 and 1,000bp from the DER were 
analyzed, as the first three introns together are spanning more then 500kbp. 
Sequencing primers were designed to cover between 500-600bp.  
Sequencing was also applied to verify qPCR reaction products. This was done for 
the intronal Avp and for the Tac1 splicing variants. In this case, fragments were 
between 100 and 250bp.  
2900019G14Rik was sequenced to explain for differences in the melting curves 
observed during qPCR (see results). qPCR fragments of Tac1 and PCR fragments 
of Avp for polymorphism detection were cloned into a vector prior to sequencing. 
 
2.3.5.1. Cloning of fragments 
If cloning of DNA fragments was required before sequencing (this is indicated for 
fragments cloned prior to sequencing), the PCR product was purified from the PCR 
reaction mix with the NucleoSpin Extract II kit (Macherey-Nagel). For this, 8.5µl of 
the PCR reaction were diluted with 91.5µl water and 200µl of the NT buffer were 
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added. Otherwise, purification was performed according to the manufacturer’s 
instructions. Then 4.2µl of each purified PCR product were incubated with 5µl 
ligation buffer, 0.3µl pGEM-T vector and 0.5µl T4-DNA ligase (pGEM-T Easy Vector 
System, Promega, Madison, WI) for 1h at room temperature. After incubation, 1µl of 
3M sodium acetate, 20µl 99% ethanol and 1µl glycogen (10mg/ml) were added to 
each sample and vigorously mixed. Samples were shock-frozen in liquid nitrogen 
and centrifuged for 30min at 13,000rpm and 4°C, the supernatant was discarded 
and pellets washed in 300µl 70% ethanol. After centrifugation under the same 
conditions for 5min and removal of the remaining liquid, pellets were dried at 65°C 
and resuspended in 5µl water.  
45µl of competent Escherichia coli DH5α cells were added to each sample and 
transferred into pre-cooled electroporation cuvettes (Bio-Rad). To permeabilize the 
cell membranes for the vector a voltage of 1.5kV was applied (GenePulser, Bio-
Rad) to all cuvettes containing the vector / E. coli suspension. Transformed bacteria 
were collected in 1ml SOB medium and incubated for 1h at 37°C. 150µl of the 
suspension were incubated overnight at 37°C on lysogeny broth/ampicillin agar 
plates inoculated with 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal: 25µl; 
10%, Fermentas, St. Leon-Rot, Germany) and isopropyl-β-D-thiogalactopyranoside 
(IPTG: 30µl; 0.1M, Fermentas) dissolved in dimethyl sulfoxide. Colonies were 
picked according to blue / white selection and their plasmid inserts amplified using 
T7 and SP6 primers and Taq polymerase (Fermentas) for 25-µl reactions under the 
following conditions: initial denaturation at 94°C for 4min, 35 cycles of denaturation 
(94°C for 1min), annealing (49°C for 1min), extension (72°C for 1min) and a final 
extension of 10min at 72°C. 5µl of each PCR product were analyzed on a 1.5% 
agarose gel, fragments with proper insert were required to have the expected 
sequence length plus 143bp. 2µl of the PCR reaction were used for further analysis.  
 
2.3.5.2. Cycle sequencing 
2µl of PCR or qPCR product were purified by washing twice with nuclease-free 
water using the NucleoFast 96 PCR Clean-up kit (Macherey-Nagel). Clean-up plates 
were centrifuged at 9°C and 4,500xg for 10min (Heraeus Multifuge 4KR, Thermo 
Fisher Scientific, Waltham, MA) and resolved during 10 more minutes in 25µl water 
on a shaker (Eppendorf). 2.4µl of cleaned up PCR product were used for the 
sequencing reaction (BigDye Terminator Kit, Applied Biosystems, Foster City, CA) 
by using 1.2µl sequencing buffer, 0.4µl BigDye reagent and 1µl of the forward 
primer per sample. If sequencing reaction results were unclear or unreadable, 
sequencing reaction was also peformed with the reverse primer. Sequencing 
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reactions were performed in ThermoFast 96 PCR plates (ABgene, Hamburg, 
Germany) using a PTC-225 Gradient MultiCycler (MJ Research, Miami, FL) under 
the following conditions: initial denaturation at 96°C for 1min, 35 cycles of 
denaturation (96°C for 10s), annealing (50°C for 5s), extension (60°C for 4min). 
Sequencing reaction products were purified by washing them twice in 20µl injection 
solution using Montage SEQ96 plates (Millipore, Billerica, MA) on a vacuum pump 
(Biomek 2000 Laboratory Automation Workstation, Beckman Coulter, Fullerton, CA) 
and transferred to 96 well plates. Sequences were resolved by capillary 
electrophoresis on a 3730 DNA Analyzer (Applied Biosystems) at the 
HelmholtzZentrum’s Institute of Human Genetics (Neuherberg, Germany). 
Sequence analysis and comparison were performed using FinchTV Ver. 1.2 
(Geospiza, Seattle, WA) and BioEdit Ver. 7.0.2 (Tom Hall, Ibis Biosciences, 
Carlsbad, CA) software programs.  
 
2.3.5.3. Vasopressin (Avp) 
For sequencing Avp (Fig. 4), all 1,944 bp of the unspliced transcript, 3,258bp of the 
promoter and 3,012bp of the DER were analyzed. The respective primers are 
described in table 5. All amplified sequences were cloned into the pGEM-T vector. 
The sequencing reaction was run with T7 and SP6 primers.  
 
Figure 4: The vasopressin (Avp) gene’s physical position on mouse chromosome 2. Exons 
are shown as red boxes, filled parts refer to translated, unfilled to untranslated regions. 
Spliced introns are indicated. As the gene is encoded on the minus strand, the start position 
has a higher value as the end position. Figure is based on data from Ensembl 
(www.ensembl.org, 08.01.2008).  
 
Table 5: Primer sequences used for sequencing of the vasopressin (Avp) gene including the 
PCR fragment length resulting from each reaction.  
 
Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward GAC ACA GTG TGC CTC TAT G Avp 1 
reverse GCT CTC CTG GAC CTT CTG 
784 
forward AAT ACT CTA GGA AGA AGA CAA Avp 2 
reverse GAA ACA GCT TCC TGG TCA 
731 
forward GGA CAT GCC ACT CAA GGG Avp 3 
reverse TAC AGG CGT GCA TCA CGG 
701 
 
5’ 3’ 
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Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward CTA GAA GCC GTG GGC TAG GT Avp 4 
reverse GGG GGT GGG AGA GCT GGG AAT AGT 
798 
forward CAT TGC CAC CAT AGC TTT CC Avp 5 
reverse CTC TTG GGC AGT TCT GGA G 
805 
forward GAG CAG AGC CTG AGC TGC ACA CAG T Avp 6 
reverse ACA TAC AAT ACA ACA GAT CTG 
673 
forward CCA TGC CCA AGT GGA GC Avp 7 
reverse GCT GGA ACG AGG CCA AG 
682 
forward AAA GCA GCA GGT GAC ACT AGG Avp 8 
reverse CTA TGC ACG ACT TCG GGT GTG 
829 
forward ACT CCG TGG ATT CTG CCA AGC Avp 9 
reverse GAT GCC TTC TGC TCC TGA GAC 
793 
forward GCA CGG AAA TAG ACA AGA TAG Avp 10 
reverse AAC TGA CCA TCC TGA GCC ACC 
815 
forward AGA GAT TAG TCT CAG TGA CCT G Avp 11 
reverse CTG GAG TTG TGA GGT GGT TGT G 
817 
forward ACG GCT CAA GGA GGT AGG CG Avp 12 
reverse AAG TGA CCA CAA AGC ACG GAG 
830 
  
 
 
 
2.3.5.4. Corticotropin-releasing hormone (Crh) 
To analyze Crh (Fig. 5) for sequence variations, all 1,916 bp of the unspliced 
transcript, 3,028bp of the promoter and 2,197bp of the DER were sequenced. The 
respective primers are described in table 6. All amplified sequences were analyzed 
in the sequencing reaction using the indicated primers in a nested PCR reaction.  
 
Figure 5: The corticotropin-releasing hormone (Crh) gene’s physical position on mouse 
chromosome 3. Exons are shown as red boxes, filled parts refer to translated, unfilled to 
untranslated regions. Spliced introns are indicated. As the gene is encoded on the minus 
strand, the start position has a higher value as the end position. Figure is based on data from 
Ensembl (www.ensembl.org, 08.01.2008).  
 
Table 6: Primer sequences used for sequencing of the corticotropin-releasing hormone (Crh) 
gene including the PCR fragment length resulting from each reaction.  
 
Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward AAA GTG CAA AGA GAT GCA G Crh 1 
reverse TCT ATT ACA AGA CTC ACA CCA AGA G 
508 
forward CTT GGT GCC CAT ATT TCT TGA Crh 2 
reverse TTA CAC AGC ATC ACG GCA TC 
538 
5’ 3’ 
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Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward GCT GAT ATG TGT GTT GCT CCA Crh 3 
reverse TTC ACC TCA GTG TTT GGG ATT 
590 
forward GAA TTG GTC AGG AAT GAA AG Crh 4 
reverse GTC TGG GAT TCG CTT CAG 
464 
forward CCA GAA ACA GGG AAC AGG AA Crh 5 
reverse CGA GGA AGG CCA TAA ACA AA 
592 
forward GGG AAC AGT CCT GAT TAA CTT T Crh 6 
reverse ATA TTT ATC GCC TCC TTG GTG A 
614 
forward CCA CAC TTG GAT AGT CTC ATT Crh 7 
reverse TTA AGG CAC AGT TAG CGA CA 
599 
forward CTG GAA TGC CTG TGC CTA TG Crh 8 
reverse CTC TGA AGC ACC GAG GTT G 
597 
forward AAG CCT AGA GCC TGT CTT GTC Crh 9 
reverse GAA GGT GAG ATC CAG AGA GATG 
616 
forward CGC CCA TCT CTC TGG ATC T Crh 10 
reverse CTA GCC ACC CCT CAA GAA TG 
501 
forward GCA GAT GGG AGT CAT CCA GT Crh 11 
reverse TCT GAC CTT CTC CAG TTG TCC 
561 
forward CTG AGG ACC GAG GAA GTG TG Crh 12 
reverse CAG TCT CCC AGC AAT TTA TTC A 
525 
forward GCC CTG GAA ATA TGC TTG AT Crh 13 
reverse GGC CAC ACG TCC ATA GTC C 
496 
forward TGT CAA AAG AGT TGC CCT AGA Crh 14 
reverse CAC ATA GGC AGC AGG AAA CA 
577 
forward AGA AAT CCT GTC CAG AGG TC Crh 15 
reverse GAA AGC CAA GCA GGG AAC 
514 
  
 
 
 
2.3.5.5. Tachykinin 1 (Tac1) 
For sequencing Tac1 (Fig. 6) all 7,903 bp of the unspliced transcript, 2,935bp of the 
promoter and 2,773bp of the DER were analyzed. The respective primers are 
described in table 7. All amplified sequences were analyzed in the sequencing 
reaction using the indicated primers in a nested PCR reaction.  
 
 
Figure 6: The tachykinin 1 (Tac1) gene’s physical position on mouse chromosome 6. Exons 
are shown as red boxes, filled parts refer to translated, unfilled to untranslated regions. 
Spliced introns are indicated. The gene is encoded on the plus strand. Figure is based on 
data from Ensembl (www.ensembl.org, 08.01.2008).  
 
5’ 3’ 
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Table 7: Primer sequences used for sequencing of the tachykinin 1 (Tac1) gene including 
the PCR fragment length resulting from each reaction.  
 
Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward GTA CGA AAT GGA TGG TGA CTG Tac1 1 
reverse GGT TTG GTG GCT GAT TAT AGG 
529 
forward AGC TAA GTC GAA AGG ATG GAC Tac1 2 
reverse GGT AAG TAG AGA CCA CAA TCC AG 
619 
forward ATG AAG TGG GAA TGG GTG TTA G Tac1 3 
reverse TCA TGC CTC CGC TTA TGT AG 
576 
forward GCT TAA ATC TGT GAG GTC TTT G Tac1 4 
reverse GAT GAA GTA AAC GAT GTT GCA G 
552 
forward AGG CTG AGT TAG GAG AAT ACC C Tac1 5 
reverse CTA GAG GAG GAA AGC AGA CTT G 
572 
forward TAC GTT CCA CAT GCT GTT CTA C Tac1 6 
reverse CCA TCC AAT CCA GAG AGA CC 
490 
forward CTC AAG ATT CCC TGA CTC CTC Tac1 7 
reverse GGT ATT TGC ACA CTT TCT CTC C 
621 
forward TCT GCT CCC ACT CCA TTC TC Tac1 8 
reverse TTA TAT TCC AGT GCG CCT CTC 
591 
forward AGA TCA AGG TGA GTC CCA AAC Tac1 9 
reverse GTG AAC AGT AGG GTG GAT GAA G 
611 
forward CAT TCA GTG CTC CAA GTT TCC Tac1 10 
reverse TAT TGC TCA TCT CAC CAG CAT C 
599 
forward GAG CCC TTT GAG CAT CTT C Tac1 11 
reverse CAT TAA CTC TTC ACA AGC TCC AC 
501 
forward CCA GGC TCA GGT GAA AGA TG Tac1 12 
reverse AAG GTA GAA CTG TGG GAC TCT TG 
459 
forward CGC GTG TAT TTT AAG CTC CTG Tac1 13 
reverse CAG ACA TGA GTG CTT GTG AGG 
650 
forward AGC AGA ACA TAG AGC CCA ATA G Tac1 14 
reverse GTT ACC AGT TTG GAG TTT ACC C 
650 
forward ATC CAG AGG TGA CAG GAA GTC Tac1 15 
reverse GCT GAA ACC CAT ATT GTG AGC 
583 
forward TCC CAC ACA CAA ATG TAT AAC C Tac1 16 
reverse CCA AAG ACT CAG GGT ATG TAA TG 
630 
forward CAA ATG TTC ATA GTG TCT GTA GCC Tac1 17 
reverse CCT GTG GCG TTT ATG TAG AAA G 
570 
forward GAT TGT CCT TGA CCC AAA GC Tac1 18 
reverse TGT GAG CAC TGA TAA ATC TGG AG 
552 
forward CCA GCC TTG AGA GAT GGA ATA TAG Tac1 19 
reverse AAT GTC TAC CAG CTT CTG TGT CC 
627 
forward AGC CAC CTG ATC CCT ACT GTC Tac1 20 
reverse GAG GGT ATT TCG TCA TCT CAG C 
626 
forward GGG CAA CTA TTT ACA GGA GCA C Tac1 21 
reverse TCT CTT CTC TCT TGG ACA CCT TC 
468 
forward AAT ATC GGT CTC AAG GGC AAT C Tac1 22 
reverse TCC TAG TTT CTT TGG GCA TCT G 
514 
forward TGT GGT AGG TAT GGT CCT TTC TC Tac1 23 
reverse ACT AAT TTC TAC TTC TGG GGA GGT C 
612 
forward ATG TGC GCT ATG AGG AAT G Tac1 24 
reverse GAA GAA AGG CTG TTG ATT TGA C 
535 
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Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward TCA ATG TAA TTC TCT GGT CTT CAG Tac1 25 
reverse CCC ATT CCT TTC AGT GTT ATG 
643 
forward TTG CTG ACA CCC ATA ATC TTC Tac1 26 
reverse GCT CCT TTG TAA TCC ACA CTT ATC 
602 
forward CGT TTT ACA GAT GGG GAA AGA G Tac1 27 
reverse CAC CAA TGT GCC TAT GAA AAT C 
617 
forward ATG CAC AGG GTA TGT TTT ATG G Tac1 28 
reverse TTA TAT GGC CTG ATC TTT GTG G 
508 
forward GTG ACT AGG GCA ATG GAA AGA G Tac1 29 
reverse GGG AGG AGA GCA GAG TTA TGT G 
485 
forward CTA GGC TCA AGA ATG AAC ACA GG Tac1 30 
reverse GCT TTA TGT AGG AGT TTG GAG CAG 
612 
  
 
 
 
2.3.5.6. Cathepsin B (Ctsb) 
To screen for sequence variations between HAB and LAB mice in Ctsb (Fig. 7), 
8,045bp of the unspliced transcript, 2,441bp of the promoter and 1,797bp of the 
DER were analyzed. Due to the size of the unspliced transcript (20,619bp), 
10,278bp from intron 1 and 2,266bp from intron 8 were ignored in the sequencing 
reaction. The respective primers are described in table 8. All amplified sequences 
were analyzed in the sequencing reaction using the indicated primers in a nested 
PCR reaction.  
 
 
Figure 7: The cathepsin B (Ctsb) gene’s physical position on mouse chromosome 14. Exons 
are shown as red boxes, filled parts refer to translated, unfilled to untranslated regions. 
Spliced introns are indicated. The gene is encoded on the plus strand. Figure is based on 
data from Ensembl (www.ensembl.org, 08.01.2008).  
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Table 8: Primer sequences used for sequencing of the cathepsin B (Ctsb) gene including the 
PCR fragment length resulting from each reaction.  
 
Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward ACA GCA AGG AAC AAC ATA GCA C Ctsb 1 
reverse GAT GGA AGC AGA AAG GTC AAA G 
502 
forward ATA GGT CAT TGG GCT GTG TAG G Ctsb 2 
reverse GAG AGA CAA GAA CCC AGA AGT ACC 
621 
forward GTG AGC AGG CAG TGA TAT GG Ctsb 3 
reverse AAA TGA GCA GCC TTT CTT GG 
554 
forward GCA GCC AGA GAC ACT TTT GG Ctsb 4 
reverse CCC ATG AAT TTT GTC CAA GG 
591 
forward AGA TCA ACT AGG TCA GCC AGC TTC Ctsb 5 
reverse AAC TGG TGG TTT GTC TGC TCT CT 
540 
forward TGC ATG TCA CGA AGA TGT TG Ctsb 6 
reverse ACT GGA AAG AAG CCG ATC AC 
562 
Intron 1: 10,278bp not sequenced  
forward TCC ACC TTA ACG CTG ACT CTT C Ctsb 7 
reverse CTC GCT CCA AAG CTC ACT TAT C 
603 
forward ATT GCT CTC CAG TCT CCA TGT T Ctsb 8 
reverse TCC CTA CAC TCC AAC ACT AGC A 
529 
forward AGG CTG GAC GCA ACT TCT AC Ctsb 9 
reverse CAA TCT TCT CCC ACC TTT CTT G 
516 
forward TCA AAT CAG GCA AGG CAT AG Ctsb 10 
reverse CGG AGG TCA GAG GGA TTA TTA G 
532 
forward CTG GAG AGA TGG CTA AGT GGT T Ctsb 11 
reverse GCA CTG GCT CTA TGC TCA TTT A 
606 
forward AGG AAG GAA GGA AGG AAG GAA C Ctsb 12 
reverse ACA GTG ATG GGA AGA AAT GGA C 
581 
forward GCA TAT CTA GGG AGG GAC CAG Ctsb 13 
reverse AGA GCC TTC AAC CTT CTG AGT G 
575 
forward ATC TGC CTT GGA ATT TGC TC Ctsb 14 
reverse TTG GAG ACG ACA GTT CTT TCT G 
537 
forward AGA TGG AGC TTG GTT GAG TCC Ctsb 15 
reverse AGG GAT GGT GTA TGG TAA GCA G 
531 
forward CCT CAA TAC AGG AGC TGA CC Ctsb 16 
reverse TGA GAC AAG ACA GAG TGT GGA C 
545 
forward AAA CAG GAG CAG TAA GGA GGA G Ctsb 17 
reverse GAA GAG AGC AGA AGG GAG ACT G 
573 
Intron 8: 2,266bp not sequenced  
forward AAA GAC TAT GGG TGC TGG AGA C Ctsb 18 
reverse AGT TCT CGT CAC ATG CTG CTC 
515 
forward CCC CTC CTC AAA CTA CAT AAG C Ctsb 19 
reverse CTC CCC TGT CTA CCT CAT TCC 
537 
forward CTG CTT TGA CTT CAT TGT CCA G Ctsb 20 
reverse AAT GTC GAT GGA TGC AGA TG 
515 
forward ACT TCA CGA GAG GAC AAA TGC Ctsb 21 
reverse GTG TGA GCA GTT ACA GGT ACG G 
545 
forward GGA ATG TCT GTG CCA ATA AAC C Ctsb 22 
reverse GCC TCA AAC CGA GTT ACA CTT C 
533 
forward TGT AAC TCG GTT TGA GGC AAC Ctsb 23 
reverse GAG GAC CAC ACA AAG AAC ACA C 
526 
forward CCA TGT CGG CAA TCA GAA C Ctsb 24 
reverse ACC ACA CAA AGA ACA CAC AAC G 
581 
 Animals, materials and methods 
51 
Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward CCG ATC TCT GGG AGT TTG AG Ctsb 25 
reverse GAT GTG CTT GCT ACC TTC CTC T 
488 
forward CGC TCT CAC TTC CAC TAC CAC Ctsb 26 
reverse CTA AGT TCA ATT CCC AGC AAC C 
591 
  
 
 
 
2.3.5.7. Metallothionein 1 (Mt1) 
For sequencing Mt1 (Fig. 8), all 1,085bp of the unspliced transcript, 2,187bp of the 
promoter and 1,878bp of the DER were analyzed. The respective primers are 
described in table 9. All amplified sequences were analyzed in the sequencing 
reaction using the indicated primers in a nested PCR reaction.  
 
Figure 8: The metallothionein 1 (Mt1) gene’s physical position on mouse chromosome 8. 
Exons are shown as red boxes, filled parts refer to translated, unfilled to untranslated 
regions. Spliced introns are indicated.The gene is encoded on the plus strand. Figure is 
based on data from Ensembl (www.ensembl.org, 08.01.2008).  
 
Table 9: Primer sequences used for sequencing of the metallothionein 1 (Mt1) gene 
including the PCR fragment length resulting from each reaction.  
 
Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward CAA GAG GTC TAA AGG CCC AAG Mt1 1 
reverse TGG TCA ACA AAG TGA GTT CCA G 
511 
forward GAT CTG GAG AGA ACT GAC CAA C Mt1 2 
reverse TTC ATG GTG GTT TAG ATA CAA GTG 
564 
forward GCT GTG TTG TCT CCT CCA AG Mt1 3 
reverse TGC ATA CCA TCA CTT CTG AGC 
601 
forward CTG AAT CCT CTG TCC TTG TGT G Mt1 4 
reverse CTC TCT CTG GAT CGA AGC TAG G 
535 
forward AGC AGA TGG GTT AAG GTG AGT G Mt1 5 
reverse CTG CCC TCT TTA TAG TCG TTG G 
546 
forward TGA CTA TGC GTG GGC TGG AG Mt1 6 
reverse CAT GAG GGA GGC AGC ATT ACA G 
659 
forward CCC TGA CTT AAC CTG TGA GGA G Mt1 7 
reverse GGG TGG AAC TGT ATA GGA GAC G 
585 
forward TCC TTT CTA GGC TGC TGG CTC Mt1 8 
reverse TAC CCA CCT CCT TAT ACC CAA C 
562 
forward TGG TCA GGT CTT GTG TTA GGG Mt1 9 
reverse GGC CAT CTT CTG CTA CAT ACG 
642 
 
5’ 3’ 
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Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward TCA GCT ATT GGA TGG AAC ACA G Mt1 10 
reverse GAG ATG GCT CAG TGG GTA AGA G 
629 
forward ATT TGA ACT CCT GAC CTT CG Mt1 11 
reverse ACG TCT CAC GGG CTA GAG 
640 
 
 
 
 
 
2.3.5.8. Transmembrane protein 132D (Tmem132d) 
To identify SNPs in Tmem132d (Fig. 9), 8,339bp of the unspliced transcript, 1,132bp 
of the promoter and 103bp of the DER were analyzed. Due to the size of the 
unspliced transcript (675,077bp), only exons, fragments of 100-500 bp around 
exons, furthermore two rather conserved intronal sequences from intron 3 (717bp 
and 389bp) and 839bp from intron 4 were considered for sequencing of the whole 
unspliced transcript. The respective primers are described in table 10. All amplified 
sequences were analyzed in the sequencing reaction using the indicated primers in 
a nested PCR reaction.  
 
 
Figure 9: The transmembrane protein 132D (Tmem132d) gene’s physical position on mouse 
chromosome 5. Exons are shown as red boxes, filled parts refer to translated, unfilled to 
untranslated regions. Spliced introns are indicated. As the gene is encoded on the minus 
strand, the start position has a higher value as the end position. Figure is based on data from 
Ensembl (www.ensembl.org, 08.01.2008).  
 
Table 10: Primer sequences used for sequencing of the transmembrane protein 132D 
(Tmem132d) gene including the PCR fragment length resulting from each reaction.  
 
Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward TGC TGC CAA GCT GTG ATA AA Tmem132d 1 
reverse TGC GGA TAA AAA TGG ACT GG 
483 
forward AGC CCA AAA CGG ACT CTC TT Tmem132d 2 
reverse GGA CAG TTC AGG AAC CCC TA 
460 
forward TCA GGG ACA GGA ATT TGA GG Tmem132d 3 
reverse TTT TTA AGC CCC ACC CTT CT 
367 
5’ 3’ 
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Gene symbol 
and primer 
number 
Orientation Primer sequence 5’3’ 
Product 
size 
[bp] 
forward CCA GGA AGG TGG GAC CTA CT Tmem132d 4 
reverse CTG AGG ACT GGC TCG TGA AT 
582 
forward CCA GCC GGA GTC CTC AGA Tmem132d 5 
reverse CCA CCC ACA TCC ACA TCT ACT 
476 
forward AAA GTG AGG CTG TGG GTA GC Tmem132d 6 
reverse GTT CTC GTC CCT GTG GTC AT 
505 
Forward CCA ACC CAT TTG GAT TCA CT Tmem132d 7 
reverse TCC TTC AAA GGT GGA CTG CT 
504 
forward AGG AGG ATT CGA GGA AGA GC Tmem132d 8 
reverse TCT GCA GAC AGT TCC ACA GC 
317 
forward TAA ACC TGA TTC CCC GTG AG Tmem132d 9 
reverse GCC CTG TGT GGG TTC ACT AT 
460 
forward CTT CCT CAA GCT CCT TCT GG Tmem132d 10 
reverse GGC TAC CCT TGG GAT ATG GT 
457 
forward ACA GGT TAA TGC CCT GTT GC Tmem132d 11 
reverse AGC TTT GCA CAC TGC ACT TC 
413 
forward GGA CTG GGA AAG ATG TGG AC Tmem132d 12 
reverse GGT CTG GAG AGT GTG GGA AC 
439 
forward GAG ACG TGA TAG GCC CAT GT Tmem132d 13 
reverse CCT TTT ACA GGG GTC GCA TA 
601 
forward TTG TGG ATG GTG GTC AGT CC Tmem132d 14 
reverse CCA TTT TTG TCC CCA TTT TG 
424 
forward TGT TGC ACC AGC GTT GTA C Tmem132d 15 
reverse ATC TGG CGT CGC TAT TAT TAG 
412 
forward GAA GCA CCG TGT GTC TAA GG Tmem132d 16 
reverse CCT GGA GCT TGC TGG TCT AC 
554 
forward ACA TTT GGC TTC CTG TGA CC Tmem132d 17 
reverse CCA GGC ATG GGT TAT AGC AG 
451 
forward ATT CCC TGG TCT GTG GAC TG Tmem132d 18 
reverse GGC AGA GTC TAG GCA CTT GG 
482 
forward AAC CAC CTG TCA TGC CTC TC Tmem132d 19 
reverse CCC TGT GTC TCC CAT GTA TC 
624 
forward TTA TAA CAT GGG ATG GCT GG Tmem132d 20 
reverse GGG ATA GAA ACC CCT GAT GG 
432 
forward ACC CAA TTC TTT TCC TCG AC Tmem132d 21 
reverse TCC ACT CTC ACT GCT GTT GG 
436 
forward TCT CCC TGA TGG CTA CAT CC Tmem132d 22 
reverse AAC AGG TTT TCC TGG CCT TC 
420 
forward TGA CAG GAG GTC CAA AAA GC Tmem132d 23 
reverse AGT CCA GAC CCC TGT CAA TG 
520 
forward TCA CTC TCA CGA CTG GGT TG Tmem132d 24 
reverse GTG TCC CCG TTA TAC GTG CT 
372 
forward TCA GAC GAT GGG TGT CCT TC Tmem132d 25 
reverse CTG ACC CAC ACA TGC TCA AC 
532 
 
 
 
 
 
2.3.6. Assessing the effects of polymorphisms 
All SNPs and other polymorphisms identified by sequencing were analyzed if they 
are located in the exons or at exon borders, if they influence the amino acid 
sequence or if they are located in the promoter or DER. Avp and Tmem132d were 
 Animals, materials and methods 
54 
additionally screened for transcription factor binding motifs via the the Transcription 
Element Search System (TESS, http://www.cbil.upenn.edu/cgi-bin/tess/tess). 
Putative binding sites of transcription factors were additionally checked for their 
function and occurrence within the brain according to the NCBI database 
(http://www.ncbi.nlm.nih.gov/). 
 
2.3.7. Allele-specific transcription analyses of vasopressin (Avp) 
For Avp, in addition to the validation of gene expression differences, an allele-
specific transcription analysis has been performed based on the identified 
polymorphisms, to analyze the effects of the identified polymorphisms on the gene’s 
expression.  
Therefore, PVN and SON were dissected from the hypothalamus of four female F1 
mice that were heterozygous for the recently described C(40)T (rs50049109) single 
nucleotide polymorphism (SNP). Total RNA was extracted using a TRIzol chloroform 
extraction protocol and reverse transcribed with Omniscript (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. 208bp of the Avp transcript 
containing the SNP at position C(40)T were amplified by PCR in 40 identical cycles 
of denaturation at 94°C for 1min, annealing at 56°C for 1min and elongation at 72°C 
for 1min using Taq polymerase (Fermentas, St. Leon-Roth, Germany) and 5’ 
gagcagagcctgagctgcacacagt 3’ as forward and 5’ agcagatgcttggtccgaagcacg 3’ as 
reverse primers (MWG Biotech, Ebersberg, München). Amplified fragments were 
ligated into a vector and transfected into competent Escherichia coli cells that were 
grown overnight as described above.  
From each agar plate, 25 colonies with proper insert (according to white/blue 
selection) were picked and sequenced. The specific alleles from each transcript 
were determined by the C(40)T polymorphism.  
 
2.4. Association and linkage of SNPs with behavioral parameters 
For the F2 panel, statistical analysis was performed using WG-Permer 
(www.mpipsykl.mpg.de/wg-permer). Trait values were rank-transformed to protect 
against artifacts. Analysis was done using a genotypic model, i.e. the three 
genotypic classes possible for each of the phenotypes were treated as a separate 
class each and global test on equality of the three means was performed.  
 
2.5. Statistical data analysis  
All data, except for data from high throughput gene expression profiling and 
genotyping were analyzed using SPSS Ver. 16.0.1 (Chicago, IL), applying the 
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Kruskal-Wallis test (KWH) for comparisons over more then two groups with 
subsequent Mann-Whitney tests (MWU) and sequential Bonferroni correction for 
multiple testing, if applicable. For allele-specific expression analysis of Avp, Χ2 test 
was applied (Preacher, 2001: Calculation for the chi-square test: An interactive 
calculation tool for chi-square tests of goodness of fit and independence [Computer 
software], available from http://www.quantpsy.org). 
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3. Results 
 
3.1. The HAB phenotype reversal by selective breeding 
Continuous breeding of rHAB mice towards a less anxious phenotype resulted in 
elevated group means for the percentage of time that these mice spent on the open 
arms of the EPM (less anxiety) although this effect was only significant for rHAB 
males (MWU: p = 0.04), not for females (MWU: p = 0.14; Fig. 10A). For females, 
only the number of full open arm entries was elevated significantly (MWU: p = 0.04; 
Fig. 10B), whereas for males in addition to the percentage of time, the latency time 
to the first entry was decreased (MWU: p = 0.03; Fig. 10C). There was no significant 
difference in body weight or any parameter assessing locomotion on the EPM, 
independent of gender. In the TST, no significant difference could be observed in 
any parameter (Fig. 10D and E). 
 
3.2. Identification of candidate genes 
 
3.2.1. Animals and behavioral tests 
At any time, HAB and LAB mice displayed the trait-specific differences, in the EPM 
and TST irrespective of gender. HAB and LAB mice never displayed significant 
differences concerning body weight or locomotion on the EPM. CD1 and NAB 
showed elevated body weight in comparison to HAB and LAB mice (data not shown, 
example for CD1 in Fig. 11F).  
For the MPI24K platform-based gene expression analyses, HAB and LAB mice were 
used that displayed significant differences regarding the percentaged time spent on 
the open arms of the EPM (MWU: p =  3.95x10-3; Fig. 11A) and in the total test time 
spent immobile in the TST (MWU: p = 3.88x10-3; Fig. 11B).  
HAB, NAB and LAB mice used for the Illumina-based gene expression profiling 
displayed significant differences in the time spent on the open arms of the EPM 
(KWH: p = 8.80x10-5; MWU: HAB and NAB vs. LAB p = 3.58x10-3; HAB vs. NAB p = 
1.75x10-3; Fig. 11C).  
HAB and NAB vs. LAB mice also showed significant differences in the total time 
spent immobile in the TST (KWH: p = 6.65x10-4; MWU: HAB and NAB vs. LAB p = 
3.55x10-3; HAB vs. NAB p = 0.84; Fig 11D). Only HAB and LAB vs. NAB mice 
showed significant differences regarding body weight (KWH: p = 3.45x10-3; MWU: 
HAB vs. NAB: 9.62x10-3; LAB vs. NAB p = 0.01; HAB vs. LAB p = 0.46) with a mean 
difference of 3.52g, with NAB mice having an increased body weight at the age of 
seven weeks. NAB mice also exhibited increased locomotion compared to both HAB 
 Results 
57 
and LAB mice, as reflected by the number of closed arm entries on the EPM (data 
not shown). 
 
 
Figure 10: Behavioral assessment of reversed HAB (rHAB – in B-E: black) mice vs. HAB (in 
B-E: white) mice with (A) the development of the percentaged time spent on the open arms 
of the elevated plus-maze (EPM) in rHAB mice in the course of breeding generations; (B) 
number of full open arm entries on the EPM for rHAB females; (C) latency time of rHAB 
males to their first open arm entry; The depression-like behavior of rHAB vs. HAB males as 
measured by the (D) total immobility time in the tail suspension test and (E) the latency to 
the first immobility. Statistical significance calculated against parental generation HAB mice. 
Data are displayed as means ± SEM in (A) and + SEM in (B-E); * p < 0.05. 
 
Similarly, in female HAB, CD1 and LAB and male HAB, NAB and LAB mice the 
differences for the percentaged time spent on the open arms of the EPM were highly 
significant in females (KWH: p = 1.73x10-4; MWU: HAB vs. LAB p = 2.39x10-3; HAB 
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vs. CD1 p = 2.33x10-3; CD1 vs. LAB p = 0.02; Fig. 11E). CD1 mice showed 
significantly increased locomotion and body weight compared to HAB and LAB mice 
(data not shown, body weight in Fig. 11F).  
 
 
Figure 11: Behavioral assessment of mice used for gene expression profiling. (A-B) Male 
mice used in the MPI24K-based gene expression analyses; (C-D) male mice used in the 
Illumina platform-based gene expression profiling; (E-F) Female and (G-H) male mice used 
for validation via qPCR. (A, C, E, G) The mice‘s anxiety-related behavior as assessed by the 
time they spent on the open arms of the elevated plus-maze and (B, D, H) their depression-
like behavior as reflected by the total immobility time in the tail suspension test. (F) Displays 
the body weight of female mice aged seven weeks. Data are displayed as means + SEM; * p 
< 0.05; ** p <0.01; *** p < 0.001. 
 
3.2.2. Gene expression profiling on the MPI24K platform 
 Results 
59 
 
3.2.2.1. Tissue dissection 
Micropunching of brain tissue achieved an accuracy of 0.1-0.2mm deviation in any 
direction relative to the expected coordinates as described in the Mouse Brain Atlas 
(Fig. 12).  
 
 
Figure 12: Brain regions acquired by micropuncture from 200µm slices. The (A) cingulate 
cortex (Cg) and nucleus accumbens (NAc) from both sides, (B) paraventricular nucleus 
(PVN) and supraoptic nuclei (SON), (C) central (CeA), (D) basolateral/lateral (BLA/LA) and 
medial amygdala (MeA).  
 
3.2.2.2. RNA amplification 
Amplification of pooled total RNA samples yielded 50-100µg of aRNA. The agarose 
gels revealed similar fragment sizes of aRNA mainly ranging from 500 to 1,500bp in 
size (Fig. 13).  
CeA 
NAc 
Cg 
MeA 
BLA/LA 
SON 
PVN 
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Figure 13: Amplified RNA samples from different brain regions including the supraoptic 
nuclei (S), basolateral/lateral (B), central amygdala (Z), cingulate cortex (C), medial 
amygdala (M) and nucleus accumbens (A).  
 
3.2.2.3. Differential expression data 
The gene expression analyses based on the MPI24K platform resulted in the 
identification of 30 to 450 genes per brain region that were significantly (p < 0.05) 
differentially regulated between HAB and LAB mice. If the threshold was set to 
detect genes potentially regulated (p < 0.1), seven transcripts were identified to be 
regulated in all analyzed brain regions, two genes in only six, 23 in five, 74 in four, 
204 in three, 545 in two and 1,651 specifically in one brain region, giving a total of 
2,507 differentially expressed sequences (excerpt of the list in supplementary table 
1). The 19 highest ranking differentially expressed sequences (according to their p-
value and number of brain regions, they were found to be differentially expressed in) 
were selected for further investigation. Additionally, three neuropeptide coding 
genes were further analyzed that were differentially expressed in at least two brain 
regions and one gene was extremely differentially expressed (14-fold expression 
difference in the BLA/LA; Table 11). 
Table 11: Gene transcripts selected for further investigation including their fold regulation, 
the respective p-value and the brain regions, where they were identified. Negative fold 
regulation values refer to an increased expression in LAB compared to HAB mice, whereas 
positive values to an increased expression in HAB compared to LAB mice. Cytochrome c 
oxidase subunits are summarized, as some subunits were higher expressed in HAB and 
others in LAB mice in at least two brain regions.   
 
Fold 
regulation 
 
p-value 
 
Brain 
regions Gene symbol Gene name 
-8.81 2.00x10-4 BLA/LA Ttr transthyretin 
-3.47 5.86x10-3 all Slc25a17 solute carrier family 25, member 17 
-2.26 0.02 all \MeA Ctsb cathepsin B 
-2.26 0.02 all \MeA Mmp15 matrix metallopeptidase 15 
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Fold 
regulation 
 
p-value 
 
Brain 
regions Gene symbol Gene name 
-2.00 0.01 all Zfp672 zinc finger protein 672 
-1.89 0.02 all Glo1 glyoxalase 1 
-1.88 0.01 all 5230400G24Rik RIKEN cDNA 5230400G24 gene 
-1.71 0.02 
all  
\BLA/LA 
and SON 
Coro7 coronin 7 
-1.66 0.02 
all 
\BLA/LA  
and SON 
Ccdc104 coiled-coil domain containing 104 
-1.56 0.03 
all 
\BLA/LA 
and SON 
Ep400 E1A binding protein p400 
-1.53 0.01 
Cg 
MeA 
NAc 
PVN 
Mt1 metallothionein 1 
-1.44 0.10 CeA Npy neuropeptide Y 
-1.42 0.03 
BLA/LA 
MeA 
PVN 
SON 
Tac1 tachykinin 1 
1.74 0.02 all \CeA Hmgn3 high mobility group nucleosomal binding domain 3 
1.80 0.05 PVN SON Avp arginine vasopressin 
4.36 2.28x10-3 all Rab6 RAB6, member RAS oncogene family 
1.72 
or 
-1.50 
0.03 all 
Cox6b 
Cox6c 
Cox7b 
Cox8a 
Cox17 
cytochrome c oxidase, subunit VIb1 
cytochrome c oxidase, subunit VIc 
cytochrome c oxidase, subunit VIIb 
cytochrome c oxidase, subunit VIIIa 
cytochrome c oxidase, subunit XVII 
 
 
3.2.3. Gene expression profiling on the Illumina platform 
3.2.3.1. Tissue laser-microdissection 
Laser-microdissection of brain tissue delivered much more accurate results 
compared to micropuncture (Fig. 12), as the outline of each brain region could be 
well adapted due to the staining of brain slices (Fig. 14) 
 Results 
62 
 
Figure 14: Brain regions acquired by laser-microdissection with the (A) cingulate cortex 
(Cg), (B) dentate gyrus (DG), hypothalamic paraventricular nucleus (PVN) and supraoptic 
nucleus (SON) and (C) central (CeA) and basolateral amygdala (BLA).  
 
3.2.3.2. Total RNA isolation and amplification 
RNA isolation from the laser-microdissected tissue yielded in average 580ng of total 
RNA, with the highest amounts isolated from the BLA (ø = 1,574ng) and the lowest 
from the SON (ø = 92ng). After individual amplification of all samples, only one 
sample from the SON yielded enough aRNA to process it on the microarray for gene 
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expression profiling. Therefore, all samples from the SON were excluded from 
further processing. Some more samples were excluded from a variety of brain 
regions based on the agarose gel picture of the samples (Fig. 15). 
 
Figure 15: Color inverted agarose gel pictures of all aRNA samples with the respective 
number of samples per line from the (A) basolateral (BLA), (B) central amygdala (CeA), (C) 
cingulate cortex (Cg), (D) dentate gyrus (DG) and (E) hypothalamic paraventricular nucleus 
(PVN). White arrows indicate samples excluded from further processing. 
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3.2.3.3. Differential expression data 
 
In the second gene expression analysis experiment based on the Illumina platform, 
2770 transcripts were identified to be differentially expressed between HAB and LAB 
mice (excerpt of the list in supplementary table 2). For about 90% of these 
transcripts, NAB mice displayed an intermediate expression level or were 
expressing the transcripts at the same level as HAB or LAB animals. In less than 4% 
of transcripts, NAB mice showed an increased or decreased expression as 
compared to both HAB and LAB mice. Additionally, about 959 transcripts could be 
identified, where only NAB animals showed deviation from the expression levels of 
HAB and LAB mice. Out of these transcripts, 231 were found to be differentially 
regulated in all regions, 99 in only four, 125 in three, 296 in two and 2019 
specifically in only one brain region. 22 transcripts were further characterized, with 
20 found regulated in nearly all regions and a further two regulated rather less 
strong but specifically in one single brain region (Table 12).  
 
Table 12: Gene transcripts selected for further investigation identified in the Illumina 
platform-based gene expression profiling including their fold regulation (HAB vs. LAB 
column), the respective p-value and the brain regions, where they were identified. Negative 
fold regulation values refer to an increased expression in LAB compared to HAB mice, 
whereas positive values indicate an increased expression HAB compared to LAB mice. The 
last column refers to the fold regulation of HAB vs. NAB mice analogous to the first column. 
Genes identified also on the MPI24K platform are indicated in bold letters.  
 
HAB vs. 
LAB p-value 
Brain 
regions Gene symbol Gene name 
HAB vs. 
NAB 
-14.15 1.33x10-9 all Enpp5 
ectonucleotide 
pyrophosphatase/ 
phosphodiesterase 5 
-5.05 
-12.29 4.88x10-31 all Ctsb cathepsin B -13.61 
-3.58 1.41x10-7 all Kcnh1 potassium voltage-gated 
channel 1 -2.59 
-2.61 1.95x10-9 all Glo1 glyoxalase 1 -1.69 
-2.15 4.53x10-21 all Apbb1 amyloid beta (A4) precursor protein-binding 1 -2.07 
-2.03 7.19x10-12 all Slc25a17 solute carrier family 25, 
member 17 -1.92 
1.34 0.02 DG Pxk PX domain containing 
serine/threonine kinase 1.43 
1.34 0.09 Cg Tmem132d transmembrane protein 132D 1.00 
1.62 1.89x10-6 all \Cg Slc1a2 solute carrier family 1, 
member 2 1.57 
1.93 4.34x10-12 all Dgkq diacylglycerol kinase, theta 1.00 
2.05 1.52x10-16 all Hmgn3 
high mobility group 
nucleosomal binding  
domain 3 
2.08 
2.14 4.38x10-23 all Pdhb 
pyruvate dehydrogenase 
beta -1.58 
2.14 4.17x10-8 all Cox6a2 cytochrome c oxidase 1.23 
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HAB vs. 
LAB p-value 
Brain 
regions Gene symbol Gene name 
HAB vs. 
NAB 
2.21 3.15x10-12 all Dgkh diacylglycerol kinase, eta 2.58 
2.57 1.26x10-13 all Abca2 ATP-binding cassette, sub-family A (ABC1), member 2 1.03 
3.46 2.23x10-19 all Aldh3a2 aldehyde dehydrogenase family 3, subfamily A2 1.48 
3.60 1.02x10-22 all Gnaq guanine nucleotide binding protein 3.72 
4.05 1.75x10-10 all Hbb-b1 hemoglobin beta adult major 
chain 3.41 
4.05 1.29x10-37 all Stx3 syntaxin 3 4.25 
4.54 1.23x10-13 all Gig1 glucocorticoid induced gene 1 1.56 
5.23 4.47x10-6 all 2900019G14Rik RIKEN cDNA 2900019G14 gene 2.16 
6.12 1.07x10-9 all Ttbk1 tau tubulin kinase 1 1.73 
 
3.2.4. Validation of results by quantitative PCR 
In whole brain material of female mice, expression differences for six genes from the 
MPI24K platform array could be confirmed (Coro7, Ctsb, Mmp15, Mt1, Slc25a17, 
and Zfp672) delivering significant results over all three mouse lines and displaying 
an overall 2-fold increased expression in LAB compared to HAB mice (Table 13). 
For two other genes (Trib2 and Mbnl1), originally tested as potential housekeeping 
genes, significant expression differences were found, too. In genes that were 
expressed region specifically, no significant differences have been observed in the 
analysis of whole brain tissue.  
 
Table 13: Gene transcripts analyzed in whole brain tissue from female mice with the relative 
(rel.) fold expression in HAB, NAB and LAB mice ±SEM, followed by the p-values of the 
Kruskal-Wallis (KWH) and Mann-Whitney tests (MWU) for HAB vs. LAB, HAB vs. NAB and 
NAB vs. LAB mice. Statistically significant results are indicated in bold letters.  
  
Gene symbol 
Rel. 
expression 
HAB 
±SEM 
Rel. 
expression 
NAB 
±SEM 
Rel. 
expression 
LAB 
±SEM 
 
 
KWH 
 
 
MWU 
HAB 
vs. 
LAB 
MWU 
HAB 
vs. 
NAB 
MWU 
NAB 
vs. 
LAB 
Ccdc104 1.00±0.16 1.06±0.19 1.05±0.12 0.77    
Coro7 1.00±0.19 1.41±0.26 1.79±0.10 0.02 0.01 0.22 0.25 
Ctsb 1.00±0.13 1.59±0.31 2.03±0.31 0.03 0.03 0.11 0.36 
Ep400 1.00±0.26 1.17±0.25 1.24±0.47 0.71    
5230400G24Rik 1.00±0.13 1.11±0.17 1.26±0.20 0.69    
Mbnl1 1.00±0.23 1.36±0.30 2.05±0.22 0.04 0.03 0.34 0.17 
Mmp15 1.00±0.27 2.03±0.45 2.34±0.36 0.03 0.03 0.10 1.00 
Mt1 1.00±0.06 2.16±0.66 1.87±0.21 0.01 3.51 
x10-3 0.11 0.30 
Npy 1.00±0.10 1.81±0.54 1.32±0.14 0.35    
Rab6 1.38±0.16 1.12±0.07 1.00±0.20 0.39    
Slc25a17 1.00±0.09 1.47±0.21 1.73±0.15 0.01 0.02 0.11 0.11 
Tac1 1.21±0.27 1.43±0.15 1.00±0.17 0.12    
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Gene symbol 
Rel. 
expression 
HAB 
±SEM 
Rel. 
expression 
NAB 
±SEM 
Rel. 
expression 
LAB 
±SEM 
 
 
KWH 
 
 
MWU 
HAB 
vs. 
LAB 
MWU 
HAB 
vs. 
NAB 
MWU 
NAB 
vs. 
LAB 
Tmem132d 1.00±0.24 1.16±0.23 1.26±0.16 0.68    
Trib2 1.00±0.27 2.57±0.45 3.06±0.49 4.36 
x10-3 0.01 0.02 0.75 
Zfp672 1.00±0.23 2.23±0.32 1.97±0.21 0.02 0.05 0.03 0.77 
 
Additionally, in whole brain material from male mice, differential expression of six 
more genes could be confirmed with remarkably high expression differences 
between HAB and LAB mice for syntaxin 3 (Stx3; 2.26-fold in LAB) ATP-binding 
cassette, sub-family A (ABC1), member 2 (Abca2; 6.16-fold in HAB) and for the 
RIKEN cDNA 2900019G14 gene (2900019G14Rik; 15.90-fold in HAB; Tables 14 
and 15). Although differences for some transcripts reached similar tendencies as in 
the microarray experiment, the differences did not reach statistical significance.  
 
Table 14: Gene transcripts analyzed in whole brain tissue from male mice with the relative 
(rel.) fold expression in HAB, NAB and LAB mice ±SEM, followed by the p-values of the 
Kruskal-Wallis (KWH) and Mann-Whitney tests (MWU) for HAB vs. LAB, HAB vs. NAB and 
NAB vs. LAB mice. Statistically significant results are given in bold letters.  
 
Gene symbol 
Rel. 
expression 
HAB 
±SEM 
Rel. 
expression 
NAB 
±SEM 
Rel. 
expression 
LAB 
±SEM 
 
 
KWH 
 
 
MWU 
HAB 
vs. 
LAB 
MWU 
HAB 
vs. 
NAB 
MWU 
NAB 
vs. 
LAB 
Apbb1 1.00±0.11 1.05±0.15 1.28±0.17 0.21    
Hbb-b1 1.34±0.16 1.62±0.27 1.00±0.15 0.11    
Kcnh1 1.00±0.11 1.16±0.20 1.15±0.15 0.83    
Scl1a2 1.12±0.14 1.21±0.23 1.00±0.14 0.98    
Stx3 1.00±0.31 1.34±0.07 2.26±0.27 0.01 0.08 0.09 0.01 
 
Table 15: Gene transcripts analyzed in whole brain tissue from male mice with the relative 
(rel.) fold expression in HAB and LAB mice ±SEM, followed by the p-values of the Mann-
Whitney tests (MWU) for HAB vs. LAB mice. Statistically significant results are given in bold 
letters.  
 
Gene symbol 
 
Rel. 
expression in 
HAB ±SEM 
Rel. 
expression 
in LAB ±SEM 
MWU 
HAB vs. 
LAB 
2900019G14Rik 15.90±1.70 1.00±0.09 4.48x10-3 
Abca2 6.16±0.80 1.00±0.22 2.70x10-3 
Dgkh 2.01±0.56 1.00±0.12 0.29 
Dgkq 1.61±0.59 1.00±0.18 0.36 
Enpp5 2.14±0.55 1.00±0.03 0.01 
Gig1 1.00±0.12 1.04±0.13 0.72 
Gnaq 1.00±0.21 1.15±0.31 0.67 
Hmgn3 2.08±0.39 1.00±0.16 0.03 
Pdhb 1.60±0.28 1.00±0.12 0.06 
Pxk 1.31±0.22 1.00±0.14 0.27 
Ttbk1 1.14±0.21 1.00±0.21 0.94 
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Altogether, the expression differences of twelve genes could be confirmed by qPCR 
out of the 28 transcripts analyzed irrespective of specific brain regions.  
Vasopressin (Avp) 
Investigation of the Avp transcript in the PVN and SON of female HAB, CD1 and 
LAB mice revealed reduced Avp expression in the PVN (Fig. 16A) and SON (Fig. 
16B) in LAB compared to HAB or CD1 animals (PVN KWH: p = 0.03; MWU: HAB 
vs. LAB p = 0.01, HAB vs. CD1 p = 0.20, CD1 vs. LAB p = 0.57; SON KWH: p = 
3.89x10-3; MWU: HAB and CD1 vs. LAB p = 0.01, HAB vs. CD1 p = 0.55).  
 
Figure 16: Vasopressin (Avp) expression patterns as measured by quantitative PCR in the 
(A) hypothalamic paraventricular nucleus and (B) supraoptic nucleus of female mice. Data 
are presented as means +SEM; ** p < 0.01; * p < 0.05. 
 
qPCR measurements also revealed slightly elevated concentrations of unspliced 
Avp in HAB compared to LAB that, however, failed to reach significance. Correct 
sequence of the Avp intron-specific amplificates was confirmed by sequencing (data 
not shown).  
Tachykinin 1 (Tac1) 
Not completely in line with the results from the gene expression screening, for Tac1 
transcripts a higher expression could be observed by qPCR in all female mice, but 
only the results for the basolateral/lateral amygdala and the supraoptic nucleus 
reached statistical significance (BLA/LA KWH: p = 0.03; MWU: HAB vs. LAB p = 
0.03, HAB vs. CD1 p = 0.05, CD1 vs. LAB p = 0.72; SON KWH: p = 6.16x10-3; 
MWU: HAB vs. LAB p = 0.02, HAB vs. CD1 p = 0.35, CD1 vs. LAB p = 0.02; PVN 
KWH: p = 0.07; MWU: HAB vs. LAB p = 0.06, HAB vs. CD1 p = 0.25, CD1 vs. LAB p 
= 0.37; Fig. 16).  
 
 Results 
68 
 
Figure 17: Tachykinin 1 (Tac1) expression patterns as measured by quantitative PCR in the 
(A) basolateral/lateral amygdala, (B) supraoptic nucleus and (C) hypothalamic 
paraventricular nucleus of female mice. Data are presented as means +SEM; T p < 0.1; * p < 
0.05; ** p < 0.01. 
 
 
Figure 18: Gene expression levels of tachykinin 1 (Tac1) transcript variants (α-, β-, γ- and δ-
PPT) in female HAB, CD1 and LAB mice (eight each) in (A) the basolateral/lateral amygdala 
and (B) the hypothalamic paraventricular nucleus. Data are presented as means +SEM;  
*** p < 0.001; ** p < 0.01; * p < 0.05; T p < 0.1. 
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Also for the detailed analysis of Tac1 splicing variants, no significant differences 
could be observed in the PVN for all transcripts variants. However, in the BLA/LA all 
four known splicing variants were significantly higher expressed in HAB compared to 
CD1 and LAB mice (Fig. 18). Especially for the -PPT and -PPT fragments HAB 
animals exhibited a 10-fold increased expression compared to LAB mice. Neither for 
the SON nor for the CeA a differential expression of single transcript variants could 
be confirmed.  
Transmembrane protein 132D (Tmem132d) 
qPCR analysis further confirmed the significantly increased expression of 
Tmem132d in the cingulate cortex of HAB compared to LAB mice with CD1 animals 
displaying an intermediate expression level (KWH: p = 0.02; MWU: HAB vs. LAB p = 
0.03, HAB vs. CD1 p = 0.13; CD1 vs. LAB p = 0.14; Fig. 19).  
 
 
Figure 19: Gene expression levels of the transmembrane protein 132D gene (Tmem132d) 
as confirmed in tissue punches from the cingulate cortex of female HAB, CD1 and LAB mice. 
Data are presented as means +SEM; * p < 0.05. 
 
Transthyretin (Ttr) 
Gene expression analysis of Ttr by qPCR failed to reveal any differences in the 
BLA/LA between HAB and LAB mice. Although there were two LAB mice that 
expressed the Ttr transcript in excess, in other mice of the LAB group expression 
levels were under the detection threshold (data not shown).   
 
3.2.5. Effects of selected candidate genes 
Further investigation of candidate gene-related phenomena revealed new and 
significant physiological differences between HAB and LAB mice.  
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3.2.5.1. Glyoxalase I (GLO1) and metabolic stimulation 
 
3.2.5.1.1. Metabolism and blood plasma parameters 
Measurement of food intake over six days in single housed HAB, CD1 and LAB 
mice demonstrated significantly elevated food intake by 25% in LAB mice compared 
to both, HAB and CD1 animals (KWH: p = 2.28x10-3; MWU: HAB vs. LAB p = 
7.49x10-3, HAB vs. CD1 p = 0.56, CD1 vs. LAB p =  9.31x10-3 ; Fig. 20). However, 
no significant differences between HAB and LAB mice could be observed, when 
tested for blood plasma concentrations of lactate, triglycerides, cholesterol, HDL and 
LDL.  
 
Figure 20: Food consumption of male HAB, CD1 and LAB mice per day and per gram of 
body weight. Data are presented as means +SEM; ** p < 0.01. 
 
3.2.5.1.2. Behavioral manipulation by metabolic stimulation 
Control measurements conducted throughout the complete experiment (15 weeks) 
confirmed that mice fed with 0.5M saccharose showed a significant increase in 
calorie uptake and likewise increased water consumption. Interestingly, they 
exhibited decreased food consumption. There was no significant difference 
detectable between saccharose-soaked and control mice regarding their body 
weight at any time-point of the experiment (Fig. 21).  
As a control parameter of physiological stress caused by dehydration, urine 
osmolality was assessed and revealed a significant decrease in the 0.5M 
saccharose-soaked group, with no difference in blood plasma osmolality was  
(Fig. 22). 
The first testing of treated vs. control mice on the EPM revealed a significant 
increase of the latency to first enter into the open arm (KWH: p = 0.03; Fig. 23 C) 
combined with a decrease in the total time spent on the open arms (KWH: p = 0.09; 
Fig. 23 B).  
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Treated mice also exhibited a decrease in the percentaged time spent on the open 
arms, but the difference for this parameter failed to reach significance (∆ = 9%; 
KWH: p = 0.12; Fig. 23A). The second EPM test showed similar results with only the 
latency still being slightly reduced in treated mice (KWH: p = 0.08; Fig. 23D, E). 
Locomotion did not differ between the treated and control group as measured by the 
total distance traveled in the OF (Fig. 23F). 
 
Figure 21: Body weight and metabolic indicators of CD1 mice drinking 0.5M saccharose and 
controls in the experimental time course. (A) The animals’ body weight at different 
experimental stages and their corresponding age in weeks. (B) Daily water consumption of 
the mice at all stages and (C) the calculated daily total calorie uptake. Data are presented as 
means +SEM; *** p < 0.001; ** p < 0.01; * p < 0.05. 
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Figure 22: (A) Urine and (B) blood plasma osmolality in CD1 mice soaked with 0.5M 
saccharose (aq) vs. controls. Data are presented as means +SEM; ** p < 0.01. 
 
 
Figure 23: Assessment of anxiety-related behavior and locomotion in CD1 mice soaked with 
0.5M saccharose (aq). (A) Anxiety-related behavior as reflected by the percentaged time 
spent on the open arms of the elevated plus-maze (EPM), mice tested for the first time; (B) 
Total time spent the open arms of the EPM in mice tested for the first time; (C) Latency time 
to first enter one open arm of the EPM in mice tested for the first time; (D) Percentaged time 
spent on the open arms of the EPM, mice tested for the second time; (E) Latency time to first 
enter one open arm of the EPM in mice tested for the second time; (F) Total distance 
traveled in the open field as a measure of locomotion. Data are presented as means +SEM; 
* p < 0.05; T p < 0.10. 
 
 
3.2.5.1.3. Western Blot analysis of glyoxalase 1 (GLO1) 
The first time point of GLO1 measurement from red blood cells pointed to a 
decreased expression in the 0.5M saccharose-treated group, failing to show 
statistical significance but still reaching a trend four weeks after the start of 
treatment (MWU: p = 0.08; Fig. 24A). Interestingly, an effect in the other direction 
(i.e. an increase in the treated group) was observed in red blood cell extracts taken 
nine weeks after treatment’s start (MWU: p = 0.09; Fig. 24B).  
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Figure 24: Measurement of glyoxalase I protein from red blood cells by Western Blot of CD1 
mice soaked with 0.5M saccharose (aq) (A) from five animals after four weeks of elevated 
calorie uptake and (B) of ten mice per group after nine weeks of elevated calorie uptake. 
Data are presented as means +SEM; T p < 0.10. 
 
3.2.5.2. Tachykinin 1 (Tac1) encoded peptides 
All measured values for NKB were below the detection limit, but all other peptides 
could be quantified by ELISA. No significant differences in peptide levels could be 
identified between HAB, CD1 and LAB mice, neither in the BLA/LA nor in the PVN. 
The quantity of substances ranged from 100-1,600fmol with the lowest 
concentrations measured for NPK and the highest for SP. While, in the 
basolateral/lateral amygdale, SP exhibited the highest level of all peptides ranging 
from 1,000 to 1,600fmol and all other peptides were present below a level of 
500fmol, in the PVN NPγ also reached concentrations of approximately 800 to 
1,200fmol for all tested mouse lines. Another interesting result is that in contrast to 
the BLA/LA, where NKA was found at a level between 200 and 800fmol and NPK 
only at 100fmol, this proportion was inverted for these two peptides in the PVN (data 
not shown).  
 
3.2.5.3. Cytochrome c oxidase (COX) activity 
Assessing the enzyme activity of the cytochrome c oxidase, significant differences 
were identified in the BLA and CeA, where HAB displayed increased enzyme activity 
compared to LAB mice (BLA and CeA MWU: p = 0.02; Fig. 25A, B). A similar 
tendency was observed for the shell of the NAc (MWU: p = 0.07; Fig. 25C), whereas 
a decreased activity of cytochrome c oxidase was observed in HAB compared to 
LAB animals in the PVN (MWU: p = 0.04; Fig. 25D). No difference in enzyme activity 
was detected in the Cg, the complete NAc or hippocampal regions between HAB 
and LAB mice.  
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Figure 25: Measurement of cytochrome c oxidase activity in diverse brains regions of HAB 
and LAB mice in the (A) basolateral amygdala, (B) central amygdala, (C) shell of the nucleus 
accumbens and (D) hypothalamic paraventricular nucleus. Data are presented as means 
+SEM; * p < 0.05; T p < 0.10. 
 
3.3. Identification of polymorphisms 
 
3.3.1. Prescreening  
Prescreening on the Illumina Mouse Medium Density Linkage Panel resulted in the 
identification of 235 individual SNPs (Table 4, SNPs with the source code ‘1’) that 
were found to display opposite homozygous genotypes in HAB vs. LAB mice (i.e. if 
all HAB mice showed the genotype ‘AA’, all LAB mice displayed the genotype ‘BB’). 
In detail, 301 autosomal SNPs were identified as having homozygous state in both 
HAB and LAB animals, but showing an inconsistent state in LAB mice (most SNPs 
with the same homozygous genotype in LABs, but some showing the opposite 
genotype). Therefore, when focusing on LAB mice, two well-defined subgroups 
could be identified, where one subgroup carried the opposite homozygous genotype 
to HAB mice at 275 loci and the other one at 277. If referred to one of the LAB 
subgroups, they are termed LAB-A and LAB-B mice. The genotypic difference 
between the two LAB mouse subgroups included 76 SNPs that left a total of 225 
autosomal SNPs as useful markers differing between the HAB and the complete 
LAB group (Fig. 26A; made up of both subgroups). Additionally, 20 HABxLAB F1 
intercross animals also consistently showed a strictly heterozygous genotype for the 
225 autosomal SNPs, identified in HAB vs. LAB animals. Results for X-
chromosomal markers were analogous.  
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Further 41 SNPs were identified, where some animals were either hetero- or 
homozygous, without displaying any consistency between lines or families within 
these lines. In average, all mice carried about ten SNPs (of the above mentioned 
41) heterozygously, displaying no significant difference between the mouse lines 
(Fig. 26). 30 SNPs were excluded from the analysis as they displayed fluorescence 
rates below the threshold, over which they can be reassigned reliably (call rate).  
 
 
Figure 26: Characterization of HAB and LAB mice based on the screening for 1449 single 
nucleotide polymorphisms (SNPs). (A) The number of SNPs detected as exclusively 
opposite homozygous between HAB and LAB mice. The dashed line indicates the total 
number of SNPs, bars show the number of SNPs for comparisons of HAB mice versus both 
LAB subgroups (LAB-A and LAB-B) and between the two LAB subgroups only. (B) The total 
number of heterozygous SNP loci detected in individual HAB and LAB mice. Data are 
presented as means +SEM. 
 
 
3.3.2. Screening of the F2 panel 
For 26 SNPs, genotypes could not be reassigned as they displayed low call rates. 
Thereof 13 SNPs were identified in the prescreening experiment (gnf05.084.686, 
CEL-7_5627457, CEL-5_87173557, rs13482712, rs13481706, rs13481161, 
rs13480092, rs13476503, rs3664408, rs3688351, rs3692362, rs4232449, 
rs6239023), 13 further loci were added to this genotyping-assay (rs30263474, 
rs3022996, rs30228387, rs29327697, rs26888739, rs13480933, rs32005588, 
rs31193418, rs31983176, rs32034601, rs32900718, rs33319598, rs29469152).  
From the added SNPs to this genotyping-assay (not included in the prescreening 
experiment), 35 loci delivered genotypes bearing with informative value, i.e. they 
were showing opposite homozygous genotypes in HAB vs. LAB mice. This includes 
two SNPs that were identified to be typical for LAB-A mice only. In F2 mice, the 
distribution of genotypes was not deviating significantly from the expected 1:2:1 ratio 
for any allele.  
Additionally, an X-chromosomal-like distribution of alleles was observed for eleven 
SNPs (rs6221690, rs6182892, rs3697198, rs13484043, rs13484004, rs13483997, 
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rs13483894, rs13483765, gnfX.148.995, gnfX.080.189, gnfX.026.801). Examination 
of their actual genomic position confirmed this hypothesis.  
All independent control samples (one HAB and LAB sample each, run once each on 
every plate), delivered concordant results throughout all assays. 12 control samples 
from plates 1-6 run on the 8th plate also delivered the same genotypes as before. 
Altogether, only 89 SNPs showed no informative value concerning the F2 panel, 
leaving a total of 267 SNPs as valid and stable markers. 
Additionally, all HAB and LAB animals could be reassigned to their line based on the 
distribution of genotypes, also confirming the results of genotyping from the pre-
screening experiment.  
 
3.3.3. Genotype frequencies in wildtype CD-1 mice 
In contrast to HAB, LAB, F1 and F2 mice, only for 46 loci no variation was 
detectable at all. For 21 SNPs, the minor allele had a frequency under 10%, for 130 
SNPs (42% of all SNPs showing variations) allele frequencies were between 35 and 
65%. Significant deviation from Hardy-Weinberg equilibrium was obtained for 13 
SNPs in CD1 animals. For 42 SNPs, sequence variation was unique to CD1, but not 
for any HAB and LAB or HABxLAB F1 intercross mouse. Not one single SNP was 
detected, where any HAB or LAB breeding-derived animal showed a new variation 
that has not been found in unselected CD1 mice.  
 
3.3.4. Sequencing of candidate genes 
To investigate whether differences in gene expression originated from differences in 
the sequences of HAB-and LAB-specific alleles, differentially expressed genes were 
sequenced. In about 50% of genes sequenced, variations between HAB and LAB 
mice were found in and around the gene loci.  
 
3.3.4.1. Vasopressin (Avp) 
Sequencing of the Avp gene resulted in the identification of nine polymorphic sites, 
of which eight correspond to SNPs and one comprises a 12bp deletion (Fig. 27).  
The upstream promoter region contains two SNPs: T(-2521)C with HABs carrying 
thymine and LABs cytosine and C(-1422)T with HABs carrying cytosine and LABs 
thymine. Furthermore, LAB mice miss a 12bp segment mapping to ∆(-2180-2191). 
The gene-coding locus contains three SNPs: position C(40)T with HABs carrying 
cytosine and LABs thymine, A(1431)G with HABs carrying adenine and LABs 
guanine, and T(1527)C with HABs carrying thymine and LABs cytosine. The 
downstream enhancer region, also referred to as intergenic region between Avp and 
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Oxt, contains three SNPs: A(+399)G with HABs carrying adenine and LABs 
guanine, T(+476)G with HABs carrying thymine and LABs guanine, and C(+2444)A 
with HABs carrying cytosine and LABs adenine.  
 
Figure 27: Vasopressin (Avp) gene sequence of HAB vs. LAB mice. Polymorphic sites are 
indicated with positions from transcription start (-1 to -2600bp) in the promoter region (two 
SNPs and deletion in LABs), within the Avp coding sequence from transcription start (1 to 
1944bp; three SNPs) and in the downstream enhancer region (+1 to +2600bp; three SNPs). 
Exons with untranslated regions (UTRs) are indicated by boxes (exons shaded, UTRs 
completely filled black or white). 
 
For both the C(40)T SNP and the 12bp deletion, NAB and F2 mice always showed 
the same linkage consisting of three variations: the homozygous HAB-specific 
combination of alleles (CC) at the 40 locus polymorphism, which appears always 
associated with the presence of the intact 12bp region of the promoter in both alleles 
(+/+) the homozygous LAB-specific combination (TT and -/-) or a heterozygous 
combination (CT and +/-). The most frequent genotype combination in NAB mice 
was the HAB-specific one (Table 16). 
 
Table 16: Genotype frequencies in a CD1 population (n = 165) for the SNP in the Avp signal 
peptide and the strictly linked promoter deletion. The same strict linkage was obvious in a 
freely-segregating F2 panel (HABxLAB intercross offspring, n = 508). 
 
CD1 mice F2 mice 
Locus (40) Genotype frequency 
∆ (-2191-
2180) Locus (40) 
Genotype 
frequency 
∆ (-2191-
2180) 
CC 73.30% +/+ CC 25.90% +/+ 
CT 26.10% +/- CT 51.90% +/- 
TT 0.60% -/- TT 23.20% -/- 
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3.3.4.2. Corticotropin-releasing hormone (Crh) 
No sequence variations have been identified at the Crh locus differing between HAB 
and LAB mice. Only some variations differing between HAB and LAB mice and the 
reference sequence, that was based on mice from the C57BL/6J strain could be 
identified (data not shown).  
 
3.3.4.3. Tachykinin 1 (Tac1) 
Also for the Tac1 locus, no sequence variations could be identified, that would allow 
for the discrimination of a HAB vs. LAB mouse line-specific allele.  
 
3.3.4.4. Cathepsin B (Ctsb) 
In contrast to Tac1 or Crh, many polymorphic loci were identified at the Ctsb locus. 
Altogether, 76 SNPs, eight insertions and nine deletions were found in HAB vs. LAB 
mice. The definition of insertion or deletion was made in reference to the sequence 
of the mouse strain C57BL/6J. In the promoter region, ten SNPs and two insertions 
were found. In the ten exons, eight polymorphic sites (all SNPs) were identified (Fig. 
28).  
Figure 28: Cathepsin B (Ctsb) gene sequence of HAB vs. LAB mice. Polymorphic sites are 
indicated with positions in the coding sequence from transcription start in the spliced mRNA. 
Exons and untranslated regions (UTRs) are indicated by boxes (exons shaded, UTRs 
completely filled black or white). 
 
The vast majority of variations was identified in the introns and the DER (Table 17). 
Interestingly, in the promoter about six variations are located within 230bp between -
2,269 and -2,045bp. Similar proximity of polymorphic sites was found in the third 
and fourth intron, where also within 550 and 400bp 18 and twelve variations were in 
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close neighborhood. Additionally, condensation of twelve variable sites could be 
identified in the DER (at a length of 350bp).  
 
Table 17: Variations identified in the cathepsin B (Ctsb) gene. Variation type refers to single 
nucleotide polymorphisms (SNPs), deletions or insertions, the genomic position to the 
physical position on chromosome 14, HAB and LAB to their line specific allele, location in the 
gene to the functional structure of the variation locus (downstream enhancer region: DER), 
relative (rel.) position to the Ctsb locus, position in mRNA to the spliced mRNA and SNP 
identifier to already described polymorphisms. Functional structures are indicated by 
horizontal disjunctions. 
. 
Variation 
type 
Genomic 
position 
 
 
HAB 
 
 
LAB 
Location 
in the 
gene 
Rel. 
position 
Pos. 
in 
mRNA 
SNP 
identifier 
SNP 63,739,084 C T Promoter -2,269   
SNP 63,739,124 C G Promoter -2,229   
Insertion 63,739,210 GAGA - Promoter -2,143   
SNP 63,739,257 C T Promoter -2,096   
SNP 63,739,273 C T Promoter -2,080   
SNP 63,739,308 G A Promoter -2,045   
Insertion 63,739,394 C - Promoter -1,959   
SNP 63,739,609 G A Promoter -1,744   
SNP 63,740,071 G C Promoter -1,282   
SNP 63,740,540 C A Promoter -826  rs30963834 
SNP 63,740,968 T C Promoter -398  rs30962992 
SNP 63,741,271 G T Promoter -95   
SNP 63,741,362 C T Exon 1 10 10 rs30962990 
SNP 63,741,423 A G Intron1 71  rs30962988 
SNP 63,752,252 A G Exon 2 10,900 150  
SNP 63,752,362 T C Intron 2 11,010   
SNP 63,752,540 A G Intron 2 11,188   
SNP 63,752,557 C T Intron 2 11,205  rs30973898 
SNP 63,752,683 C T Intron 2 11,331  rs16791841 
SNP 63,752,876 G A Exon 3 11,524 276 rs16791842 
SNP 63,753,119 C T Intron 3 11,767  rs16791844 
SNP 63,753,163 A G Intron 3 11,811   
SNP 63,753,224 A G Intron 3 11,872  rs30972751 
SNP 63,753,468 T C Intron 3 12,116   
SNP 63,753,529 C T Intron 3 12,177   
SNP 63,753,684 T A Intron 3 12,332   
SNP 63,753,699 C G Intron 3 12,347   
SNP 63,753,705 C T Intron 3 12,353   
Insertion 63,753,712 A - Intron 3 12,360   
SNP 63,753,733 T A Intron 3 12,381   
SNP 63,753,745 C T Intron 3 12,393   
SNP 63,753,778 C T Intron 3 12,426   
Deletion 63,753,885 - 
AATAAAT 
CTAAGAG 
AAGGATG 
AGTCACT 
Intron 3 12,533   
SNP 63,753,914 G A Intron 3 12,562   
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Variation 
type 
Genomic 
position 
 
 
HAB 
 
 
LAB 
Location 
in the 
gene 
Rel. 
position 
Pos. 
in 
mRNA 
SNP 
identifier 
SNP 63,753,930 T G Intron 3 12,578   
Deletion 63,753,945 - TAAAAATAA GCCTGAAG Intron 3 12,593   
SNP 63,754,102 A G Intron 3 12,750   
SNP 63,754,112 C A Intron 3 12,760   
Deletion 63,754,125 - GGAA Intron 3 12,773   
Insertion 63,754,163 ACA - Intron 3 12,811   
SNP 63,754,221 T C Intron 3 12,869   
SNP 63,754,227 C T Intron 3 12,875  rs30972744 
SNP 63,754,228 G A Intron 3 12,876   
SNP 63,754,279 C T Intron 3 12,927  rs30971633 
SNP 63,754,724 G A Intron 4 13,372   
Deletion 63,754,741 - G Intron 4 13,389   
SNP 63,754,763 T C Intron 4 13,411   
SNP 63,754,764 G C Intron 4 13,412   
SNP 63,754,866 A G Intron 4 13,514   
SNP 63,754,907 A C Intron 4 13,555   
SNP 63,754,931 A T Intron 4 13,579   
SNP 63,754,948 C T Intron 4 13,596  rs30971631 
SNP 63,755,037 C T Intron 4 13,685   
SNP 63,755,050 C G Intron 4 13,698   
SNP 63,755,110 C G Intron 4 13,758   
SNP 63,755,122 C A Intron 4 13,770  rs30971628 
SNP 63,755,186 C T Intron 4 13,834   
SNP 63,755,315 A G Exon 5 13,963 474 rs13462712 
SNP 63,755,474 G A Intron 5 14,122   
Deletion 63,755,498 - T Intron 5 14,146   
SNP 63,755,500 G T Intron 5 14,148   
Deletion 63,756,855 - AA Intron 5 15,503   
SNP 63,757,503 T C Intron 7 16,151   
SNP 63,758,010 A G Intron 8 16,658   
SNP 63,760,454 G A Intron 8 19,102  rs30969648 
SNP 63,760,495 G A Intron 8 19,143  rs30969646 
Insertion 63,760,849 
CACATGG 
TTTTGTAG 
ACAGTTCC 
- Intron 9 19,497   
SNP 63,761,222 C T Exon 10 19,870 1,151 rs13462709 
SNP 63,761,241 T G Exon 10 19,889 1,170  
SNP 63,761,536 C G Exon 10 20,184 1,466  
SNP 63,761,844 G T Exon 10 20,492 1,774 rs13462707 
SNP 63,762,117 C G DER +144   
SNP 63,762,512 T C DER +539   
SNP 63,762,597 A C DER +624   
SNP 63,762,653 A G DER +680  rs30967661 
SNP 63,762,668 A C DER +695   
SNP 63,762,783 T A DER +810  rs30967657 
SNP 63,763,038 C A DER +1,065   
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Variation 
type 
Genomic 
position 
 
 
HAB 
 
 
LAB 
Location 
in the 
gene 
Rel. 
position 
Pos. 
in 
mRNA 
SNP 
identifier 
SNP 63,763,124 C T DER +1,151  rs30967655 
SNP 63,763,140 C T DER +1,167  rs30966673 
Insertion 63,763,172 CA - DER +1,199   
Deletion 63,763,184 - TC DER +1,211   
SNP 63,763,230 A C DER +1,257   
Deletion 63,763,303 - TTA DER +1,330   
SNP 63,763,356 C T DER +1,383   
Insertion 63,763,385 CC - DER +1,412   
Deletion 63,763,400 - GTTT DER +1,427   
SNP 63,763,441 C G DER +1,468   
SNP 63,763,452 A C DER +1,479   
SNP 63,763,470 A G DER +1,497   
SNP 63,763,474 A G DER +1,501   
Insertion 63,763,662 ATA - DER +1,689   
SNP 63,763,715 A G DER +1,742   
 
3.3.4.5. Metallothionein 1 (Mt1) 
Comparison of the HAB and LAB mouse sequences at the Mt1 locus failed to reveal 
any differences. 
 
3.3.4.6. Transmembrane protein 132D (Tmem132d) 
By sequencing Tmem132d, several polymorphic loci could be identified, among 
them, two SNPs in the promoter of the gene at positions A(-519)G and A(-310)G.  
 
Figure 29: Transmembrane protein 132D (Tmem132d) gene sequence of HAB vs. LAB 
mice. Polymorphic sites are indicated with minus sign for promoter positions in bp, with 
positions in the coding sequence from transcription start in the spliced mRNA (in bp) or with 
chromosomal positions for single nucleotide polymorphisms in introns (in bp). Exons and 
untranslated regions (UTRs) are indicated by boxes (exons shaded, UTRs completely filled 
 Results 
82 
black or white). Unfilled circles with numbers ‘1’ and ‘2’ refer to two deletions in HAB mice. 
For ‘1’ at position 128,577,978bp (deletion of CAAA) and ‘2’ at position 128,577,906 
(deletion of ACA).  
 
Four further SNPs were identified located in exons, with C(470)T and C(573)T in the 
untranslated region and A(1,747)G in exon 3 (also known as rs36596918) and 
A(3,164)G in exon 9 (rs13478518) as part of the protein coding sequence. 
Furthermore, three SNPs and 2 deletions were discovered in introns, among them 
C(128,616,797)T (rs13478520), A(128,577,729)T, ∆(128,577,906-128,577,903) 
and ∆(128,577,978-128,577,974) in the third and T(128,344,853)A in the fifth intron 
(Fig. 29). 
 
3.3.4.7. Further sequencing results 
2900019G14Rik amplificates from qPCR were also sequenced, as qPCR resulted in 
well detectable products. All products showed slightly shifted melting peaks, when 
analyzing the melting curves, with HAB animals dispalying a slightly decreased 
melting peak temperature. Sequencing of the 137bp-sized amplificate resulted in the 
identification of two SNPs, C(90)A and C(110)T (positions relative to the amplicon’s 
sequence; Fig. 30).  
 
AGAGTATTTC     TCGTTCTCAT GTGACCTGAG TGAAGAACTT     AACCTAGAAA 
CCCCTGTACT     CATTATTGTT TGCAAATCTC TGAGTCCAG[C/A] ACCTTTGTAA 
ATACAGCCC[C/T] GAGGAGGAAT GGGGGTGAAT GTGTTTA 
 
Figure 30: Sequence of the RIKEN cDNA 2900019G14 gene amplificate generated by 
quantitative PCR.  
 
3.3.5. The effects of polymorphisms  
Analysis of the identified SNPs of sequenced genes in the coding sequence 
revealed that most SNPs in Ctsb, Tmem132d and Avp were synonymous mutations 
at the third (degenerate) codon. The only exceptions to that are C(40)T and 
G(1747)A. Whereas C(40)T is located in the coding sequence of the AVP signal 
peptide, resulting in the change of the amino acid residue from alanine to valine and 
G(1747)A in Tmem132d causing the substitution of an arginine residue by lysine.  
A detailed in silico search for potential transcription factor binding sites at the 
polymorphic loci at the Avp locus led to the identification of a number of candidates 
that are summarized in Table 18. 
For the polymorphisms in Tmem132d, TGA[A/G]CT was identified as a possible 
binding site for the glucocorticoid receptor (locus refered to as glucocorticoid 
response element – GRE). The mentioned polymorphism is the A(-310)G, with LAB 
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animals carrying the A, HAB mice the G allele homozygously. Additionally, at the A(-
519)G locus, where also LAB mice carry the A and HAB animals the G allele 
homozygously, the LAB-specific sequence creates a binding site for a repressor 
(E12), whereas the HAB-specific site for a transcription factor (NF1).  
In Ctsb at position A(-2045)G a binding site for CBF1 was predicted that would 
increase binding in in LAB, but not in HAB mice. Same applies to T(-95)G, where 
binding of WT1 would be possible in LAB but only at decreased efficiency in HAB 
mice. 
 
Table 18: Polymorphisms in the promoter and downstream enhancer region of Avp between 
the HAB and LAB specific sequence, with probable binding factors.  
 
Polymorphism 1st binding factor 2nd binding factor Reference 
T(-2521)C NF-1 C/EBPalpha Kraus et al., 2001 
∆(-2180-2191) NF-1 C/EBPbeta Ji et al., 1999 
C(-1422)T --- --- --- 
A(+399)G c-Ets-2 C/EBPbeta Chakrabarty and Roberts, 2007 
T(+476)G AP-1 / GATA-1 --- --- 
C(+2444)A --- --- --- 
 
3.3.6. Allele-specific transcription analyses of vasopressin (Avp) 
To obtain evidence for a functional role of the polymorphisms in Avp contributing to 
different levels of expression in LAB versus HAB mice, the activity of each allele was 
studied in an F1 cross between these two lines. Under this condition, both alleles 
were contained in the same cellular background, thus eliminating differential 
synaptic input as a confounding factor. Assessing the allele-specific transcription 
rate, the LAB-specific allele displayed a significantly decreased expression relative 
to the HAB-specific one in the PVN and SON (p=1.4x10-4; Fig. 31). This is 
consistent with Avp mRNA expression data of LAB versus HAB mice (see Fig. 16).  
 
Figure 31: Proportion of HAB vs. LAB allele-specific vasopressin (Avp) transcripts from 
heterozygous F1 (HABxLAB intercross) mice in the paraventricular nucleus (PVN; χ²=14.4) 
and the supraoptic nucleus (SON; χ²=15.2). Data are shown as means +SEM; *** p < 0.001. 
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3.4. Association and linkage of SNPs with behavioral parameters 
To further test the functional involvement of the identified SNPs, all SNP loci from 
the Illumina experiment with the custom-designed oligo pool were associated with a 
variety of behavioral parameters (excerpt in supplementary table 3). 
Most significant and interesting results were obtained for SNPs in Enoph1, 
Tmem132d, Zfp672, near methionine sulfoxide reductase B2 (Msrb2), in Avp and 
hornerin (Hrnr).  
For Enoph1, SNPs in a total of 514 male mice, 111 animals were identified as 
carrying the HAB-typical SNPs rs13460000 and rs13460001 (GG and CC), 116 
animals the LAB-typical AA and TT, and 287 animals the heterozygous AG and CT 
genotypes. If these SNPs impact on anxiety-related behavior, homozygous GG and 
CC F2 animals should behave more anxious than their AA and TT counterparts. 
Indeed, a co-segregation could be detected with AA and TT mice being less anxious 
on the EPM (p = 1.05x10-6) and tending to show reduced depression-like behavior in 
the tail suspension test, although failing to reach statistical significance (p = 0.23; 
Fig. 32).  
 
Figure 32: Association between anxiety-related and depression-like behavior and enolase-
phosphatase 1 (Enoph1) genotypes in the freely-segregating F2 panel. Phenotypic indices of 
male F2 mice with HAB-specific Enoph1 genotypes GG and CC (HAB-specific homozygotes, 
N = 113), AG and CT (heterozygotes, N = 292), or AA and TT (LAB-specific homozygotes, N 
= 117). (A) Percentaged time spent on the open arms of the elevated plus-maze (EPM) and 
(B) total immobility time in the tail suspension test. LAB-specific homozygotes were less 
anxious and also displayed less immobility, although failing to reach statistical significance. 
Data are presented as means +SEM; *** p < 0.001. 
 
The functional impact of Tmem132d was substantiated by the association analysis, 
where rs13478518 located in exon 9 of Tmem132d was found to be associated with 
anxiety-related behavior on the EPM (p = 9.80x10-4), with less anxious animals 
carrying the LAB-specific (i.e. GG) and more anxious ones the HAB-specific (i.e. 
AA) genotype (Fig. 33). Both depression-like behavior and locomotor activity failed 
to show an association (data not shown). 
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Figure 33: Association between anxiety-related behavior and the transmembrane protein 
132D (Tmem132d) genotypes in the freely-segregating F2 panel. Phenotypic indices of male 
F2 mice with LAB-specific Tmem132d genotypes GG (LAB-specific homozygotes, N = 128), 
AG (heterozygotes, N = 276) or AA (HAB-specific homozygotes, N = 118). Percentaged time 
spent on the open arms of the elevated plus-maze (EPM). LAB-specific homozygotes were 
less anxious. Data are presented as means +SEM; ** p < 0.01. 
 
Anxiety-related behavior as reflected by the percentaged time spent on the open 
arms of the EPM also delivered a significant linkage with a SNP (rs29402173) in the 
3’ UTR of Zfp672. Whereas animals bearing the HAB-specific variant (GG) 
displayed high anxiety-like behavior, mice with the LAB-specific genotype (AA) were 
less anxious (p = 1.18x10-9; Fig. 34). Also in this case locomotor activity and 
depression-like behavior did not reveal any significant differences between animals 
bearing different genotypes (data not shown). Zfp672 was identified in the 
microarray and qPCR analyses as differentially regulated between HAB and LAB 
mice.  
 
Figure 34: Association between anxiety-related behavior and the zinc finger protein 672 
(Zfp672) genotypes in the freely-segregating F2 panel. Phenotypic indices of male F2 mice 
with LAB-specific Zfp672 genotypes AA (LAB-specific homozygotes, N = 117), AG 
(heterozygotes, N = 271), or GG (HAB-specific homozygotes, N = 134). Percentaged time 
spent on the open arms of the elevated plus-maze (EPM). LAB-specific homozygotes were 
less anxious. Data are presented as means +SEM; *** p < 0.001. 
 
A polymorphism, rs13476366, near (approximately 1,500bp downstream) Msrb2, 
exhibited very high association with depression-like behavior as reflected in both, 
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the TST (p = 4.66x10-19; Fig. 35A) and the FST (p = 1.23x10-37; data not shown). F2 
mice carrying the HAB-specific (CC) genotype homozygously, spent significantly 
more time immobile or floating as their counterparts carrying TT. Interestingly, 
locomotor activity was significantly elevated in the CC carrying group by 25% 
compared to the TT carrying group (p= 3.38x10-7; data not shown). Also anxiety-
related behavior was attenuated, but in the group carrying the HAB-specific CC 
genotype (p = 3.73x10-4; Fig. 35B). This polymorphism maps to a location, where 
also another gene, Abca2, is in close neighborhood (and in the SNP screening with 
the Illumina custom designed oligo pool, this SNP was the closest to Abca2) that 
was also detected in the microarray and qPCR analysis as differentially regulated. 
 
Figure 35: Association between depression-like, anxiety-related behavior and rs13476366 
genotypes in the freely-segregating F2 panel. Phenotypic indices of male F2 mice with LAB-
specific TT genotypes (LAB-specific homozygotes, N = 121), CT (heterozygotes, N = 249), 
or CC (HAB-specific homozygotes, N = 152). (A) Total immobility time in the tail suspension 
test of F2 mice with the respective genotypes and (B) percentaged time spent on the open 
arms of the elevated plus-maze (EPM). LAB-specific homozygotes were more anxious, but 
displayed attenuated depression-like behavior. Data are presented as means +SEM; *** p < 
0.001. 
 
The Avp-related polymorphisms were also assessed in a total of 258 male mice with 
HAB grandmothers, 67 animals were identified as carrying the HAB-typical 
polymorphisms positive for the 12bp deletion and C(40)T (+/+ and CC), 49 animals 
the LAB-typical -/- and TT, and 142 animals the heterozygous +/- and CT 
genotypes. If these polymorphisms impact on anxiety-related behavior, homozygous 
-/- and TT F2 animals should behave less anxious than their +/+ and CC 
counterparts. Indeed, a co-segregation could be detected with -/- and TT mice being 
significantly less anxious on the EPM (p = 0.01; Fig. 36A). Importantly, this 
association between genetic polymorphisms and anxiety levels was independent of 
locomotor activity, as measured in the open field (Fig. 36B). In the remaining 250 F2 
male mice with LAB grandmothers no association was detectable (data not shown). 
The allele frequency in the F2 panel roughly reflects a 1:2:1 distribution (Table 16). 
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Figure 36: Association between anxiety-related behavior and the vasopressin (Avp)-related 
genotypes in the freely-segregating F2 panel. Phenotypic indices of male F2 mice with HAB 
grandmothers and Avp-related genotypes (+/+) and CC (HAB-typical homozygotes, n = 67), 
(+/-) and CT (heterozygotes, n = 142), or (-/-) and TT (LAB-typical homozygotes, n = 49). (A) 
Percentaged time spent on the open arms of the elevated plus-maze (EPM) and (B) total 
distance traveled in the open field (OF). LAB-typical homozygotes were less anxious, 
independent of locomotor activity. Data are presented as means +SEM; * p < 0.05. 
 
Genotype-phenotype association also revealed a significant linkage of a SNP 
(rs13477268) located 1,500bp downstream hornerin (Hrnr) with CORT response to 
a stressor as measured from the blood plasma. F2 mice carrying the HAB-specific 
AA genotypes displayed a strongly attenuated increase in blood plasma CORT 
concentrations, in contrast to their counterparts bearing the LAB-specific GG 
genotype (p = 1.20x10-50; Fig. 37). 
 
Figure 37: Association between corticosterone increase in blood plasma after restraint 
stress and rs13477268 genotypes in the freely-segregating F2 panel. Phenotypic indices of 
male F2 mice with LAB-specific GG genotypes (LAB-specific homozygotes, N = 128), AG 
(heterozygotes, N = 274), or AA (HAB-specific homozygotes, N = 120). Data are presented 
as means +SEM; *** p < 0.001. 
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4. Discussion 
In the present study, it has been shown that anxiety-related and depression-like 
behaviors are adequately mirrored in the HAB/LAB mouse model on a complex 
multigenic basis. A quite solid genetic background underlying the behavioral trait 
can be testified for HAB and assumed for LAB mice, as the results of the rHAB-
breeding suggests.  
Furthermore, 30 candidate genes for anxiety-related (and depression-like) behavior 
have been identified and elaborated using microarray-based gene expression 
profiling and further validation either by qPCR or by testing peptide levels, enzyme 
activity or the influence of gene products on further physiological parameters. 
Thereby, 14 gene transcripts weathered all tests as possible candidates for anxiety. 
Among them, Slc25a17, Stx3, Abca2, Avp, Zfp672, Tac1 and Ctsb exhibited the 
most convincing effects and are already described (not necessarily in connection to 
psychiatric disorders), whereas others like 2900019G14Rik or Tmem132d are not 
described at all yet.  
Although many gene products were found to be regulated in metabolic pathways, 
their regulation in the brain failed to affect the whole organism’s physiology, as – 
except for the higher amount of food consumption in LAB compared to HAB or CD1 
mice – many metabolism-related parameters in the blood plasma did not reflect any 
differences between HAB and LAB mice. Additionally, an approach to influence 
behavior by a forced enhancement of metabolism via feeding with 0.5M saccharose 
solution only showed very moderate effects on the animals’ anxiety-related 
behavior. This might be also attributed to the multifactorial nature of behavioral 
regulation.  
Basic analysis of CD1 mice revealed a predictability for SNPs based on inbred strain 
comparisons, but also showed that HAB and LAB mice have lost more than 70% of 
the variability in CD1.  
Additionally, sequencing of candidate genes mentioned above, shed light on 
variations in the genome that might influence gene expression, by either enhancing 
or repressing gene expression, affecting mRNA stability, translation efficiency or 
enzyme activity. 
Screening for variations in the DNA sequences of HAB and LAB mice that would 
allow for a causal association of single chromosomal regions with selected 
phenotypes, resulted in the identification of 267 SNPs as viable markers for this 
purpose. These associations in F2 mice revealed among others a high influence of 
regions on chromosomes 5 and 11 on anxiety-related behavior, as reflected by the 
EPM, with genes involved, that have been either characterized by qPCR before 
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(Zfp672 and Tmem132d), or were highlighted in other studies assessing qualitative 
differences (Enoph1). Further causal associations of single chromosomal regions 
were detected for depression-like behavior (chromosome 2) and the level of CORT 
increase in blood plasma in response to a stressor (chromosome 3).  
Reversing the HAB phenotype 
With the HAB and LAB mouse lines, an animal model has been established, that 
reflects anxiety-related behavior in a number of behavioral paradigms, including the 
EPM (selection criterion) and additionally depression-like behavior as reflected by 
the TST or FST (Kessler et al., 2007; Kromer et al., 2005; Landgraf et al., 2007). As 
breeding of these mice has now been performed for more than 20 generations with 
the inbreeding starting as of G8, with G28 a complete inbred status would have 
been achieved by definition. Therefore, mice of G23 were selected to serve as the 
basis of rHAB mice, to analyze, if the remaining genetic variance in HAB mice would 
still be enough to reverse the highly anxious towards a less anxious phenotype. The 
results suggest on the one hand, that still prevailing variability in HAB mice would be 
enough to shift the phenotype towards a less anxious behavioral range as reflected 
by EPM data. On the other hand, behavioral effects on the rHAB-breeding only 
reached statistical significance with the 7th generation of the reversal of the selection 
criterion and only in male but not in female mice. However, the level of anxiety was 
still in a range, which is still considered as high anxiety-related behavior, as even in 
the HAB/LAB breeding, average anxiety in HAB mice only developed below 15% 
starting at the 6th generation (Kromer et al., 2005). Also in a recently finished study 
dealing with the reproduction of the HAB/LAB lines starting from new independent 
CD1 animals, which was planned and performed as a short-term breeding, the 
mean value of the percentaged time spent on the open arms of the EPM firstly 
reached a range around 15% in the 6th and 7th generation (Salvamoser, 2008). As 
most studies dealing with short-term selective breeding consider the 4th or 5th 
generation of offspring already as individuals with fully developed phenotype 
(Belknap et al., 1997; Hitzemann et al., 2008; Palmer et al., 2005; Ponder et al., 
2007; Wilhelm et al., 2007), if the phenotype that is selected for is not significantly 
deviating from the original one, there is probably not enough variability left, to allow 
for more variability regarding that specific phenotype. Furthermore, many studies 
suggest an anxiolytic effect by raising mice under non-standard enriched 
environment (Fox et al., 2006), or an effect of more or less intensive maternal care 
on the developing mice (Weaver et al., 2006). To dissect genetic effects from effects 
mediated by maternal care, cross-fostering paradigms are usually applied, where 
pups of one mother (e.g. HAB animals) are replaced by pups of the other line 
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(Wigger et al., 2001). Both possibilities have already been investigated in HAB and 
LAB mice, with environmental enrichment causing significant decrease in anxiety-
related behavior in HAB mice (Baier and Bunck, unpublished) and cross-fostering 
only exerting minor anxiolytic effects on HAB mice with the mean still remaining in a 
HAB-typical range (Kessler et al., in preparation). Thus, while changes in anxiety-
related behavior seem to be possible by applying different approaches, HAB mice 
do not escape the frame typical of this line (0 - 15% of total test time spent on the 
open arms of the EPM; except for the enriched environment paradigm, with the 
values between 20 and 25%). 
Genotypes in HAB LAB and CD1 mice 
As the present study provided the opportunity to investigate the poorly described 
genetic background of outbred mouse strains (Chia et al., 2005), the current study 
allows for an estimation of variability in CD1 mice. As 42 SNPs were identified 
uniquely in CD1 mice, additional 31 SNPs were also identified displaying variation 
also in HAB vs. LAB mice giving a total of 73 SNPs. Given the total number of 
previously (prior to the custom-designed oligo pool genotyping) uncharacterized 
polymorphisms, 149 SNPs were included to the new assay. Hence, 49% of all 
tested genotypes showed variability in CD1 mice, in contrast to only 21% being also 
applicable to HAB vs. LAB mice. This would allow the conclusion that nearly 50% of 
all already described sequence variations in the MGD would be identifiable in CD1 
mice, whereas only about 20% would represent genotypic markers applicable to the 
HAB and LAB mouse lines. It is important to mention, that most of the currently 
known polymorphisms rely on comparisons of inbred strains (Bult et al., 2008).  
In so far, it’s not surprising that results of single gene locus sequencing suggest that 
overall variation in CD1, HAB and LAB mice would by far exceed the variation 
known from the database, as for Tmem132d, only three of ten identified SNPs were 
listed there. Similarly, for Avp only three of the eight SNPs and for Ctsb, 22 out of 76 
SNPs were listed in the MGD. Altogether, half of the SNPs known from the MGD are 
probably identifiable as variable site in CD1 mice, but approximately twice the 
number of polymorphic sites is not even described at the moment. The discrepancy 
of genotypes as identified in LAB mice that resulted in the identification of the 
genetically distinct LAB-A and LAB-B subgroups could be traced back and verified 
according to a pedigree of LAB mice (Fig. 38). The genealogy of LAB mice makes it 
obvious that offspring of all LAB animals can be tracked back to common ancestor 
in the G10. At that point, inbreeding only started two generations earlier, so genetic 
variability was still nearly unaffected. But if so, why were no HAB sublines 
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identifiable? Obviously, the HAB mouse line went through a genetic bottle neck quite 
late in G16, what also makes the smaller variability in the HAB group allegeable. 
 
Figure 38: Genealogy of HAB and LAB mice from outbred CD1 progenitors until the parental 
generation of F2 mice (G21). Each point at each generation represents one breeding pair of 
mice. 
 
 
Gene expression analyses and genotype-phenotype associations 
Many gene products were characterized in detail, as far as their confirmation of 
differential expression between HAB and LAB mice or their genetic sequence is 
concerned. For about 13 of those gene products identified in microarray gene 
expression profiling analyses, no significant difference in regulation could be verified 
in HAB vs. LAB mice using qPCR. This can be attributed to multiple causes. First of 
all, some of the identified gene transcripts might have been differentially expressed 
between the mouse lines only in that specific generation or at that specific time of 
the year. Independent observations suggest that annual seasons affect litter sizes 
even under standardized laboratory conditions, what implicates the possibility on 
other physiological parameters and especially consequences on the neurochemistry 
and neurogenetics of the brain (Chesler et al., 2002). Nevertheless, this also 
implicates, that if these changes in gene expression between the mouse lines is not 
constant over the year, or even within two distinct generations, their effect on the 
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phenotypes of interest (anxiety) is negligible. Further, some technical aspects might 
come into consideration like the non-exclusion of probes in the assay that show only 
low fluorescence values (Yauk and Berndt, 2007) has been mentioned, but also the 
selection of housekeeping genes affects the outcome of validation by qPCR 
(Coulson et al., 2008; Nygard et al., 2007). Furthermore, as the probes used for 
hybridization using the Illumina platform have a length of 50bp, polymorphisms in 
the sequence might severely impair the binding capacity of aRNA bearing SNPs. 
This might also be the reason for a measured 12-fold upregulation of Ctsb in LAB 
mice in the Illumina experiment, although only a 2-fold overexpression could be 
confirmed (Tables 11-13). 
Nevertheless, the differential expression of 15 genes could be confirmed, partially 
even independent of gender. This increases the value of the corresponding 
candidate genes for anxiety, as both, males and females of each mouse line always 
display the line-specific phenotypes. The confirmed candidate genes are: Coro7, 
Mmp15, Slc25a17, Zfp672, 2900019G14Rik, Abca2, Enpp5, Hmgn3, Pdhb, Ctsb, 
Mt1 and Stx3 as whole brain tissue is concerned, whereas Mbnl1 and Trib2 (Tables 
13-15) can be added to the list of candidate genes as based on qPCR. Tac1, 
Tmem132d and Avp (Fig. 16-19) are also part of the genes confirmed by qPCR, 
even if their differential expression is restricted to specific brain areas. This results in 
an overall reproducibility of over 50%, which seems to be acceptable.  
Coro7 
As Coro7 is concerned, this gene transcript and its protein have been shown to be 
important in brain development. Although it is present in most organs of the adult 
organism, the highest amounts can be found in the brain, kidneys, thymus and 
spleen. The protein has been identified in the cytosol and as a membrane-bound 
protein as well. Although not many studies have been dealing with this gene 
product, they suggest a function in the membrane of the Golgi apparatus and in 
vesicle trafficking (Rybakin et al., 2004; Rybakin et al., 2006). Elevated expression 
of this gene in LAB compared to HAB animals, with CD1 mice displaying an 
intermediate expression level, might contribute to differences at the behavioral level 
as well as general protein levels would be affected or their homeostatic state 
disturbed or the transport of vesicles within neurons could be more or less effective 
between the mouse lines. These effects have not been assessed in HAB and LAB 
mice yet, but would be an interesting target for further studies.  
Mmp15, Slc25a17 and 2900019G14Rik 
Mmp15 or its gene product is not well-characterized, as far as brain function is 
concerned, but it seems to bear a role in inflammation- and oncogenesis-related 
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processes (Do et al., 2006; Wang et al., 2008). Also Slc25a17 is poorly described, 
except for its function as peroxisomal ATP transporter (Visser et al., 2002), what 
makes this candidate gene interesting as a player involved in neurometabolism. For 
2900019G14Rik no description is available at all, although some connection to 
Slc1a2 might be assumed, as the physical proximity is below 10kbp (NCBI). It is 
nevertheless important to mention that this gene exhibited the highest expression 
difference that could be confirmed in HAB vs. LAB mice (16-fold). Unfortunately, the 
two polymorphisms identified in the analyzed part of the gene transcript can’t reveal 
any further insight into their functionality at this stage. 
Further investigations are required to elucidate possible effects of these four genes 
on anxiety or any other phenotypic correlate in HAB and LAB mice. 
Zfp672 
The zinc finger protein, Zfp672 is a putative transcription factor (NCBI) that has been 
identified as differentially expressed between HAB and LAB mice. What makes this 
gene even more important as a candidate gene for anxiety, is the association 
between one SNP in the 3’ UTR and anxiety-related behavior as measured on the 
EPM in F2 mice (Fig. 34). Importantly, in this case, no significant association has 
been found with locomotor activity or depression-like behavior.  
Hmgn3 
This gene was found to be 2-fold overexpressed in HAB vs. LAB mice. HMGN family 
proteins were identified to promote chromatin unfolding, to enhance accessibility of 
nucleosomes and to regulate transcription. Especially Hmgn3 was displaying a 
significant upregulation of a glycine transporter (Slc6a9 / GLYT1), a protein that 
modulates glycine concentration in the synaptic cleft. Furthermore, transcriptional 
regulation of 0.8% of all genes in a microarray experiment could be attributed to 
Hmgn3 (West et al., 2004). So, by altering this gene’s expression, the expression of 
many other gene products is changed that directly affect the capacities required for 
maintaining synaptic activity (including Slc6a9), what can have a major impact on 
shaping the behavioral phenotypes characteristic of HAB and LAB mice.  
Pdhb 
Mutations in Pdhd have been found to cause severe symptoms in humans, if they 
lead to a deficiency in that enzyme (Okajima et al., 2008). Its deficiency is especially 
severe, as the enzyme plays a vital role in alanine and aspartate metabolism, 
butanoate metabolism, in valine, leucine and isoleucine biosynthesis and in the citric 
acid cycle. Therefore, if LAB mice would show global signs of PDHB deficiency 
(gene expression or protein levels have not yet been assessed outside the brain), 
this could contribute to their elevated food consumption (Fig. 20), without leading to 
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increased body weight within this line compared to HAB mice. But this deficiency 
affects definitely the brain, so minor modifications of behavior by deficiency of amino 
acids can be expected in LAB mice, as many disorders connected with anxiety, 
hyperactivity, attention deficit or aggression are known to be in direct association 
with neurometabolic changes or deficiency (Knerr et al., 2008).  
Ctsb 
Also Ctsb is well known to play an important role to assure regular brain 
development, as neuronal loss and brain atrophy were found to be characteristic to 
Ctsb and cathepsin L (Ctsl) knockout mice. These knockout mice also exhibited 
deficiency in locomotor abilities (Felbor et al., 2002; Stahl et al., 2007), although 
behavioral alterations have never been screened in knockout mice for Ctsb only until 
now. This would make a great addition to the gene expression data obtained in this 
work, as a strongly increased expression could be verified for LAB mice, compared 
to HAB animals, with CD1 mice expressing this gene at intermediate levels. 
Furthermore a large number of genetic polymorphisms at this gene locus has been 
identified in sequencing HAB vs. LAB mice (Table 17), where the identified 
polymorphisms don’t affect protein structure, but could definitely affect either mRNA 
stability (Shabalina et al., 2006) or the recruitability of transcription enhancing or 
repressing factors.  
Mt1 
It has been demonstrated for Mt1 that neurodegenerative diseases as well as 
metabolic stress enhances its expression in perivascular regions of the cerebral 
cortex predominantly in astrocytes (Vorbrodt et al., 2006). Further experiments 
highlighted a connection of physical stress with increased Mt1 expression in a 
variety of brain regions and also increased expression has been observed upon 
subcutaneous administration of steroid hormones (Beltramini et al., 2004a; 
Beltramini et al., 2004b). High expression of Mt1 also has been proven to decrease 
the concentrations of zinc that is required to maintain efficient functioning of immune 
responses and might contribute to the effects of age-related degenerative diseases 
(Cipriano et al., 2003). According to all these indices, Mt1 might play a key role for 
the HAB/LAB mouse model, where besides the differential expression of Mt1, an 
increased stress response of CORT-release to physical stressors in LAB mice has 
been demonstrated (Keßler et al., in preparation). Most interestingly, the higher 
release of CORT in LAB mice upon a stressor could also be shown in an 
independent short-term breeding approach for trait anxiety (Salvamoser, 2008; 
Czibere, unpublished), connecting the higher stress response in LAB mice to the 
anxiety-related phenotype and excluding a co-selection of this trait or artifacts 
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related to genetic drift. Furthermore, no genetic polymorphisms have been identified 
in HAB vs. LAB mice that might underlie differential expression. Except of that, only 
epigenetic factors that affect regulation might play a role in the described expression 
differences (Majumder et al., 2006).  
Stx3 
Darios and Davletov (2006) described the importance of Stx3 that encodes a 
membrane protein required for neurite growth and neural development as an 
activator of SNARE complexes. Also arachidonic acid plays an important role for 
STX3 action, highlighting the impact of metabolism as a potential cofactor 
fundamental to neurometabolism and thereby brain function (Darios and Davletov, 
2006). In HAB vs. LAB mice expression differences in Stx3 have been identified with 
NAB mice expressing intermediate levels of that gene. Differential expression of this 
candidate gene points again to basic differences between HAB and LAB mice 
regarding neuronal function that has the potential to shape the phenotypic 
differences.  
Abca2 
Recently, a research group from Japan created a knockout mouse model for Abca2, 
showing a decrease in body weight and decreased locomotor abilities. Furthermore, 
the knockout mice displayed an increased susceptibility to environmental stress 
(Sakai et al., 2007). Especially the last point vindicates to draw parallels to LAB 
mice, as qPCR also confirmed that LAB only expressed 1/6th of the Abca2 mRNA as 
compared to HAB mice indicating a defined deficiency in LAB mice. Also, the results 
of the phenotype-genotype association in the F2 panel proved a highly significant 
association of the genomic location of Abca2 with locomotor activity that was also 
significantly associated with anxiety-related behavior, but to a lower extent (larger p-
value, absolute difference in locomotor activity difference (OF-based): 25%, 
absolute difference in anxiety-related behavior (EPM-based): 20%). In addition, F2 
mice carrying the HAB-specific genotype showed increased depression-like 
behavior spending much more time immobile in the TST and FST as their 
counterparts bearing the LAB-specific genotype. Taken together, this makes the 
genomic locus around Abca2 a valuable marker for locomotor activity as well as 
depression-like behavior, as the mice displaying increased locomotor activity were 
simultaneously displaying increased depression-like behavior. A possible role for 
other gene products in that region cannot be excluded, as the SNP (rs13476366 – a 
genomic marker for the region around it) covers a genomic region of more than 
5Mbp. Similarly strong associations might be given for any other gene locus around 
that marker which is also near Msrb2. The latter is described to possess cell-
 Discussion 
96 
protective function in case of oxidative stress (Cabreiro et al., 2008). Differences 
regarding gene expression between HAB and LAB mice have also been identified in 
the microarray analyses for Msrb2 but have not been confirmed up to date.  
Enpp5 
This gene is encoding a nucleotide-metabolizing ecto-enzyme, a class of enzymes 
that is required to regulate the availability of extracellular nucleotides, thereby 
controlling the signaling through purinoceptors, like the P2X ion channels. 
Interestingly, especially one P2X ion channel, the P2RX7, has been identified by a 
number of studies as bearing polymorphic sites (SNPs) that are significantly 
associated with major depressive disorder in a large number of patients (Barden et 
al., 2006; Erhardt et al., 2007; Hejjas et al., 2008; Lucae et al., 2006). Further, in 
knockout mice it has been demonstrated that P2RX7 locates predominantly in the 
synaptic cleft that would make it interesting for neuronal transmission (Marin-Garcia 
et al., 2008). If thus a variant of Enpp5 is higher expressed in HAB compared to 
LAB, this gene becomes a major candidate gene bearing a high potential to 
contribute to the behavioral phenotype of our mice making this gene interesting for 
clinical treatment. Furthermore, the Enpp5 locus did not show any associations with 
anxiety or depression-like behavior, in contrast to the loci around P2rx7 
(Supplementary table 3). This gene is located on chromosome 5 in a region that 
also displayed highly significant association with anxiety-related behavior (p < 10-7). 
Thus, by the expression differences observed for Enpp5, the association in the F2 
panel can be directly observed as a highly significant effect on the respective 
behavior at the P2rx7 locus.  
Tac1 
As far as Tac1 expression is concerned, this study revealed quite discrepant results, 
if compared to the results of the microarray analysis. Indeed, an overexpression has 
been revealed in the PVN and BLA/LA of HAB mice (Fig. 17) that is the result of 
elevated levels of all splicing variants and especially γ-PPT in these brain regions. 
These differences were not confirmable regarding the tachykinin-derived peptides, 
but a different distribution of peptide expression patterns was revealed in the PVN 
and BLA/LA. Altogether, the discrepancies are most likely to be caused by 
differences in the sensitivity of the techniques applied. Gene expression differences 
between male and female mice for Tac1 might be explained by a sequence in its 
promoter that displays a homology of 85% to an estrogen-response element (Carter 
and Krause, 1990). Indeed, in many brain regions, among others the amygdala, 
differences for tachykinins between male and female animals were observed 
(Otsuka and Yoshioka, 1993). As the amygdala is considered essential for 
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processing emotions, whereas the PVN initiates the reaction to stressors (Herman 
and Cullinan, 1997), the expression differences of Tac1 might play a role at multiple 
levels of anxiety in males and females. As for all brain regions and genders a similar 
expression pattern of all splicing variants has been observed (Fig. 18), differential 
expression is unlikely to be caused by the increased or decreased expression of one 
single splicing variant. The cause for differential expression cannot be traced back 
to polymorphisms in the gene sequence, since at the whole Tac1 locus, no single 
polymorphic site has been identified in HAB vs. LAB mice. Alternatively, differences 
in promoter methylation could be an underlying cause of differential expression 
(Bock and Lengauer, 2008). For the quantification of tachykinin-peptides, no 
differences between the analyzed mouse lines could be detected. This might be due 
to technical reasons, as during the ELISA experiment, the measured optical density 
was highly variable within each peptide. Furthermore, even the quantified standards 
using the same amount of purified peptides showed variances that reached the 
variance reflected by inter-individual samples. Hence, even if different levels of 
peptides would be detectable, they might have been masked by the technical 
variance of the ELISA quantifying the small peptide amounts contained in brain 
tissue micropunches. Nevertheless, the result that Tac1 and its splicing variants are 
expressed at increased rates in highly vs. less anxious mice, is in one line with other 
studies, confirming the anxiogenic effect of Tac1 derived peptides and the anxiolytic 
effects of NK1 antagonist (Bilkei-Gorzo et al., 2002; Ebner and Singewald, 2006; 
Quinn et al., 2000; Saria, 1999). Importantly, NK1 antagonists have also been 
demonstrated to exert an anxiolytic effect in HAB mice (Sartori, unpublished). 
Glo1 
As revealed by all gene expression profiling assays, Glo1 was found to be 
overexpressed in all brain nuclei investigated in LAB compared to CD1 and HAB 
mice. As the overexpression in LAB mice was confirmed at peptide level using 
Western Blot analysis from the brain and even red blood cells (Kromer et al., 2005; 
Landgraf et al., 2007), confirmation of differential expression of Glo1 between the 
mouse lines by qPCR was waived. Overall effects of Glo1 overexpression in LAB 
mice were found to be negligible on lactate concentrations, as no differences could 
be detected between HAB and LAB mice. No differences could be detected between 
HAB and LAB mice regarding further metabolic parameters assessed from blood 
plasma samples. This is also important in respect to the function of the previously 
described Abca2, Pdhb, Stx3 or Enoph1.  
Interestingly, CD1 mice that were saccharose-soaked over ten weeks did not show 
any increase in body weight compared to control mice (Fig.21). This is remarkable, 
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as most studies on human health consider soft drinks as one of the main causes 
together with increased food consumption as the leading causes for increasing 
obesity in the general population, especially in adolescents (Harrington, 2008). If 
now considered together with food consumption, the effect of elevated water 
consumption (with saccharose solution) could not reach levels as expected, 
because increased water intake in those animals was accompanied by a significant 
decrease in food consumption. This is mirrored by the lower extent of total calorie 
intake compared to the clearly higher amount of water consumption. Decreased 
food intake in combination with elevated water intake, if the latter one was drugged 
with saccharose, has already been reported in other cases (Scalera and Tarozzi, 
2001). This only slight elevation of total caloric intake is probably the reason for the 
minor behavioral and molecular effects measured in the mice. The effects on 
physiology might be better mirrored by the measured osmolalities of urine and blood 
plasma. The clear effect on urine osmolality that was decreased by nearly 80% in 
the treated group was not accompanied by a decreased plasma osmolality (Fig. 22), 
so a dehydration effect that could have affected the test animals’ behavior can be 
excluded as a cause (Scalera and Tarozzi, 2001). 
Interestingly, saccharose-soaked mice were slightly more anxious as the results on 
the EPM suggested, although many parameters taken failed to show significant 
differences. Whereas the effects on anxiety-related behavior were significant in the 
first EPM test, even the latency time to the first entry onto an open arm failed to 
reach statistical significance in the second test, only reaching a statistical trend (Fig. 
23). Furthermore, a slight decrease in the percentaged time spent on the open arms 
of the EPM in both the treated and control group could be observed from the first to 
the second testing. This is not unusual, as this effect has been described for 
repeated testing on the EPM before (Stern et al., 2008).  
In line with our previous findings (Ditzen et al., 2006; Kromer et al., 2005), mice that 
were more anxious in the EPM test (saccharose-soaked mice) also displayed lower 
levels of GLO1 protein in their red blood cells after the first test (Fig. 24). In contrast 
to that, mice tested for GLO1 expression after the second EPM exhibited higher 
levels of the protein while still being anxious, what would be contrary to our findings 
and in one line with the findings published by another research group (Hovatta et al., 
2005). It is important to mention that in both cases of GLO1 measurement, the 
effects only reached a statistical trend, so in either way the effect of the saccharose 
treatment on GLO1 expression is marginal. Second, as the effects on the EPM were 
less divergent between the control and treatment group, probably first a direct effect 
of saccharose treatment was observed and by depletion of food intake a negative 
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regulation of GLO1 expression might have predominated. Longer treatment, over six 
weeks, could have elevated the protein levels and also caused the behavior to be 
less divergent between the treated and control group. Additional analysis of the 
brains of treated and control animals could reveal the causes for the difference, 
although another kind of treatment such as direct injection of methylglyoxal or a 
GLO1 inhibitor would be more promising to reveal the inducibility of this protein and 
demonstrate a behavioral effect, as there would be less enzymatic steps to be 
considered for their action (Kuhla et al., 2006; Thornalley, 2006). 
COX 
As cytochrome c oxidase activity is valid marker for long-term cellular activity and 
also mRNA expression (Christen, 2000; Simonian and Hyman, 1993), this enzyme 
activity-assessing assay revealed basal differences in long-term activity. 
Interestingly, in the PVN, HAB showed a decreased activity in comparison to LAB 
mice, whereas for both amygdala nuclei (the CeA and the BLA) HAB showed an 
increased activity compared to LAB mice. Thus, the results suggest that for the 
behavioral trait of high anxiety, a higher activity of the amygdala (i.e. for the 
processing of emotions) seems to be more important than an increased activity of 
the PVN. This is also supported by a number of other studies describing the 
amygdala as a key processor of anxiogenic stimuli and the PVN as the center to 
control the adequate stress response (Bishop et al., 2004; Bishop, 2008; Herman et 
al., 2003). Probably this holds also true for the analogous conclusion for LAB mice 
that a decreased long-term activity in the amygdala is necessary to allow for a low 
anxiety trait. On the other hand, a higher activity of the PVN in LAB mice explains 
the higher reactivity of the HPA axis in terms of higher CORT concentrations in 
response to a physical stressor, as already mentioned before. Although, generally, 
high levels of CORT response are described to be associated with high anxiety 
states (Maccari et al., 2003; Wigger et al., 2004), in HAB vs. LAB mice this seems to 
be the other way round. This finding was even replicated in a short-term breeding 
experiment (Salvamoser, 2008) and also in CD1 mice, bred for differences in CORT 
response to a stressor, mice exhibiting lower CORT reactivity tended to be more 
anxious (Touma et al., 2008). Additionally, even in the HAB/LAB rat model, a strong 
increase of CORT has been demonstrated after social defeat (strong social stressor) 
in LAB, but a less strong increase in HAB rats. This might be attributed to a more 
passive coping style in HAB animals in response to any kind of stressors (Frank et 
al., 2006). Analogously, the passive coping style of HAB mice in various tests for 
depression-like behavior might also be the reason for the observed decreased 
stress reactivity.  
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Taken together, these findings reveal that high anxiety can be accompanied by 
lower responsiveness concerning CORT release and suggest that the major effect 
on anxiety in CD1 mice is probably exerted by mechanisms largely independent of 
HPA axis function or the decreased responsiveness is connected to the passive 
coping strategy found in HAB mice. 
Further, the results reveal that no direct conclusions from the gene expression 
pattern of individual COX subunits can be drawn on overall COX activity, as Cox8a 
is similarly higher expressed in the PVN, BLA/LA and Cg of HAB mice, or the 
regulation in the same direction was found for Cox6a2 in all brain regions.  
Examining the effect of differential gene expression in HAB vs. LAB mice on the 
phenotype, the characteristics have been best evaluated in this study concerning 
Tmem132d, Avp and Enoph1. 
Avp 
Also for Avp, decreased expression of Avp mRNA in the hypothalamus of LAB 
animals under basal conditions compared to HAB and CD1 mice could be identified 
in combination with genetic polymorphisms underlying these Avp expression 
differences. Additional studies underline these findings by extending them to male 
mice and also including HABxLAB F1 intercross animals (Bunck et al., submitted). 
Correlative and causative evidence indicates that reduced Avp expression 
contributes to locomotion-independent reduction of anxiety, confirming 
corresponding results in HAB/LAB rats (Murgatroyd et al., 2004). Sequencing of the 
Avp gene, including the upstream promoter and the downstream enhancer region, 
resulted in the identification of nine polymorphic loci reliably differing between the 
HAB and LAB line (Fig. 27). These loci comprised eight SNPs and a 12bp deletion 
in LAB mice. Additionally, the allele frequency of the ∆(-2180-2191) deletion and the 
strictly linked C(40)T SNP was determined in CD1 and F2 populations (Table 16). 
Both polymorphic sites are likely to be involved in the regulation of gene expression 
and the processing of the AVP precursor (Kessler et al., 2007), respectively. While 
there were no polymorphisms identified in the noncoding (untranslated region and 
intronic) sequences, all three SNPs in the gene locus were located in the coding 
sequence. Two of these are silent mutations A(1431)G and T(1527)C and the third 
one C(40)T causes a substitution of alanine to valine in the third amino acid of the 
AVP signal peptide. As already reported (Kessler et al., 2007), this genetic marker 
co-segregated in an F2 panel with symptoms of central diabetes insipidus in LAB 
mice and, partially, with anxiety-related behavior, further confirming the strict linkage 
between the promoter deletion ∆(-2180-2191) and C(40)T. This linkage, also 
detected in 258 mice of a freely-segregating F2 panel, suggests an association of 
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specific polymorphisms in the Avp gene and its expression with the corresponding 
phenotype.  
The individual phenotype is known to be shaped by phenomena that are or are not 
mediated by sequence variations in DNA, i.e. inheritance is both genetic and 
behavioral (epigenetic), with the latter primarily relying on the quality of mother-
infant interaction (Champagne, 2008). To eliminate possible influences of different 
epigenetic effects, deriving from the fact that half of the F2 had HAB and the other 
half LAB grandmothers, split calculations according to the grandmaternal 
background were performed for associations. Indeed, in addition to correlative 
evidence, a moderate, though significant association between the promoter deletion 
and the C(40)T SNP and locomotion-independent anxiety-related behavior was 
demonstrated in a freely segregating F2 panel (Fig. 36). Thus, while the 
polymorphisms identified in the Avp gene are unlikely to generally cause hypo-
anxiety, their variation might contribute to the severity of the phenotype, further 
supporting the estimate that several dozen quantitative trait loci may be involved in 
anxiety regulation (Turri et al., 2004). Further studies have to focus on the 
importance of the (grand)parental background for anxiety-related behavior, as genes 
regulated by (grand)parent-specific epigenetic modifications can lead to monoallelic 
gene expression (Delaval and Feil, 2004; Wilkins and Haig, 2003a; Wilkins and 
Haig, 2003b) or are simply X-linked.  
Another explanation might be, based on the higher prevalence of anxiety and 
depression in women than in men (Jacobi et al., 2004), the (grand)parental influence 
on anxiety-related behavior, as revealed in our F2 panel, due to a modulating effect 
of a sex-specific locus. HAB/LAB mice might thus represent a model to further 
investigate the complex pattern of genetic vs. epigenetic inheritance.  
As LAB mice exhibit a deficit not only in AVP precursor processing and 
neuropeptide release from both dendrites and axon terminals (Kessler et al., 2007), 
but also in Avp expression, additive effects at multiple levels are likely to produce a 
“global” deficit in bioactive AVP. Remarkably, recent studies in Brattleboro rats and 
humans confirmed that an AVP deficit may be accompanied by symptoms of central 
diabetes insipidus, reduced anxiety-related or attenuated depression-like behavior 
(Mlynarik et al., 2007) and signs of diminished agoraphobia and impaired memory 
processing (Bruins et al., 2006), respectively, suggesting complementary inter-
species genetics. It is of note in this context that impaired social discrimination 
abilities in LAB mice have also been observed recently (Bunck, unpublished). Still, 
to make sure that Avp under-expression in LAB mice is definitely due to the 
described genetic polymorphisms rather than to differences in other variables 
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including epistatic gene-gene interactions or synaptic input to the hypothalamic 
nuclei an allele-specific transcription analysis was performed, which had already 
been successfully applied in HAB/LAB rats (Murgatroyd et al., 2004). By breeding 
HABxLAB F1 intercross animals that host both HAB and LAB line-specific alleles in 
each cell. Indeed, allele-specific transcription analysis of heterozygous F1 animals 
revealed a 75% reduced expression of the LAB-specific compared to the HAB-
specific allele (Fig. 31), suggesting a causal role of this hypomorphic allele in 
exerting a reduced drive on Avp expression and hypo-anxiety.  
Importantly, differences in Avp expression were not associated with changes in V1a 
receptors that could confound the analysis of the behavioral involvement of AVP in 
these lines (Bunck et al., submitted) Several groups independently reported an 
association of the V1a receptor with anxiety-related behavior. V1a receptor knockout 
mice, although at times providing inconsistent results, showed impaired social 
interaction, social recognition and reduced anxiety-related behavior (Bielsky et al., 
2004; Bielsky et al., 2005; Egashira et al., 2007). Furthermore, V1a antisense RNA, 
targeting the septum, made rats less anxious (Landgraf et al., 1995). In HAB vs. 
LAB mice, V1a receptor autoradiography revealed no differences in a variety of 
anxiety-associated brain regions, suggesting that line-specific divergences in 
behavior are due to events upstream of the receptor, i.e. differential expression and 
release of AVP, rather than to differences in V1a receptor binding (Bunck et al., 
submitted). The functional relevance of central AVP and its V1a receptor subtype is 
underlined by anxiogenic effects of centrally administered AVP in LAB mice (Bosch, 
unpublished).  
How may the identified polymorphisms in the promoter region translate into different 
expression profiles and phenotypes? While the C(-1422)T SNP is not located in a 
transcription factor binding site, the T(-2521)C SNP and the ∆(-2180-2191) deletion 
are located directly in the center of a binding site for nuclear factor 1 (NF-1), a well-
known transcription factor in the brain that promotes transcription in combination 
with C/EBPalpha or C/EBPbeta (Ji et al., 1999). Impaired binding of NF-1, here 
driven by both polymorphisms, the T(-2521)C SNP and the ∆(-2180-2191) deletion, 
has recently been demonstrated to result in decreased gene transcription (Alikhani-
Koupaei et al., 2007). Both polymorphic sites are also in the proximity of a C/EBP 
binding site, but only the ∆(-2180-2191) site flanks a C/EBPbeta binding site. Even 
the T(-2521)C SNP might have a minor effect on reduced Avp expression in LABs, 
though it creates a binding site for NF-1 in LABs, but NF-1 might act as a repressor 
(Kraus et al., 2001) if a neighboring C/EBP binding site is lacking. Although there is 
a C/EBPalpha binding site, C/EBPalpha expression is much lower than that of 
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C/EBPbeta (Horvath, unpublished). Also SNPs in the DER can have an impact on 
expression, as recently described. There is a repetition of motifs from that 178-bp 
region mentioned in the publication on the Avp DER (Fields et al., 2003) between 
+370bp and +480bp, where two HAB- and LAB-specific SNPs have been identified. 
Analysis of this region resulted in the identification of a binding site for c-Ets-2 near 
to a binding site of C/EBPbeta (Chakrabarty and Roberts, 2007). In the center of the 
c-Ets-2 binding site, the A(+399)G polymorphism would allow for an enhanced 
transcription rate in the HAB-specific but not the LAB-specific DNA sequence. 
Finally, even polymorphisms in the coding region are likely to contribute to lower 
Avp mRNA content by negatively influencing mRNA secondary structure and 
stability (Shabalina et al., 2006). Determining the most common genotypes in CD1 
mice revealed that the HAB-specific polymorphisms represent the most common 
genetic variant (Table 16). More than 70% of the CD1 mice were found to be 
homozygous for the HAB-specific sequence, whereas less than 1% carried the LAB-
specific allele homozygously. Nevertheless, the respective distribution is in Hardy-
Weinberg equilibrium, although with the LAB-specific allele at a decreased 
frequency.  
Despite the higher long-term activity of the PVN in LAB as revealed by the COX 
activity measurement, Avp was found to be expressed at lower level in the PVN as 
compared to HABs. As mentioned before, probably mechanisms independent of 
HPA axis function might be involved in mediating the HAB and LAB mouse line-
specific effects. Anxiolytic activity of decreased AVP concentrations in LAB and a 
more anxiogenic activity of AVP in HAB mice might thus be mediated by 
intracerebral axonal or dendritic release e.g. in the amygdala (Caldwell et al., 2008; 
Landgraf and Neumann, 2004; Wotjak et al., 1994), rather than by differential 
activation of the HPA axis. Interestingly, gene expression of Avp was significantly 
elevated in LAB but not in HAB mice 3h after a stressor (TST; Bunck, unpublished), 
although this might be an effect caused by a more severe shortage of AVP in LAB 
mice. Nevertheless, this phenomenon requires further investigation, probably AVP 
localization in different stages after a stressor and electrophysiological studies 
conducted in the PVN and amygdala might shed light on mechanisms underlying 
this phenomenon.  
Hrnr 
Highest association was detected for Hrnr regarding the whole genotype-phenotype 
association study in F2 mice with CORT response to a physical stressor (Fig. 37). 
No other phenotype showed association with that locus and altogether the 
differences between the HAB- and LAB-specific homozygous genotypes in CORT-
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mirrored stress responsiveness reached nearly 50% of the complete difference that 
is reachable by selective breeding for that phenotype (Touma et al., 2008). The 
gene seems to play a role for keratinization, but a function in the central nervous 
function is not described yet. As one domain (S100B) of the protein putatively has 
the capacity of binding calcium ions (NCBI), a concentration dependant influence of 
HRNR on neuronal cells in the brain (Sorci et al., 2003) has to be investigated in 
detail.  
Enoph1 
Two different isoforms of the E-1 enzyme (encoded by Enoph1) could be detected in 
the HAB and LAB mouse lines (Ditzen et al., 2006). As the HAB isoform displayed 
decreased mobility in SDS gels, sequencing of the underlying gene revealed two 
SNPs that result in two amino acid changes in the protein’s sequence. The altered 
mobility is likely due to a slightly different structure of the HAB vs. LAB E-1 enzyme 
isoforms, since the two amino acid differences only result in a minor change in 
molecular weight between the two proteins. Another consequence of the altered 
HAB E-1 enzyme sequence is a lower enzymatic activity compared to the LAB 
isoform (Ditzen et al., submitted). The activity difference can have consequences for 
the methionine salvage pathway, of which E-1 enzyme is a member. However, S-
adenosyl-L-methionine is one of the major methylating agents in the cell and hence 
a necessary compound for epigenetic mechanisms, which are receiving increased 
attention in the affective disorder field (Mill and Petronis, 2007). S-adenosyl-L-
methionine is also known to be involved in the biosynthesis of the polyamines that 
exert potent effects on neurotransmission due to their modulation of different types 
of ion channels (Williams, 1997) creating a direct link to affective disorders 
(Skolnick, 1999). Furthermore, significantly increased amounts of two polyamines 
were found in HAB relative to LAB mice. Although the evidence is still lacking yet, 
one can speculate that the reduced E-1 enzyme activity affects the synthesis of the 
polyamines in HAB mice. As a consequence, a differential modulation of glutamate 
receptors may result in altered channel properties known to play a role in behavioral 
phenotypes related to anxiety and depression (Ditzen et al., submitted; Skolnick, 
1999). Due to the comorbidity of anxiety and depression and the high probability of 
shared underlying neuronal circuits (Levine et al., 2001), the lower enzymatic activity 
of the HAB E-1 enzyme isoform is likely involved in the pathophysiology of the HAB 
phenotype. Yet, this hypothesis remains to be tested in further experiments.  
In F2 mice it was demonstrated that the two SNPs in Enoph1 likely contribute to 
both enzymatic activity and phenotype. Indeed, AA and TT mice spent significantly 
more time on the open arms of the EPM than their GG and CC counterparts (Fig. 
 Discussion 
105 
32), thus confirming the hypothesized association between the SNPs and also the 
E-1 enzyme isoform enzymatic activity, metabolic consequences and their functional 
contribution to the phenotype. Importantly, it was also demonstrated that the co-
segregation of genotype and phenotype is independent of locomotor activity, which 
often contaminates anxiety-related behavior (Kromer et al., 2005). The latter is a 
polygenic, multifactorial trait presumed to have a complex inheritance and to involve 
the interaction of multiple genes with epigenetic and environmental factors 
(Henderson et al., 2004; Landgraf et al., 2007; Turri et al., 2004). It is therefore quite 
remarkable that F2 animals adopt an anxiety-related behavior if their genetic 
constellation at the E-1 enzyme locus is HAB-like, i.e. homozygous GG and CC.  
Tmem132d 
A first genome-wide association study of panic disorder has detected and replicated 
evidence for association with the gene TMEM132D in samples collected from three 
independent studies with a combined number of 876 cases and 915 controls 
(Erhardt et al., submitted). A haplotype consisting of two SNP remained significant 
after genome-wide correction for multiple testing in the combined sample. Although 
the size of the discovery sample (216 cases) was modest, the study had adequate 
power to detect an effect size of odds ratio 1.4 in the combined sample of 876 
cases. Genetic effect sizes of this magnitude are probably the exception in complex 
psychiatric disorders and thus very likely important genes of more modest effects in 
panic disorder were missed. In addition, the Illumina HumanHap300 chip is 
providing good but not complete coverage of the european genome so that some 
susceptibility loci might have been missed due to insufficient marker density (Baum 
et al., 2008; Consortium, 2007; Erhardt et al., submitted). The top SNPs were 
retested in two additional samples, where a haplotype association with genome-
wide significance in the combined sample (despite the lack of genome-wide 
significance in the discovery sample) could be confirmed.  
In the initial sample, only non-comorbid panic disorder patients were analyzed 
against “super-healthy” controls, whereas in the second sample panic patients were 
compared to blood donor controls and in the third sample comorbid panic and 
anxiety patients were compared to controls screened with a brief questionnaire. The 
additional evidence from associations with dimensional anxiety measures, as well as 
human gene expression provided strong support for a role of TMEM132D in anxiety-
related disorders. Two SNPs in this gene were associated with anticipatory anxiety 
in patients with panic disorder as well as the severity of anxiety symptoms in 
patients with major depression and a population-based cohort but not the severity of 
depressive symptoms. This pointed towards the possibility that these genetic effects 
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are specific for anxiety-related symptoms but not restricted to a certain disorder, 
which is further supported by the fact that the case-control associations could be 
replicated in a sample containing panic disorder patients comorbid with major 
depression, bipolar disorder and schizophrenia. The two associated loci were 
located in intron 3 and 4 of TMEM132D, respectively. The linkage disequilibrium 
structure of both regions suggested that the potential functional variants tagged by 
these associations do not likely lie in exonic or classic 5’ regulatory regions. (Erhardt 
et al., submitted). Regulatory regions, however, have also been described for introns 
(Hubler and Scammell, 2004).  
In HAB vs. LAB mice, it could be shown that Tmem132d mRNA expression in the 
cingulate cortex was increased with CD1 mice displaying intermediate levels (Fig. 
19). This observation was consistent in both microarray and qPCR experiments in 
male and female HAB, CD1 and LAB animals, suggesting a relationship of 
Tmem132d with anxiety-related behavior independent of gender. The correlation of 
higher Tmem132d expression with extreme anxiety-related behaviors in this animal 
model is consistent with the finding that the risk genotype AA of rs11060369, over-
represented in panic disorder patients, was also associated with increased 
TMEM132D expression in the frontal cortex. Importantly, this anxiety-dependent 
difference in HAB vs. LAB mice was specific for the Cg. Only the Cg but not the 
BLA, CeA, DG and PVN showed an upregulation of Tmem132d in HAB animals in 
the microarray experiment. The cingulate cortex is closely connected to the 
amygdala, the brain region central to the generation of fear and anxiety and its 
activation seems to modulate the response of the amygdala to anxiety-evoking 
stimuli and expression of fear in humans (Coplan and Lydiard, 1998; Milad et al., 
2007; Milad and Rauch, 2007; Ohman, 2005). A series of functional imaging studies 
have implicated activity changes in the anterior cingulate cortex not only in fear but 
also in pathological anxiety states in humans such as phobic fear, panic disorder, 
generalized anxiety disorder, social anxiety disorder and post traumatic stress 
disorder studies (Etkin and Wager, 2007; Hasler et al., 2007; Mobbs et al., 2007; 
Straube et al., 2007). Given the fact that anxiety-related brain circuits seem to be 
strongly conserved across species, these results could suggest that an altered 
expression of Tmem132d in the Cg may contribute to an altered activation profile of 
this brain region in the presence of anxiogenic stimuli and thus to a predisposition to 
pathological states of anxiety. 
In addition to differences in expression, an exonic Tmem132d SNP was found to co-
segregate with anxiety-related behavior in an F2 panel independent of both 
depression-like behavior and locomotor activity (Fig. 33), thus suggesting an 
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evolutionary conserved, causal involvement of this gene in anxiety-related 
phenomena. The molecular function of the gene product, also called 
transmembrane protein 132D, KIAA1944 and MOLT, is still unclear. TMEM132D is 
predicted as a single pass type I membrane protein. The predicted 1,099-amino acid 
protein has a calculated molecular mass of about 130kDa and contains an N-
terminal hydrophobic signal peptide, 7 predicted N-glycosylation sites, 2 predicted 
O-glycosylation sites, a number of phosphorylation sites, and a C-terminal 
transmembrane domain (NCBI). Immunohistochemical studies showed a 5:1 ratio of 
TMEM132D expression in white matter compared to gray matter in the cerebral 
cortex (Nagase et al., 2001). TMEM132D was also detected in corpus callosum and 
in white matter in the spinal cord and optic nerve. Using cultured rat oligodendrocyte 
lineage cells and stage-specific markers, they showed that TMEM132D was 
expressed by mature oligodendrocytes but not by oligodendrocyte precursor cells. 
The conclusion was that oligodendrocytes start expressing TMEM132D in the 
course of maturation and that this protein could be involved in the neural 
interconnection and also signaling (Nomoto et al., 2003). Its involvement in 
oligodendrocyte maturation may be relevant for the efficient connection of the Cg to 
other anxiety-related brain regions.  
Furthermore, sequencing revealed ten more polymorphic sites in and around the 
Tmem132d locus differing between HAB and LAB mice. As the complete gene 
covers a genomic distance of more than half a million bp, a complete linkage of all 
variable Tmem132d loci in all F2 mice is not expected. Furthermore, a glucocorticoid 
response element has been identified in the gene with one SNP located directly in 
its center, what could be the reason of differential expression but its functionality 
remains to be elucidated.  
 
Altogether, this study demonstrates the strength of combined sequence-, 
transcriptome- and proteome-based analyses best in further combination with cross-
species studies. Using a robust and valid animal model resulted in the identification 
of candidate genes that are part of neuronal and metabolic pathways pertinent to the 
disease phenotype.  
By genotype-phenotype association analyses in F2 mice, strong evidence for the 
involvement of specific genomic loci, selected candidate genes and polymorphisms 
in shaping the anxiety-related, depression-like and stress responsiveness 
phenotypes could be validated. Although the role of specific mechanisms 
contributing to the respective phenotypes remains still elusive, a definite 
involvement can be assured for Enpp5 (via P2RX7), Abca2 or Msrb2, Zfp672, 
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Enoph1 and Hrnr. Additionally, cross-species approaches further highlight the 
causal role of Tmem132d (in HAB/LAB mice and in panic disorder patients) and of 
Avp (HAB/LAB mice, HAB/LAB rats and patients) in direct connection to the anxiety-
related phenotype (Erhardt et al., submitted; Frank and Landgraf, 2008; Murgatroyd 
et al., 2004; Scott and Dinan, 2002).  
Also other gene transcripts identified by gene expression profiling but showing no 
direct association within the F2 study, can be defined as valuable candidate genes 
for the respective traits. These include 2900019G14Rik, Tac1, Mmp15, Mt1, Coro7, 
Ctsb and Slc25a17, as they all show robust and reproducible expression differences 
between HAB and LAB mice. Nevertheless, possible interactions of these genes 
with loci highly associated in the F2 mice are possible, however due to the lack of 
obvious connections like for Enpp5 they require further investigation. But already 
today, all of these candidate genes may serve as valuable targets for further 
molecular characterization of anxiety- and depression-related phenotypes, not 
restricted to mice. Furthermore, they might also play a vital role for the development 
of novel therapeutics, facilitating the treatment of anxiety disorders and depression. 
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5. Perspectives 
 
Having identified some important molecular players that shape anxiety and 
emotionality in mice and humans, one major focus in future studies should be the 
development and testing of substances that are capable of inhibiting or activating 
the described proteins, thus allowing for the development of novel therapeutics. 
Therefore, as a first step, targeted overexpression of some gene products might be 
the tool of choice, as this in general creates less problems as compared to knockout 
of the respective genes, where the total loss might even cause lethality of the 
animals. Furthermore, the influence on other genes around the targeted location 
might be less pronounced than in knockout mice. Also a further functional 
characterization of some genes and their products is required, as hardly anything is 
known about the molecular functionality of Tmem132d or Zfp672, to name just few. 
Enzyme binding assays, localization in the brain and the identification of further 
polymorphisms that might interfere with enzyme or protein activity are required for 
most of the described genes and gene products. For 2900019G14Rik, absolutely 
nothing is known, so first of all an identification of the complete gene structure is 
required.  
Testing of already existing knockout mice for some of the described genes might be 
a complementary approach to investigate gene products that were identified in the 
gene expression analyses but show no obvious association in the F2 panel, like 
Ctsb. Also siRNA, antisense targeting and other methods directly acting on the 
transcripts might be the method of choice for further investigations. Similarly, the 
functional relevance of other gene products not yet mentioned or characterized in 
the literature published up to date, should be investigated especially with the focus 
on connections to other phenotypes associated with anxiety, e.g. cognitive abilities. 
Furthermore, whole-genome sequencing (as it is now available with the “Genome 
Analyzer II” technique and provided by Illumina based on the Solexa system) of 
HAB vs. LAB mice would be necessary to receive a complete picture of genetic 
diversity in these animals, thus providing the basis for a comprehensive overview on 
genomic interactions. 
Furthermore, this study highlighted the genetically stable predisposition of HAB and 
LAB mice for their line-typical traits. The association of Avp with anxiety-related 
behavior points to an additional effect of inheritable epigenetic factors directly 
connected to the described phenotypes. Therefore special emphasis is required to 
unveil the epigenetic factors contributing to this complex trait. 
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Thus, HAB and LAB mice are a valuable animal model for the future testing some of 
the hypotheses arising from this study with the potential to provide promising targets 
for psychiatric and pharmacopsychiatric research, independent of their usage in 
basic research on mechanisms influencing behavior or as model to test anxiolytic 
and antidepressant compounds. Considering the genome itself as a target for 
pharmacological intervention may be a first step in the development of a new 
generation of anxiolytic drugs. 
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6. Supplementary tables  
Supplementary table 1: Excerpt of transcripts identified on the MPI24K gene 
expression screening platform, with positive fold regulation values meaning an 
overexpression in HAB compared to LAB and negative an overexpression of LAB 
compared to HAB mice. P-values are adjusted to multiple testing. Number of brain 
regions for significant regulation differences between HAB and LAB mice. Data are 
presented as means. Most transcripts are at least differentially regulated in three 
brain regions. 
 
Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
-8.81 0.0002 1 Ttr Transthyretin 
-3.47 0.0059 7 Slc25a17 Solute carrier family 25, member 17 
-2.29 0.0016 3 A430106J12Rik RIKEN cDNA A430106J12 gene 
-2.26 0.0147 6 Ctsb Cathepsin B 
-2.26 0.0147 6 Mmp15 Matrix metallopeptidase 15 
-2.09 0.0020 3 Gnao1 Guanine nucleotide binding protein, alpha o 
-2.09 0.0123 3 Tbl3 Transducin (beta)-like 3 
-2.06 0.0002 3 Loxl3 Lysyl oxidase-like 3 
-2.02 0.0004 3 AI854703 Expressed sequence AI854703 
-2.00 0.0100 7 Zfp672 Zinc finger protein 672 
-1.96 0.0011 3 Chtf18 CTF18, chromosome transmission fidelity factor 18   
-1.95 0.0003 3 B930037P14Rik RIKEN cDNA B930037P14 gene 
-1.93 0.0001 3 Gpx4 Glutathione peroxidase 4 
-1.89 0.0197 7 Glo1 Glyoxalase 1 
-1.88 0.0082 7 5230400G24Rik RIKEN cDNA 5230400G24 gene 
-1.85 0.0087 3 Spata2 Spermatogenesis associated 2 
-1.81 0.0094 3 9030612M13Rik RIKEN cDNA 9030612M13 gene 
-1.75 0.0235 3 Il1b Interleukin 1 beta 
-1.71 0.0230 5 Coro7 Coronin 7 
-1.71 0.0334 4 Pias4 Protein inhibitor of activated STAT, 4 
-1.66 0.0005 3 Spnb3 Spectrin beta 3 
Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
-1.66 0.0023 3 Tebp Prostaglandin E synthase 3  
-1.66 0.0244 5 Ccdc104 Coiled-coil domain containing 104 
-1.66 0.0244 5 4931428D14Rik RIKEN cDNA 4931428D14 gene 
-1.64 0.0010 3 Sparcl1 SPARC-like 1 (mast9, hevin) 
-1.64 0.0073 4 4930438D12Rik RIKEN cDNA 4930438D12 gene 
-1.63 0.0317 4 Sdc2 Syndecan 2 
-1.62 0.0014 3 Adpn Adiponutrin 
-1.62 0.0019 3 4933427L07Rik Dymeclin 
-1.61 0.0016 3 Slc1a3 solute carrier family 1, member 3 
-1.60 0.0578 3 Mocs2 Molybdenum cofactor synthesis 2 
-1.58 0.0002 3 Phtf2 RIKEN cDNA 9330189K18 gene 
-1.56 0.0347 5 Ep400 E1A binding protein p400 
-1.55 0.0004 3 A730042J05Rik RIKEN cDNA A730042J05 gene 
-1.55 0.0012 3 Kif21b Kinesin family member 21B 
-1.55 0.0050 3 Nts Neurotensin 
-1.55 0.0077 3 Arl6ip1 ADP-ribosylation factor-like 6 interacting protein 1 
-1.55 0.0182 4 Extl2 Exotoses-like 2 
-1.54 0.0019 3 5830417I10Rik RIKEN cDNA 5830417I10 gene 
-1.54 0.0051 3 Mgrn1 Mahogunin, ring finger 1 
-1.54 0.0270 3 Ctss Cathepsin S 
-1.54 0.0532 4 Ptprz1 Protein tyrosine phosphatase, 
receptor type Z, polypeptide 1 
-1.53 0.0018 4 2510009E07Rik RIKEN cDNA 2510009E07 gene 
-1.53 0.0070 4 Mt1 Metallothionein 1 
-1.52 0.0012 3 1700030A21Rik Zinc finger, CSL-type containing 3 
-1.52 0.0091 3 Deadc1 Deaminase domain containing 1 
-1.51 0.0016 3 Epm2aip1 EPM2A (laforin) interacting protein 1 
-1.51 0.0048 3 BC026585 cDNA sequence BC026585 
-1.50 0.0256 4 Pycs Aldehyde dehydrogenase 18 family, member A1 
-1.50 0.0352 4 Sqrdl Sulfide quinone reductase-like  
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Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
-1.50 0.0436 3 Prkcb1 Acid phosphatase 1, soluble 
-1.49 0.0223 3 Zfp148 Zinc finger protein 148 
-1.49 0.0474 4 Btrc Beta-transducin repeat containing protein 
-1.48 0.0016 3 Ndufv1 NADH dehydrogenase (ubiquinone) flavoprotein 1 
-1.48 0.0334 3 Tcf1 Transcription factor 1 
-1.47 0.0111 3 Bace2 Beta-site APP-cleaving enzyme 2 
-1.47 0.0245 3 Aldoc Aldolase 3, C isoform 
-1.44 0.0008 3 Cox6c Cytochrome c oxidase, subunit VIc  
-1.44 0.0306 3 Bteb1 RIKEN cDNA 2310051E17 gene 
-1.44 0.1045 1 Npy Neuropeptide Y 
-1.43 0.0015 3 Hrmt1l1 
Heterogeneous nuclear 
ribonucleoprotein 
methyltransferase-like 1  
-1.43 0.0414 3 C6.1A C6.1a protein 
-1.42 0.0341 4 Tac1 Tachykinin 1 
-1.41 0.0030 3 Galnt10 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 
10 
-1.40 0.0011 4 2410066E13Rik RIKEN cDNA 2410066E13 gene 
-1.40 0.0048 4 Mef2d Myocyte enhancer factor 2D 
-1.40 0.0346 3 Polm Polymerase (DNA directed), mu 
-1.39 0.0117 3 Igsf4c Immunoglobulin superfamily, 
member 4C 
-1.39 0.0134 4 8430420C20Rik RIKEN cDNA 8430420C20 gene 
-1.39 0.0184 3 Tcf19 Transcription factor 19 
-1.39 0.0290 3 AI851716 Expressed sequence AI851716 
-1.39 0.0411 4 Gpd2 Glycerol phosphate dehydrogenase 2, mitochondrial 
-1.39 0.0744 3 Ssbp4 Single stranded DNA binding protein 4 
-1.38 0.0258 3 Ehf Ets homologous factor 
Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
-1.37 0.0094 3 Dusp18 Dual specificity phosphatase 18 
-1.37 0.0332 3 Ube2m Ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) 
-1.36 0.0395 5 Actb Actin, beta, cytoplasmic 
-1.36 0.0368 3 Mef2c Myocyte enhancer factor 2C 
-1.36 0.0498 4 Hkr2 GLI-Kruppel family member HKR2 
-1.35 0.0386 4 1110015K06Rik RIKEN cDNA 1110015K06 gene 
-1.35 0.0561 3 Sepp1 Selenoprotein P, plasma, 1 
-1.34 0.0002 3 Tpd52 Tumor protein D52 
-1.34 0.0245 3 Rad21 RAD21 homolog (S. pombe) 
-1.34 0.0321 3 AI481105 Expressed sequence AI481105 
-1.33 0.0192 4 1110018D06Rik RIKEN cDNA 1110018D06 gene 
-1.33 0.0561 3 Cog3 Component of oligomeric golgi 
complex 3 
-1.32 0.0026 3 Serpini1 Serine (or cysteine) peptidase inhibitor, clade I, member 1 
-1.32 0.0486 3 Egfl7 EGF-like domain 7 
-1.31 0.0030 3 Idh1 Isocitrate dehydrogenase 1 (NADP+), soluble 
-1.31 0.0087 3 Aarsl Alanyl-tRNA synthetase like 
-1.31 0.0238 3 Fbxw8 F-box and WD-40 domain protein 8 
-1.31 0.0957 3 Gprasp2 G protein-coupled receptor 
associated sorting protein 2 
-1.31 0.0994 3 Gusb Glucuronidase, beta 
-1.29 0.0005 3 Wdr45l Wdr45 like 
-1.29 0.0118 3 Gas1 Growth arrest specific 1 
-1.29 0.0179 3 Rarb Retinoic acid receptor, beta 
-1.29 0.0643 3 Ppt2 Palmitoyl-protein thioesterase 2 
-1.29 0.0049 3 2900010J23Rik RIKEN cDNA 2900010J23 gene 
-1.28 0.0379 3 Nckap1 NCK-associated protein 1 
-1.28 0.0055 3 Rnpep Arginyl aminopeptidase (aminopeptidase B) 
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Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
-1.28 0.0141 3 Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 
-1.28 0.0144 3 Adam10 A disintegrin and 
metallopeptidase domain 10 
-1.28 0.0207 3 Sod2 Superoxide dismutase 2, 
mitochondrial 
-1.27 0.0383 3 4933402J24Rik RIKEN cDNA 4933402J24 gene 
-1.26 0.0098 3 Ckmt1 Creatine kinase, mitochondrial 1, 
ubiquitous 
-1.26 0.0574 3 Rpl27a Ribosomal protein L27a 
-1.26 0.0665 3 AI196514 Expressed sequence AI196514 
-1.25 0.0129 3 Ubb Ubiquitin B 
-1.24 0.0712 5 Smo smoothened homolog (Drosophila) 
-1.24 0.0024 3 Max Max protein 
-1.23 0.0606 3 Zfp162 Zinc finger protein 162 
-1.22 0.0291 3 Lu Lutheran blood group 
-1.21 0.0115 3 Tgfb1i4 Transforming growth factor beta 1 induced transcript 4 
-1.21 0.0749 4 Ubc Ubiquitin C 
-1.20 0.0237 3 2310047M10Rik RIKEN cDNA 2310047M10 gene 
-1.20 0.0258 3 Mrps33 Mitochondrial ribosomal protein S33 
-1.20 0.0555 3 Pros1 Protein S (alpha) 
-1.18 0.0463 3 E430002G05Rik RIKEN cDNA E430002G05 gene 
-1.18 0.0626 3 Glul Glutamate-ammonia ligase  
-1.17 0.0745 3 Slc26a3 Solute carrier family 26, member 3 
-1.17 0.0840 4 Sap18 Sin3-associated polypeptide 18 
-1.17 0.0041 3 Calm1 Calmodulin 1 
-1.15 0.0269 3 Nsg2 Neuron specific gene family 
member 2 
-1.15 0.0603 3 Olfml3 Olfactomedin-like 3 
 
Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
-1.15 0.0924 3 Taf6l 
TAF6-like RNA polymerase II, 
p300/CBP-associated factor 
(PCAF)-associated factor 
-1.14 0.0516 3 Hap1 Huntingtin-associated protein 1 
-1.12 0.0263 3 Abca2 ATP-binding cassette, sub-family A (ABC1), member 2 
1.09 0.0482 3 Tgfb1i4 Transforming growth factor beta 1 induced transcript 4 
1.11 0.0585 3 Rit2 Ras-like without CAAX 2 
1.13 0.0224 3 Rpl17 Ribosomal protein L17 
1.14 0.0401 3 Tde2 Tumor differentially expressed 2 
1.16 0.0851 3 Atrx RIKEN cDNA 4833408C14 gene 
1.20 0.0072 3 Cpe Carboxypeptidase E 
1.20 0.0503 3 Canx Calnexin 
1.20 0.0528 3 Smn1 Survival motor neuron 1 
1.21 0.0074 3 Rbbp7 Retinoblastoma binding protein 7 
1.21 0.0144 3 D2Bwg1356e 
DNA segment, Chr 2, Brigham & 
Women's Genetics 1356 
expressed 
1.21 0.0394 3 Dctn6 Dynactin 6 
1.21 0.0670 3 Nap1l5 Nucleosome assembly protein 1-like 5 
1.22 0.0023 3 Nme4 Expressed in non-metastatic cells 4, protein 
1.22 0.0453 3 Rab10 RIKEN cDNA 1700012B15 gene 
1.22 0.0723 3 D9Wsu20e Transmembrane protein 30A 
1.23 0.0164 3 BC051244 CDNA sequence BC051244 
1.24 0.0149 3 9130413I22Rik Morf4 family associated protein 1 
1.24 0.0218 3 2700046G09Rik RIKEN cDNA 2700046G09 gene 
1.24 0.0253 4 Spnb2 Spectrin beta 2 
1.24 0.0639 3 Golga7 Golgi autoantigen, golgin 
subfamily a, 7 
1.25 0.0768 3 Pcoln3 procollagen (type III) N-
endopeptidase 
1.25 0.0074 3 Gpm6a Glycoprotein m6a 
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Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
1.26 0.0288 3 Qdpr Quininoid dihydropteridine 
reductase 
1.26 0.0904 3 Ndfip1 Nedd4 family interacting protein 1 
1.27 0.0406 5 3830421F13Rik Forty-two-three domain 
containing 1 
1.27 0.0027 3 D19Ertd144e CDK2-associated protein 2 
1.27 0.0029 3 Ap1s2 Adaptor-related protein complex 1, sigma 2 subunit 
1.27 0.0634 3 Arhgap5 Rho GTPase activating protein 5 
1.28 0.0006 3 Idh3a Isocitrate dehydrogenase 3 (NAD+) alpha 
1.29 0.0288 3 Snap91 Synaptosomal-associated protein 91 
1.29 0.0451 3 Elovl5 
ELOVL family member 5, 
elongation of long chain fatty 
acids (yeast) 
1.29 0.0775 3 Luzp2 Leucine zipper protein 2 
1.31 0.0225 4 Slc25a12 RIKEN cDNA 5730410E19 gene 
1.31 0.0874 3 Syt11 Synaptotagmin XI 
1.32 0.0241 3 Rps3a ribosomal protein S3a 
1.33 0.0153 3 Slc39a6 Solute carrier family 39 (metal ion transporter), member 6 
1.33 0.0268 4 Peg3 Paternally expressed 3 
1.33 0.0404 4 Cldn12 Claudin 12 
1.33 0.0154 5 Ext2 Exostoses 2 
1.34 0.0253 4 Zmynd11 Zinc finger, MYND domain 
containing 11 
1.35 0.0110 3 Ncald Neurocalcin delta 
1.35 0.0266 4 Rab11a RAB11a, member RAS oncogene family 
1.36 0.0020 4 Raf1 V-raf-1 leukemia viral oncogene 1 
1.36 0.0118 3 1300006C19Rik RIKEN cDNA 1300006C19 gene 
1.36 0.0394 3 Hspca Heat shock protein 1, alpha 
1.37 0.0368 3 Nap1l5 Nucleosome assembly protein 1-like 5 
Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
1.37 0.0498 3 Mbp Myelin basic protein 
1.38 0.0411 3 Slc36a4 
Solute carrier family 36 
(proton/amino acid symporter), 
member 4 
1.39 0.0012 3 Stmn1 Stathmin 1 
1.39 0.0046 3 Calm2 Calmodulin 2 
1.39 0.0266 3 6330439K17Rik RIKEN cDNA 6330439K17 gene 
1.39 0.0270 4 Gnas GNAS complex locus 
1.41 0.0085 3 Clic4 Chloride intracellular channel 4  
1.41 0.0144 4 Incenp Inner centromere protein 
1.41 0.0177 4 Ctso Cathepsin O 
1.41 0.0189 5 Gprasp1 G protein-coupled receptor 
associated sorting protein 1 
1.41 0.0291 3 Wnt10b Wingless related MMTV integration site 10b 
1.42 0.0053 4 1700045I19Rik RIKEN cDNA 1700045I19 gene 
1.42 0.0712 3 Aak1 AP2 associated kinase 1 
1.43 0.0040 3 Sfrs10 Splicing factor, arginine/serine-
rich 10  
1.44 0.0284 4 Mtss1 Metastasis suppressor 1 
1.45 0.0130 3 Ywhaq 
Tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, theta polypeptide 
1.45 0.0424 4 Suclg2 Succinate-Coenzyme A ligase, GDP-forming, beta subunit 
1.46 0.0002 3 Ddx27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 
1.46 0.0020 3 Atp6ap2 ATPase, H+ transporting, lysosomal accessory protein 2 
1.46 0.0022 4 Rtn1 Reticulon 1 
1.46 0.0584 4 Ogfrl1 Opioid growth factor receptor-like 1 
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Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
1.47 0.0267 5 Wsb2 WD repeat and SOCS box-
containing 2 
1.47 0.0017 3 Kctd12 
Potassium channel 
tetramerisation domain containing 
12 
1.47 0.0018 3 Hspa8 Heat shock protein 8 
1.48 0.0009 4 Matr3 Matrin 3 
1.48 0.0018 3 Nedd4l 
Neural precursor cell expressed, 
developmentally down-regulated 
gene 4-like 
1.48 0.0031 3 Mtpn Myotrophin 
1.48 0.0112 3 Hnrpk Heterogeneous nuclear 
ribonucleoprotein K 
1.49 0.0014 4 Rab25 RAB25, member RAS oncogene family 
1.50 0.0019 3 Sdha 
Succinate dehydrogenase 
complex, subunit A, flavoprotein 
(Fp) 
1.50 0.0077 4 Prph1 Peripherin 1 
1.51 0.0056 4 Elavl2 
ELAV (embryonic lethal, 
abnormal vision, Drosophila)-like 
2 (Hu antigen B) 
1.53 0.0005 3 Dusp6 Dual specificity phosphatase 6 
1.53 0.0017 3 Spag9 Sperm associated antigen 9 
1.53 0.0048 3 Uhmk1 U2AF homology motif (UHM) kinase 1 
1.53 0.0105 4 Amd1 Regulator of G-protein signaling 12 
1.54 0.0029 3 Ppp3ca RIKEN cDNA 4930599N24 gene 
1.54 0.0207 4 Hadhb 
Hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-
Coenzyme A hydratase beta 
subunit 
1.54 0.0534 4 Ppia Peptidylprolyl isomerase A 
1.56 0.0110 3 Stmn2 Stathmin-like 2 
Fold 
regulation 
p-
value 
# of  
regions Gene symbol Gene name 
1.58 0.0014 3 Sdccag33 Serologically defined colon 
cancer antigen 33 
1.58 0.0073 3 Nudt4 Nudix-type motif 4 
1.58 0.0118 3 Ddx3x DEAD/H box polypeptide 3, X-linked 
1.59 0.0042 3 Hbb-y Hemoglobin Y, beta-like 
embryonic chain 
1.59 0.0175 5 Pgm2l1 Phosphoglucomutase 2-like 1 
1.59 0.0018 3 Clcn3 RIKEN cDNA 9030622M22 gene 
1.60 0.0154 4 Foxp1 Forkhead box P1 
1.64 0.0022 4 Slc36a2 Solute carrier family 36 member 2 
1.64 0.0055 3 Rpa2 Replication protein A2 
1.66 0.0163 3 Dpysl2 Dihydropyrimidinase-like 2 
1.68 0.0160 5 Hmgb1 High mobility group box 1 
1.68 0.0038 4 Vipr1 Vasoactive intestinal peptide 
receptor 1 
1.68 0.0110 4 Rab20 RAB20, member RAS oncogene family 
1.68 0.0409 4 Wsb1 WD repeat and SOCS box-
containing 1 
1.74 0.0006 3 Rnf11 Ring finger protein 11 
1.74 0.0210 6 Hmgn3 High mobility group nucleosomal binding domain 3 
1.77 0.0026 4 Egr1 Early growth response 1 
1.80 0.0484 2 Avp Arginine vasopressin 
1.87 0.0005 3 Snap25 Synaptosomal-associated protein 25 
1.89 0.0670 4 Loxl3 Lysyl oxidase-like 3 
2.08 0.0085 4 Syt4 Synaptotagmin IV 
2.09 0.0110 3 Slc12a3 Solute carrier family 12, member 3 
2.49 0.0123 3 Atp9a ATPase, class II, type 9A 
2.62 0.0051 4 Unc84a Unc-84 homolog A 
4.36 0.0029 7 Rab6 RAB6, member RAS oncogene 
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Supplementary table 2: Excerpt of transcripts identified on the Illumina mouse gene 
expression screening platform, with positive fold regulation values meaning an 
overexpression in HAB compared to LAB mice and negative values an 
overexpression of LAB compared to HAB mice. P-values are adjusted to multiple 
testing. Number of brain regions for significant regulation differences between HAB 
and LAB mice. Last columns shows fold regulation of HAB vs. NAB mice. Data are 
presented as means.  
 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
-14.15 8.35E-12 5 Enpp5 
ectonucleotide 
pyrophosphatase/ 
phosphodiesterase 5  
-5.05 
-12.29 4.18E-35 5 Ctsb cathepsin B  -13.61 
-5.79 1.29E-32 5 Sc4mol sterol-C4-methyl oxidase-like  -5.86 
-5.74 3.13E-27 5 Slco1c1 solute carrier organic anion transporter family -0.75 
-5.37 1.67E-39 5 B3galt6 UDP-Gal:betaGal beta 1 -5.56 
-4.09 2.48E-25 5 2610511O17Rik RIKEN cDNA 2610511O17 gene  0.61 
-4.06 1.83E-30 5 Ccrn4l CCR4 carbon catabolite 
repression 4-like  -4.30 
-3.93 1.44E-10 5 Mela melanoma antigen  -0.81 
-3.85 5.56E-26 5 Kras2 Kirsten rat sarcoma oncogene 2 -4.31 
-3.75 9.28E-10 5 9030612M13Rik RIKEN cDNA 9030612M13 gene  -2.13 
-3.61 3.79E-19 5 A430106J12Rik RIKEN cDNA A430106J12 gene  -1.25 
-3.58 1.19E-09 5 Kcnh1 potassium voltage-gated 
channel 1 -2.59 
-3.26 9.18E-29 5 4933421G18Rik RIKEN cDNA 4933421G18 gene  -3.96 
-2.97 1.12E-25 5 Pygb brain glycogen phosphorylase  -3.07 
-2.84 4.53E-20 5 6330416L07Rik RIKEN cDNA 6330416L07 gene  -2.68 
-2.71 1.19E-18 5 Mipep mitochondrial intermediate peptidase  0.19 
-2.68 3.51E-20 5 Cntn2 contactin 2  -1.09 
-2.63 1.72E-12 5 Mrps27 mitochondrial rib. protein S27  -0.92 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
-2.62 3.15E-11 5 Pip5k2a phosphatidylinositol-4-phosphate 5-kinase -1.03 
-2.61 1.25E-11 5 Glo1 glyoxalase 1  -1.69 
-2.50 4.42E-10 5 Frs3 fibroblast growth factor 
receptor substrate 3  -1.57 
-2.47 2.85E-16 5 Pop4 processing of precursor 4 -0.14 
-2.39 6.34E-28 5 0610033H09Rik RIKEN cDNA 0610033H09 gene  -2.52 
-2.35 3.25E-12 5 Brf2 BRF2 -2.03 
-2.34 8.31E-12 5 Slc25a18 solute carrier family 25  
member 18 -7.57 
-2.30 4.90E-05 5 A630042L21Rik RIKEN cDNA A630042L21 gene  -1.67 
-2.23 2.33E-02 5 4933427D14Rik RIKEN cDNA 4933427D14 gene  -0.24 
-2.18 9.84E-17 5 Dutp deoxyuridine triphosphatase  -0.79 
-2.17 7.63E-22 5 D330038K10Rik RIKEN cDNA D330038K10 gene  -2.31 
-2.14 2.15E-17 5 Hbb-b2 hemoglobin -2.56 
-2.10 7.94E-14 5 Myst2 MYST histone 
acetyltransferase 2  -2.18 
-2.08 3.53E-33 2 Ghrh growth hormone releasing hormone  -2.45 
-2.08 1.04E-25 5 Arl8 ADP-ribosylation factor-like 8  -2.16 
-2.06 3.70E-23 5 1200003M09Rik RIKEN cDNA 1200003M09 gene  -2.02 
-2.04 1.83E-24 5 2610040E16Rik RIKEN cDNA 2610040E16 gene  -2.09 
-2.03 3.05E-14 5 Slc25a17 solute carrier family 25  
member 17 -1.92 
-1.98 1.34E-29 2 1700008P20Rik RIKEN cDNA 1700008P20 gene  -1.71 
-1.98 1.64E-04 5 Fjx1 four jointed box 1  -1.58 
-1.97 2.35E-07 5 2410129H14Rik RIKEN cDNA 2410129H14 gene  -1.80 
-1.95 2.35E-07 5 Drctnnb1a down-regulated by Ctnnb1 0.22 
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HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
-1.93 1.06E-05 5 Dok5 downstream of tyrosine kinase 5  -0.24 
-1.92 2.27E-14 5 Rpp14 ribonuclease P 14kDa subunit  -1.73 
-1.92 9.14E-08 5 Rfng radical fringe gene homolog  -0.75 
-1.84 1.28E-16 5 Me2 malic enzyme 2 0.71 
-1.83 2.11E-06 5 Gukmi1 guanylate kinase membrane-
associated inverted 1 -1.42 
-1.83 5.66E-05 5 Baiap1 BAI1-associated protein 1  -1.42 
-1.83 1.24E-12 5 LOC381259 similar to hypothetical protein FLJ33282  -1.83 
-1.77 1.77E-17 5 E130307J04Rik RIKEN cDNA E130307J04 gene  -1.61 
-1.76 2.40E-12 5 Rpl30 ribosomal protein L30  3.81 
-1.76 4.63E-16 5 Aldh4a1 aldehyde dehydrogenase 4 family member 1 -1.62 
-1.75 1.62E-08 5 2610524H06Rik RIKEN cDNA 2610524H06 gene  -0.68 
-1.71 6.06E-13 5 Pdk2 pyruvate dehydrogenase kinase 2 -1.57 
-1.68 2.05E-14 4 Pigl phosphatidylinositol glycan -0.79 
-1.66 2.40E-10 3 Nupr1 nuclear protein 1  -0.93 
-1.64 1.60E-09 5 Myh9 myosin heavy chain IX  -1.44 
-1.63 9.36E-08 3 Sepw1 selenoprotein W -0.74 
-1.62 5.08E-06 5 Sv2a synaptic vesicle glycoprotein 2 
a  
-0.38 
-1.62 4.56E-03 4 Omg oligodendrocyte myelin glycoprotein  0.02 
-1.61 1.28E-14 3 Ube2i ubiquitin-conjugating enzyme E2I  -1.58 
-1.59 1.00E-12 5 Aebp2 AE binding protein 2 -0.26 
-1.58 1.45E-12 4 Fads3 fatty acid desaturase 3  -1.77 
-1.57 3.63E-05 5 9230117N10Rik RIKEN cDNA 9230117N10 gene  -1.57 
-1.56 1.63E-06 5 4432411E13Rik RIKEN cDNA 4432411E13 gene  -0.70 
 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
-1.52 1.03E-04 4 Bub3 budding uninhibited by benzimidazoles 3 homolog  -1.32 
-1.52 1.80E-14 4 Frmd3 FERM domain containing 3  -1.63 
-1.52 6.74E-07 5 F2r coagulation factor II  -1.25 
-1.52 1.94E-13 4 Spag1 sperm associated antigen 1  0.17 
-1.52 1.90E-13 5 Vars2l valyl-tRNA synthetase 2-like  -1.29 
-1.51 9.95E-12 5 1700009P03Rik RIKEN cDNA 1700009P03 gene  -0.25 
-1.51 9.43E-07 5 C1qb complement component 1 -1.26 
-1.50 5.36E-11 5 4930519N13Rik RIKEN cDNA 4930519N13 gene  -1.53 
-1.49 1.64E-18 2 Tmie transmembrane inner ear  -1.51 
-1.48 6.77E-05 2 2810036L13Rik RIKEN cDNA 2810036L13 gene  -0.69 
-1.48 1.71E-02 3 Dbt dihydrolipoamide branched 
chain transacylase E2  -0.24 
-1.47 5.15E-14 5 9830001H06Rik RIKEN cDNA 9830001H06 gene  -1.53 
-1.47 8.11E-18 3 Reck reversion-inducing-cysteine-
rich protein with kazal motifs  0.19 
-1.47 2.08E-05 4 D430033N04Rik RIKEN cDNA D430033N04 gene  -1.20 
-1.47 1.50E-10 4 C1qtnf5 C1q and tumor necrosis factor 
related protein 5  -1.54 
-1.46 3.22E-08 5 5430437P03Rik RIKEN cDNA 5430437P03 gene  -0.61 
-1.45 6.10E-08 4 4930455C21Rik RIKEN cDNA 4930455C21 gene  -1.34 
-1.45 4.38E-08 1 Zfp297b zinc finger protein 297B  -1.49 
-1.45 1.83E-07 4 2610319K07Rik RIKEN cDNA 2610319K07 gene  -1.19 
-1.44 9.23E-06 5 3200001K10Rik RIKEN cDNA 3200001K10 gene  -1.30 
-1.44 3.23E-12 4 Rrm1 ribonucleotide reductase M1  -1.38 
-1.42 5.19E-04 5 C1qg complement component 1 -0.75 
-1.42 1.07E-05 4 Epb7.2 erythrocyte protein band 7.2  -0.32 
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HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
-1.42 3.63E-03 3 Igf2r insulin-like growth factor 2 
receptor  -0.86 
-1.41 2.02E-08 3 Hist3h2ba histone 3 -0.73 
-1.41 1.25E-07 3 Brp17 brain protein 17  -1.38 
-1.41 2.45E-10 5 Pik3cg phosphoinositide-3-kinase -0.21 
-1.41 1.85E-06 3 Atpaf2 ATP synthase mitochondrial F1 complex assembly factor 2  -1.17 
-1.40 1.36E-13 2 BC003993 cDNA sequence BC003993  2.33 
-1.40 5.31E-05 2 Kptn kaptin  -1.32 
-1.40 1.73E-03 2 Arl10c ADP-ribosylation factor-like 10C  -1.24 
-1.40 8.25E-10 2 Gtf3c1 general transcription factor III C 1  -1.67 
-1.39 5.21E-06 3 2410012H22Rik RIKEN cDNA 2410012H22 gene  -0.69 
-1.38 4.96E-05 3 1200016B10Rik RIKEN cDNA 1200016B10 gene  -1.43 
-1.38 7.60E-02 1 Sep3 septin 3  -1.31 
-1.38 2.30E-02 4 Peg3 paternally expressed 3  -0.70 
-1.38 5.87E-18 3 Nkiras1 NFKB inhibitor interacting Ras-like protein 1  -1.39 
-1.38 5.85E-08 3 6330583M11Rik 
hypothetical 
Esterase/lipase/thioesterase 
family active site containing 
protein 
-1.34 
-1.37 4.65E-04 1 Cxcl12 chemokine  0.21 
-1.37 5.14E-13 2 Pdzk2 PDZ domain containing 2  -1.29 
-1.37 1.02E-03 3 Peg3 paternally expressed 3  -1.11 
-1.37 1.75E-04 3 Cln2 ceroid-lipofuscinosis 2 -1.26 
-1.36 1.14E-13 2 Mftc mitochondrial folate transporter/carrier  0.60 
-1.36 1.37E-03 2 Lpin2 lipin 2  -1.18 
-1.36 4.17E-03 1 Dlk1 delta-like 1 homolog  -0.70 
-1.36 2.22E-09 2 Ogdh oxoglutarate dehydrogenase  -2.48 
-1.36 3.09E-14 3 Phtf1 putative homeodomain transcription factor 1  -1.41 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
-1.36 4.28E-02 2 Nefh neurofilament -0.68 
-1.36 1.21E-02 3 Ski Sloan-Kettering viral 
oncogene homolog  -1.46 
-1.36 7.52E-06 3 A430079E08 hypothetical protein A430079E08  0.24 
-1.36 1.88E-08 3 A730017C20Rik RIKEN cDNA A730017C20 gene  -1.07 
-1.35 4.80E-10 2 9130404D08Rik RIKEN cDNA 9130404D08 gene  0.20 
-1.35 2.84E-06 5 Anxa6 annexin A6 -1.20 
-1.35 4.10E-03 2 Ttc4 tetratricopeptide repeat domain 4  -0.72 
-1.35 4.49E-08 2 Usp49 ubiquitin specific protease 49  -1.19 
-1.35 1.25E-05 2 1110054H05Rik RIKEN cDNA 1110054H05 gene  0.17 
-1.35 2.09E-03 3 Wars2 tryptophanyl tRNA synthetase 2  -0.68 
-1.34 2.13E-03 1 Fjx1 four jointed box 1  -0.14 
-1.34 1.45E-05 2 Ssbp2 single-stranded DNA binding protein 2 -1.30 
-1.34 1.08E-04 4 4930471O16Rik RIKEN cDNA 4930471O16 gene  -0.62 
-1.34 5.15E-06 2 D130078K04Rik GRP1 BINDING PROTEIN GRSP1  -1.29 
-1.33 4.70E-04 3 1500041J02Rik RIKEN cDNA 1500041J02 gene  -0.23 
-1.33 1.01E-03 2 AW060207 expressed sequence AW060207  0.12 
-1.33 6.00E-04 1 6820402O20Rik RIKEN cDNA 6820402O20 gene  -1.50 
-1.32 1.85E-07 3 1700064K09Rik RIKEN cDNA 1700064K09 gene  -0.22 
-1.30 5.35E-03 1 6030413G23Rik RIKEN cDNA 6030413G23 gene  -0.26 
1.30 3.95E-03 1 Noxo1 NADPH oxidase organizer 1  1.36 
1.30 7.48E-03 3 Rasgrp1 RAS guanyl releasing protein 1  0.70 
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HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
1.30 3.65E-03 3 Ppil1 peptidylprolyl isomerase  1.14 
1.30 5.49E-10 2 Tnfrsf4 tumor necrosis factor receptor 
superfamily 1.32 
1.30 1.90E-04 1 Scp2 sterol carrier protein 2 1.14 
1.30 3.11E-02 2 Stim1 stromal interaction molecule 1 1.17 
1.31 2.49E-05 1 Aass aminoadipate-semialdehyde 
synthase  1.35 
1.31 1.39E-03 4 Abcb4 ATP-binding cassette 0.72 
1.31 3.23E-02 3 Egr3 early growth response 3  -0.18 
1.31 9.77E-07 3 Gfpt2 glutamine fructose-6-phosphate transaminase 2  1.12 
1.31 7.92E-04 2 Ltc4s leukotriene C4 synthase  1.30 
1.32 2.47E-09 2 Laptm4b lysosomal-associated protein transmembrane 4B  0.24 
1.32 2.36E-02 2 Plvap plasmalemma vesicle 
associated protein  0.65 
1.32 2.59E-16 1 2310012P17Rik RIKEN cDNA 2310012P17 gene  1.29 
1.32 2.23E-10 1 Ctsb cathepsin B  1.41 
1.33 4.52E-12 2 4933439J20Rik 
hypothetical XRCC1 N 
terminal domain containing 
protein 
1.26 
1.33 8.90E-10 3 1810009N02Rik RIKEN cDNA 1810009N02 gene  -1.71 
1.34 1.67E-03 4 H2-Q2 histocompatibility 2 1.35 
1.34 3.94E-13 3 4931440B09Rik RIKEN cDNA 4931440B09 gene  1.35 
1.35 4.73E-07 3 2410015N17Rik RIKEN cDNA 2410015N17 gene  -0.16 
1.35 9.60E-02 2 Timm10 
translocase of inner 
mitochondrial membrane 10 
homolog  
1.48 
1.35 1.03E-07 1 Mvp major vault protein  0.67 
1.35 1.20E-05 3 Dmwd dystrophia myotonica-
containing WD repeat motif  0.91 
1.38 1.26E-04 3 Rbm9 RNA binding motif protein 9  0.65 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
1.38 3.38E-07 2 Elmo3 engulfment and cell motility 3 1.46 
1.38 1.18E-02 4 Rpo1-1 RNA polymerase 1-1  0.81 
1.38 3.40E-09 3 Gfra1 
glial cell line derived 
neurotrophic factor family 
receptor alpha 1  
0.82 
1.38 2.49E-03 4 Dnajc5 DnaJ  1.45 
1.39 2.35E-09 4 Mopt protein containing single MORN motif in testis  -0.68 
1.39 2.36E-10 5 Tnfrsf13b tumor necrosis factor receptor 
superfamily 1.16 
1.40 4.66E-05 4 Mad2l1bp MAD2L1 binding protein  0.65 
1.40 1.04E-08 4 1810073G14Rik RIKEN cDNA 1810073G14 gene  1.14 
1.40 7.17E-04 3 Mag myelin-associated glycoprotein  1.30 
1.41 1.87E-15 4 Creb3 cAMP responsive element binding protein 3  0.22 
1.41 7.34E-05 1 Zfp68 zinc finger protein 68  -0.74 
1.43 7.85E-07 5 Slc35b1 solute carrier family 35 1.16 
1.43 1.61E-07 4 2610528C06Rik RIKEN cDNA 2610528C06 gene  0.73 
1.43 5.48E-05 3 Alad aminolevulinate 0.29 
1.44 2.43E-06 5 Ercc1 
excision repair cross-
complementing rodent repair 
deficiency 
1.47 
1.45 1.65E-10 4 Ntsr2 neurotensin receptor 2  1.55 
1.45 2.31E-02 5 2310007A19Rik RIKEN cDNA 2310007A19 gene  1.30 
1.45 1.99E-05 4 Laf4l lymphoid nuclear protein 
related to AF4-like  0.74 
1.46 1.55E-06 4 9330196J05Rik RIKEN cDNA 9330196J05 gene  0.17 
1.46 1.94E-14 4 Map1lc3a microtubule-associated protein 1 light chain 3 alpha  1.59 
1.46 5.16E-09 5 Bcl2a1b B-cell leukemia/lymphoma 2 
related protein A1b  0.68 
1.46 6.84E-08 3 6720463L11Rik SPLICING FACTOR -0.69 
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HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
1.47 5.07E-10 3 Alg1 asparagine-linked glycosylation 1 homolog  -0.18 
1.48 4.44E-10 4 Eml1 echinoderm microtubule 
associated protein like 1  0.66 
1.48 9.00E-08 4 6330530A05Rik RIKEN cDNA 6330530A05 gene  0.72 
1.48 1.41E-06 3 G2-pending G2 protein  1.40 
1.49 8.25E-07 5 1110012N22Rik RIKEN cDNA 1110012N22 gene  1.14 
1.49 5.53E-02 3 Hbb-b1 hemoglobin 0.86 
1.49 1.44E-07 4 Syt4 synaptotagmin 4  -0.29 
1.51 4.23E-06 4 Rutbc2 RUN and TBC1 domain 
containing 2  -0.25 
1.51 7.46E-07 5 Eppb9 endothelial precursor protein B9  1.28 
1.52 7.96E-10 2 BC034099 cDNA sequence BC034099  1.19 
1.52 4.27E-14 2 LOC226654 similar to KAT protein  0.66 
1.52 2.42E-19 4 H2-T23 histocompatibility 2 1.50 
1.52 5.10E-12 5 1110029E03Rik RIKEN cDNA 1110029E03 gene  -0.69 
1.53 1.77E-04 3 A530072M07Rik hypothetical protein 0.25 
1.54 1.71E-09 5 0610012D14Rik RIKEN cDNA 0610012D14 gene  1.58 
1.54 8.46E-15 5 LOC210245 similar to WTAP protein  0.63 
1.54 3.31E-06 5 Cd59a CD59a antigen  1.44 
1.55 1.76E-04 4 5031425E22Rik RIKEN cDNA 5031425E22 gene  0.28 
1.55 3.40E-10 5 1700023O11Rik RIKEN cDNA 1700023O11 gene  0.28 
1.55 3.26E-07 3 2310036D22Rik RIKEN cDNA 2310036D22 gene  3.32 
1.56 9.09E-17 5 1300019C06Rik RIKEN cDNA 1300019C06 gene  1.65 
1.56 5.76E-03 5 Prkag2 protein kinase 1.30 
1.57 1.96E-09 5 1110032N12Rik RIKEN cDNA 1110032N12 gene  -0.18 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
1.57 1.36E-08 4 Trim3 tripartite motif protein 3  1.12 
1.58 6.22E-05 2 Wnt9a wingless-type MMTV integration site 9A  0.85 
1.59 2.15E-15 4 Elac1 elaC homolog 1  -0.18 
1.60 1.90E-11 5 1700027N10Rik RIKEN cDNA 1700027N10 gene  1.20 
1.60 6.26E-05 4 Rps3a ribosomal protein S3a  -0.79 
1.62 1.85E-08 4 Slc1a2 solute carrier family 1 member 2 1.57 
1.62 3.48E-12 5 Slc35b1 solute carrier family 35 
member b1 1.13 
1.63 1.90E-07 3 Sox5 SRY-box containing gene 5 1.54 
1.65 4.36E-10 5 Zfp365 zinc finger protein 365  1.64 
1.65 3.95E-05 4 Zfp318 zinc finger protein 318  0.65 
1.67 7.06E-09 4 Twistnb TWIST neighbor  1.49 
1.68 5.71E-21 5 2700008N14Rik RIKEN cDNA 2700008N14 gene  1.86 
1.69 4.22E-14 5 1300010F03Rik RIKEN cDNA 1300010F03 gene  1.84 
1.70 7.59E-12 4 Chic1 cysteine-rich hydrophobic domain 1 -1.14 
1.71 1.50E-02 5 Hba-a1 hemoglobin alpha 0.90 
1.72 1.36E-02 5 Hbb-b1 hemoglobin beta 1.08 
1.77 2.08E-19 5 Mpeg1 macrophage expressed gene 1  1.81 
1.80 1.03E-10 4 Vti1b arginase type II  0.63 
1.86 1.67E-11 5 LOC384154 similar to ribosomal protein L31  1.20 
1.87 1.34E-06 5 1700024K14Rik RIKEN cDNA 1700024K14 gene  0.87 
1.89 2.19E-14 5 Mpg N-methylpurine-DNA glycosylase  0.61 
1.89 9.64E-10 4 Gtpbp4 GTP binding protein 4  1.87 
1.89 1.37E-12 4 Ddr1 discoidin domain receptor family 1.89 
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HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
1.91 9.30E-09 5 Rapgef5 Rap guanine nucleotide 
exchange factor  5 0.70 
1.91 6.08E-04 4 Ppfibp1 PTPRF interacting protein 1.49 
1.93 1.76E-14 5 Dgkq diacylglycerol kinase theta 0.20 
1.94 1.02E-10 5 Tnnt1 troponin T1 2.42 
1.96 8.43E-15 5 Add3 adducin 3  -0.28 
1.99 1.70E-18 5 Ercc5 
excision repair cross-
complementing rodent repair 
deficiency 
1.99 
1.99 4.51E-09 5 Arhgef10 Rho guanine nucleotide 
exchange factor  1.47 
2.00 5.35E-10 5 Rapgef5 Rap guanine nucleotide 
exchange factor  0.75 
2.03 5.24E-20 5 1110032N12Rik RIKEN cDNA 1110032N12 gene  0.71 
2.05 3.35E-19 5 Hmgn3 high mobility group 
nucleosomal binding domain 3  2.08 
2.05 1.61E-06 5 Rapgef5 Rap guanine nucleotide 
exchange factor 5 0.86 
2.06 3.66E-18 5 Trim11 tripartite motif protein 11  1.20 
2.08 1.80E-13 5 Sirt7 sirtuin 7  0.29 
2.08 6.89E-25 5 Rtn4 reticulon 4  2.09 
2.08 7.65E-05 4 Erdr1 erythroid differentiation 
regulator 1  -0.48 
2.12 1.51E-17 5 Usp29 ubiquitin specific protease 29  0.26 
2.12 9.72E-16 5 Ahcy S-adenosylhomocysteine hydrolase  2.18 
2.14 3.38E-26 5 Pdhb pyruvate dehydrogenase  -1.58 
2.14 3.23E-10 5 Cox6a2 cytochrome c oxidase 1.23 
2.15 2.31E-12 4 Cxadr coxsackievirus and adenovirus 
receptor  0.30 
2.16 2.87E-04 4 Hspcb heat shock protein 1 0.63 
2.18 4.78E-23 5 Tpr translocated promoter region  2.15 
2.21 2.10E-08 4 Mef2c myocyte enhancer factor 2C 0.78 
2.21 1.25E-14 5 Dgkh diacylglycerol kinase eta 2.58 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
2.21 6.97E-14 5 Elovl4 elongation of very long chain fatty acids  1.32 
2.22 1.20E-15 5 Fstl5 ollistatin-like 5  2.27 
2.22 6.02E-05 5 Ehd3 EH-domain containing 3  0.82 
2.23 8.50E-22 4 H2-T9 histocompatibility 2 2.39 
2.26 5.26E-25 5 2310034L04Rik RIKEN cDNA 2310034L04 gene  -0.27 
2.27 2.66E-13 4 Kcnj16 potassium inwardly-rectifying 
channel 0.69 
2.29 1.75E-14 5 6430559E15Rik RIKEN cDNA 6430559E15 gene  0.17 
2.30 3.83E-12 5 Map4k3 mitogen-activated protein kinase kinase kinase kinase 3  0.15 
2.31 3.74E-09 5 Twistnb TWIST neighbor  1.86 
2.34 3.12E-24 5 Vars2l valyl-tRNA synthetase 2-like  2.38 
2.38 1.97E-24 5 1110015E22Rik RIKEN cDNA 1110015E22 gene  2.79 
2.47 2.71E-22 5 1600014C10Rik RIKEN cDNA 1600014C10 gene  -0.21 
2.51 1.24E-18 5 2410131K14Rik RIKEN cDNA 2410131K14 gene  1.84 
2.55 1.80E-14 5 Sdf4 stromal cell derived factor 4  2.51 
2.56 4.35E-17 5 Pmp22 peripheral myelin protein  1.34 
2.57 4.15E-16 5 Abca2 ATP-binding cassette 0.63 
2.60 5.51E-08 5 Hbb-b1 hemoglobin beta 1 2.23 
2.61 2.03E-16 5 Cars cysteinyl-tRNA synthetase  0.14 
2.62 8.59E-20 5  16 days neonate cerebellum 
cDNA 0.15 
2.73 7.58E-08 5 Erdr1 erythroid differentiation 
regulator 1  0.37 
3.05 1.26E-11 5 LOC380983 similar to 60S ribosomal protein L15  3.09 
3.07 1.59E-10 5 Slc25a3 solute carrier family 25 
member 3  3.09 
3.39 1.17E-21 5 Rfng radical fringe gene homolog  0.71 
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HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
3.46 3.35E-22 5 Aldh3a2 aldehyde dehydrogenase family 3 1.48 
3.60 8.56E-26 5 Gnaq guanine nucleotide binding protein 3.72 
3.63 7.16E-12 5 BC018472 cDNA sequence BC018472  1.91 
3.76 2.46E-13 5 Satb1 special AT-rich sequence binding protein 1  0.90 
3.79 6.53E-29 5 BC002216 cDNA sequence BC002216  4.13 
4.05 9.41E-13 5 Hbb-b1 hemoglobin 3.41 
4.05 2.76E-42 5 Stx3 syntaxin 3  4.25 
4.31 1.14E-13 5 Msr2 macrophage scavenger 
receptor 2  1.43 
HAB 
vs. LAB p-value 
# of 
regions Gene symbol Gene name 
HAB vs. 
NAB 
4.34 5.47E-30 5 BC003331 cDNA sequence BC003331  5.10 
4.54 4.05E-16 5 Gig1 glucocorticoid induced gene 1  1.56 
4.75 5.85E-38 5 H2-T17 histocompatibility 2 5.03 
5.23 4.68E-08 5 2900019G14Rik RIKEN cDNA 2900019G14 gene 2.16 
6.12 6.54E-12 5 C330008L01Rik RIKEN cDNA C330008L01 gene  1.73 
6.27 1.19E-24 5 Grim19 
genes associated with 
retinoid-IFN-induced mortality 
19  
0.24 
17.58 1.38E-17 5 Hbb-b1 Hemoglobin beta 1 14.41 
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Supplementary Table 3: Association between 
selected phenotypes and selected chromosomal loci.  
Distance (OF) refers to the total distance travelled in 
the open field, immobility time to the tail suspension 
test, percent time to the elevated plus-maze test and 
response to the level of corticosterone concentration 
increase in blood plasma after 15 minutes of restraint 
stress.  
 
SNP Phenotype p-value 
mCV23695025 distance (OF) 6.05E-01 
mCV24784983 distance (OF) 5.86E-01 
rs3677683 distance (OF) 5.63E-01 
rs4137502 distance (OF) 5.60E-01 
rs3707642 distance (OF) 5.99E-01 
rs3683997 distance (OF) 4.25E-01 
rs13475827 distance (OF) 3.62E-01 
CEL-1_44668113 distance (OF) 7.98E-01 
rs13475881 distance (OF) 6.71E-01 
rs13475919 distance (OF) 6.38E-01 
rs30238169 distance (OF) 4.68E-01 
rs30238168 distance (OF) 4.68E-01 
rs30237262 distance (OF) 4.68E-01 
rs30236408 distance (OF) 4.68E-01 
rs30242174 distance (OF) 4.68E-01 
UT_1_89.100476 distance (OF) 4.88E-01 
rs13476012 distance (OF) 4.07E-01 
CEL-1_103251925 distance (OF) 3.73E-01 
rs3685919 distance (OF) 2.99E-01 
rs13476050 distance (OF) 2.76E-01 
rs3699561 distance (OF) 9.81E-02 
rs3672697 distance (OF) 7.17E-01 
rs13476163 distance (OF) 7.17E-01 
rs6393307 distance (OF) 7.75E-01 
rs13476187 distance (OF) 7.06E-01 
SNP Phenotype p-value 
rs6157620 distance (OF) 2.87E-01 
rs3667164 distance (OF) 6.90E-02 
rs6240512 distance (OF) 5.84E-05 
CZECH-
2_15618849 distance (OF) 2.06E-07 
rs13476366 distance (OF) 3.38E-07 
rs4223189 distance (OF) 1.95E-01 
rs3664661 distance (OF) 6.78E-01 
CEL-2_73370728 distance (OF) 6.61E-01 
rs13476639 distance (OF) 8.35E-01 
rs6406705 distance (OF) 6.18E-01 
rs13476666 distance (OF) 6.26E-01 
rs13476689 distance (OF) 7.06E-01 
rs13476723 distance (OF) 4.90E-01 
cmlcsnpavp1 distance (OF) 4.99E-01 
rs13476783 distance (OF) 4.97E-01 
CEL-2_168586738 distance (OF) 1.53E-02 
rs13477043 distance (OF) 5.72E-02 
gnf03.030.222 distance (OF) 7.36E-02 
rs6376008 distance (OF) 3.52E-01 
rs6211610 distance (OF) 1.91E-02 
rs13477268 distance (OF) 2.39E-01 
rs4138887 distance (OF) 1.61E-01 
CEL-3_120379605 distance (OF) 1.21E-01 
rs13477379 distance (OF) 8.29E-02 
rs3671119 distance (OF) 4.25E-01 
rs3676039 distance (OF) 3.38E-01 
rs6407142 distance (OF) 2.61E-01 
gnf03.160.599 distance (OF) 7.21E-03 
CEL-4_30653207 distance (OF) 3.92E-01 
rs3708471 distance (OF) 5.85E-01 
rs3023025 distance (OF) 4.56E-01 
SNP Phenotype p-value 
rs13478110 distance (OF) 8.48E-01 
rs3714258 distance (OF) 8.41E-01 
rs6341620 distance (OF) 1.12E-01 
CEL-5_45872918 distance (OF) 1.75E-02 
rs3664008 distance (OF) 1.10E-02 
mCV23386455 distance (OF) 1.01E-02 
rs3667334 distance (OF) 4.21E-03 
rs13459087 distance (OF) 9.54E-03 
rs3673049 distance (OF) 9.54E-03 
rs3661241 distance (OF) 2.06E-02 
rs13460000 distance (OF) 3.81E-02 
rs13460001 distance (OF) 3.81E-02 
rs13478433 distance (OF) 9.14E-03 
rs13459186 distance (OF) 1.48E-02 
rs13478483 distance (OF) 7.76E-02 
rs13478518 distance (OF) 5.94E-02 
rs13478520 distance (OF) 6.21E-02 
rs36247439 distance (OF) 2.03E-01 
rs33343556 distance (OF) 2.03E-01 
rs36309698 distance (OF) 2.03E-01 
rs37452785 distance (OF) 2.03E-01 
mCV23695025 immobility time 7.88E-02 
mCV24784983 immobility time 1.76E-02 
rs3677683 immobility time 1.45E-02 
rs4137502 immobility time 1.28E-02 
rs3707642 immobility time 1.89E-02 
rs3683997 immobility time 1.93E-02 
rs13475827 immobility time 1.14E-01 
CEL-1_44668113 immobility time 5.90E-01 
rs13475881 immobility time 6.69E-02 
rs13475919 immobility time 4.18E-01 
rs30238169 immobility time 1.06E-01 
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SNP Phenotype p-value 
rs30238168 immobility time 1.06E-01 
rs30237262 immobility time 1.06E-01 
rs30236408 immobility time 1.06E-01 
rs30242174 immobility time 1.06E-01 
UT_1_89.100476 immobility time 8.20E-03 
rs13476012 immobility time 3.93E-03 
CEL-1_103251925 immobility time 3.72E-03 
rs3685919 immobility time 1.04E-03 
rs13476050 immobility time 1.17E-03 
rs3699561 immobility time 5.66E-06 
rs3672697 immobility time 7.45E-08 
rs13476163 immobility time 7.45E-08 
rs6393307 immobility time 3.77E-08 
rs13476187 immobility time 1.00E-07 
rs6157620 immobility time 1.04E-04 
rs3667164 immobility time 9.25E-04 
rs6240512 immobility time 1.76E-13 
CZECH-
2_15618849 immobility time 1.42E-17 
rs13476366 immobility time 4.66E-19 
rs4223189 immobility time 3.40E-05 
rs3664661 immobility time 2.15E-03 
CEL-2_73370728 immobility time 6.18E-03 
rs13476639 immobility time 1.78E-01 
rs6406705 immobility time 1.71E-01 
rs13476666 immobility time 3.11E-01 
rs13476689 immobility time 3.53E-01 
rs13476723 immobility time 6.47E-01 
cmlcsnpavp1 immobility time 7.31E-01 
rs13476783 immobility time 8.21E-01 
CEL-2_168586738 immobility time 4.56E-02 
rs13477043 immobility time 3.25E-01 
SNP Phenotype p-value 
gnf03.030.222 immobility time 3.21E-01 
rs6376008 immobility time 2.75E-01 
rs6211610 immobility time 5.94E-01 
rs13477268 immobility time 2.64E-01 
rs4138887 immobility time 2.22E-01 
CEL-3_120379605 immobility time 2.46E-01 
rs13477379 immobility time 7.71E-01 
rs3671119 immobility time 7.01E-01 
rs3676039 immobility time 7.80E-01 
rs6407142 immobility time 3.94E-01 
gnf03.160.599 immobility time 9.32E-01 
CEL-4_30653207 immobility time 7.07E-01 
rs3708471 immobility time 5.89E-02 
rs3023025 immobility time 3.23E-01 
rs13478110 immobility time 9.04E-01 
rs3714258 immobility time 8.84E-01 
rs6341620 immobility time 4.77E-01 
CEL-5_45872918 immobility time 2.75E-01 
rs3664008 immobility time 1.91E-01 
mCV23386455 immobility time 1.99E-01 
rs3667334 immobility time 1.38E-01 
rs13459087 immobility time 2.19E-01 
rs3673049 immobility time 2.19E-01 
rs3661241 immobility time 2.22E-01 
rs13460000 immobility time 2.32E-01 
rs13460001 immobility time 2.32E-01 
rs13478433 immobility time 1.31E-01 
rs13459186 immobility time 7.36E-02 
rs13478483 immobility time 4.98E-01 
rs13478518 immobility time 4.58E-01 
rs13478520 immobility time 3.18E-01 
rs36247439 immobility time 8.67E-01 
SNP Phenotype p-value 
rs33343556 immobility time 8.67E-01 
rs36309698 immobility time 8.67E-01 
rs37452785 immobility time 8.67E-01 
mCV23695025 percent time 5.81E-01 
mCV24784983 percent time 4.13E-01 
rs3677683 percent time 4.49E-01 
rs4137502 percent time 3.72E-01 
rs3707642 percent time 3.40E-01 
rs3683997 percent time 3.32E-01 
rs13475827 percent time 9.41E-02 
CEL-1_44668113 percent time 6.98E-02 
rs13475881 percent time 3.19E-01 
rs13475919 percent time 8.13E-01 
rs30238169 percent time 7.90E-01 
rs30238168 percent time 7.90E-01 
rs30237262 percent time 7.90E-01 
rs30236408 percent time 7.90E-01 
rs30242174 percent time 7.90E-01 
UT_1_89.100476 percent time 7.88E-01 
rs13476012 percent time 3.86E-01 
CEL-1_103251925 percent time 1.75E-01 
rs3685919 percent time 2.83E-01 
rs13476050 percent time 3.00E-01 
rs3699561 percent time 2.50E-01 
rs3672697 percent time 5.52E-01 
rs13476163 percent time 5.52E-01 
rs6393307 percent time 4.83E-01 
rs13476187 percent time 5.48E-01 
rs6157620 percent time 2.23E-01 
rs3667164 percent time 1.65E-01 
rs6240512 percent time 6.41E-04 
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SNP Phenotype p-value 
CZECH-
2_15618849 percent time 1.20E-03 
rs13476366 percent time 3.73E-04 
rs4223189 percent time 5.13E-01 
rs3664661 percent time 2.03E-01 
CEL-2_73370728 percent time 3.13E-01 
rs13476639 percent time 9.96E-02 
rs6406705 percent time 3.56E-02 
rs13476666 percent time 2.16E-02 
rs13476689 percent time 5.41E-02 
rs13476723 percent time 5.65E-02 
cmlcsnpavp1 percent time 1.84E-01 
rs13476783 percent time 3.18E-01 
CEL-2_168586738 percent time 2.89E-01 
rs13477043 percent time 1.41E-05 
gnf03.030.222 percent time 1.01E-05 
rs6376008 percent time 8.12E-02 
rs6211610 percent time 2.29E-02 
rs13477268 percent time 1.30E-01 
rs4138887 percent time 8.75E-02 
CEL-3_120379605 percent time 9.00E-02 
rs13477379 percent time 3.06E-02 
rs3671119 percent time 4.09E-01 
rs3676039 percent time 3.13E-01 
rs6407142 percent time 2.03E-01 
gnf03.160.599 percent time 2.06E-02 
CEL-4_30653207 percent time 7.52E-01 
rs3708471 percent time 2.41E-01 
rs3023025 percent time 2.19E-01 
rs13478110 percent time 5.05E-01 
rs3714258 percent time 7.44E-01 
rs6341620 percent time 2.28E-01 
SNP Phenotype p-value 
CEL-5_45872918 percent time 3.85E-02 
rs3664008 percent time 2.63E-04 
mCV23386455 percent time 1.24E-04 
rs3667334 percent time 9.66E-07 
rs13459087 percent time 2.06E-06 
rs3673049 percent time 2.06E-06 
rs3661241 percent time 7.94E-07 
rs13460000 percent time 1.05E-06 
rs13460001 percent time 1.05E-06 
rs13478433 percent time 3.52E-07 
rs13459186 percent time 2.44E-07 
rs13478483 percent time 9.97E-08 
rs13478518 percent time 2.04E-03 
rs13478520 percent time 9.80E-04 
rs36247439 percent time 6.98E-01 
rs33343556 percent time 6.98E-01 
rs36309698 percent time 6.98E-01 
rs37452785 percent time 6.98E-01 
mCV23695025 response 5.88E-01 
mCV24784983 response 6.27E-01 
rs3677683 response 5.63E-01 
rs4137502 response 5.30E-01 
rs3707642 response 4.82E-01 
rs3683997 response 4.79E-01 
rs13475827 response 3.62E-02 
CEL-1_44668113 response 1.27E-01 
rs13475881 response 3.63E-01 
rs13475919 response 7.74E-02 
rs30238169 response 7.97E-02 
rs30238168 response 7.97E-02 
rs30237262 response 7.97E-02 
rs30236408 response 7.97E-02 
SNP Phenotype p-value 
rs30242174 response 7.97E-02 
UT_1_89.100476 response 1.32E-01 
rs13476012 response 3.63E-01 
CEL-1_103251925 response 4.22E-01 
rs3685919 response 5.43E-01 
rs13476050 response 5.43E-01 
rs3699561 response 5.02E-01 
rs3672697 response 8.92E-01 
rs13476163 response 8.92E-01 
rs6393307 response 7.76E-01 
rs13476187 response 8.38E-01 
rs6157620 response 1.94E-01 
rs3667164 response 1.26E-01 
rs6240512 response 7.93E-01 
CZECH-
2_15618849 response 5.78E-01 
rs13476366 response 3.28E-01 
rs4223189 response 5.97E-01 
rs3664661 response 1.08E-01 
CEL-2_73370728 response 9.86E-02 
rs13476639 response 2.49E-01 
rs6406705 response 1.25E-01 
rs13476666 response 1.33E-01 
rs13476689 response 3.60E-01 
rs13476723 response 2.53E-01 
cmlcsnpavp1 response 9.82E-02 
rs13476783 response 5.38E-02 
CEL-2_168586738 response 9.89E-02 
rs13477043 response 2.04E-07 
gnf03.030.222 response 3.98E-07 
rs6376008 response 7.35E-46 
rs6211610 response 5.56E-23 
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SNP Phenotype p-value 
rs13477268 response 1.20E-50 
rs4138887 response 2.31E-50 
CEL-3_120379605 response 2.02E-34 
rs13477379 response 1.64E-30 
rs3671119 response 7.01E-28 
rs3676039 response 4.13E-16 
rs6407142 response 9.80E-10 
gnf03.160.599 response 1.96E-03 
CEL-4_30653207 response 9.84E-02 
rs3708471 response 3.51E-01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Phenotype p-value 
rs3023025 response 5.49E-01 
rs13478110 response 1.44E-01 
rs3714258 response 1.47E-01 
rs6341620 response 4.34E-01 
CEL-5_45872918 response 4.68E-01 
rs3664008 response 3.80E-01 
mCV23386455 response 2.41E-01 
rs3667334 response 2.38E-01 
rs13459087 response 2.43E-01 
rs3673049 response 2.43E-01 
rs13460000 response 9.15E-02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Phenotype p-value 
rs3661241 response 6.70E-02 
rs13460001 response 9.15E-02 
rs13478433 response 1.57E-01 
rs13459186 response 1.23E-01 
rs13478483 response 6.09E-02 
rs13478518 response 3.74E-01 
rs13478520 response 4.88E-01 
rs36247439 response 5.34E-01 
rs33343556 response 5.34E-01 
rs36309698 response 5.34E-01 
rs37452785 response 5.34E-01 
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